University of Louisville

ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
12-2014

Study of novel nanoparticle transport and drug release for cancer
treatment.
Christopher Gene England 1988University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
England, Christopher Gene 1988-, "Study of novel nanoparticle transport and drug release for cancer
treatment." (2014). Electronic Theses and Dissertations. Paper 1712.
https://doi.org/10.18297/etd/1712

This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of
the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.

STUDY OF NOVEL NANOPARTICLE TRANSPORT AND DRUG RELEASE FOR CANCER
TREATMENT

By
Christopher England
B.S.; Bellarmine University, 2011
M.S.; University of Louisville, 2013

A Dissertation
Submitted to the Faculty of the
School of Medicine of the University of Louisville
In Partial Fulfillment of the Requirements
For the Degree of

Doctor of Philosophy

Department of Pharmacology and Toxicology
University of Louisville
Louisville, Kentucky

December 2014

STUDY OF NOVEL NANOPARTICLE TRANSPORT AND DRUG RELEASE FOR CANCER
TREATMENT
By
Christopher England
B.S; Bellarmine University, 2011
M.S., University of Louisville, 2013

A Dissertation Approved on

November 13, 2014

By the following Dissertation Committee:

________________________________________
Hermann Frieboes (Chair)

________________________________________
Brian Ceresa

________________________________________
Jill Steinbach

________________________________________
Martin O’Toole

________________________________________
Albert Cunningham

ii

ACKNOWLEDGEMENTS
I would like to thank my advisor, Dr. Hermann Frieboes, for his guidance throughout my graduate
studies. I would also like to thank the other committee members for their valuable assistance, including Dr.
Brian Ceresa, Dr. Martin O’Toole, Dr. Jill Steinbach, and Dr. Albert Cunningham. Additionally, my
gratitude is extended to all collaborators at the University of Louisville, without whom the work for this
thesis could not have been accomplished.

iii

ABSTRACT
STUDY OF NOVEL NANOPARTICLE TRANSPORT AND DRUG RELEASE FOR CANCER
TREATMENT
Christopher G. England
November 13, 2014

Nano-scale particles sized 10—400 nm administered systemically preferentially extravasate from tumor
vasculature due to the enhanced permeability and retention effect. Therapeutic success remains elusive,
however, because of inhomogeneous particle distribution within tumor tissue. Insufficient tumor
vascularization limits particle transport and also results in avascular hypoxic regions with non-proliferating
cells, which can regenerate tissue after nanoparticle-delivered cytotoxicity or thermal ablation. In this
study, gold nanoparticles were functionalized with phosphatidylcholine (two-layer) or phosphatidylcholine
and HDL (three-layer) in the formation of “layered” nanoparticles. The diffusivity of both two- and three
layered colloidal gold nanoparticles and silica gold nanoshells were examined in 3D cell cultures. Both
two- and three layered nanoparticles showed enhanced diffusivity in comparison to previously developed
PEGylated nanoparticles. As the two layer nanoparticles displayed enhanced diffusivity in comparison to
three layer nanoparticles, the two layered nanoparticles were further examined in vivo using mice implanted
with orthotopic pancreatic adenocarcinomas. The two layer colloidal gold nanoparticles showed enhanced
diffusivity in comparison to silica gold nanoshells in vivo, suggesting that smaller nanoparticles were able
to localize and diffuse from vasculature better than larger nanoparticles. Overall accumulation of solid gold
nanoparticle accumulated in the tumor and filtering organs (liver and spleen) was 2X higher than silica gold
nanoshells. Thus, two layer colloidal gold nanoparticles were loaded with cisplatin or paclitaxel to
determine optimal drug release kinetics. Drug release from paclitaxel-loaded nanoparticles displayed a
slower release while cisplatin-loaded nanoparticles experienced an initial burst of drug release followed by
a slower release of remaining drug. Lastly, drug-loaded colloidal gold nanoparticles were tested in 3D cell
cultures to determine their cytotoxicity. Both two and three layer nanoparticles loaded with cisplatin or
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paclitaxel showed similar efficacy to drug alone, suggesting their viable use in vivo for cancer treatment.
This study has demonstrated the potential use of layered nanoparticles for increasing the delivery of
chemotherapeutics deeper into tumor tissue.
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CHAPTER I
INTRODUCTION TO NANOTHERAPEUTICS IN CANCER TREATMENT

Biological Barriers to Successful Treatment
Several biological differences between the microenvironment found within solid tumors and that
of normal tissue effectively limit the efficacy of chemotherapeutic drugs as well as nanotherapeutics. Noncancerous tissue contains organized vasculature providing oxygen, nutrients, and drug delivered
systemically to all of the surrounding cells. Cancerous tissue presents multiple barriers to the successful
delivery of oxygen, nutrients and therapeutics. These barriers are “hallmarks” of the microenvironment of
solid tumors and include: (1) irregular and disorganized vasculature, (2) high interstitial fluid pressure
(IFP), (3) low oxygen tension and hypoxia, (4) low extracellular pH, (5) and a dense extracellular matrix
(ECM) (Figure 1) [1, 2].
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Figure 1. Microenvironment of Solid Tumors. Solid tumors elicit several characteristics different from
healthy tissue primarily attributed to irregular vasculature. Cells distant from surrounding blood vessels
will experience hypoxia as oxygen diffusion is limited, thus certain regions of tissue will have inadequate
access to oxygen and other nutrients (e.g. glucose). Those cells distant from vasculature will also have
impaired means of eliminating metabolic waste, resulting in an increased extracellular acidity. The cells
distant from vasculature can become quiescent or necrotic due to the lack of nutrients. Also, an increase in
IFP results from the irregular vasculature along with impaired lymphatic function. This increase can further
decrease the diffusion of small molecules, effectively limiting the access of drugs and nanoparticles to the
tumor.
The irregular and leaky vasculature in solid tumors arises from un-balanced regulation of proangiogenic and anti-angiogenic factors [3]. As a result, portions of tissue will become hyper-vascularized
while other portions will become hypo-vascularized. Another leading contributor to the disorganized tumor
vasculature are the disproportional mitotic rates between endothelial and tumor cells, as the latter
proliferate much faster than endothelial cells making up the vasculature, thus leading to sporadic blood
vessel formation [4]. As a consequence of irregular vasculature, malignant cells will become distant from
surrounding blood vessels, possibly beyond the diffusion limit of oxygen (100µm). This results in the
development of oxygen and nutrient gradients in which cells closer to vessels will receive most of the
nutrients and proliferate, while cells distal to the vasculature will receive insufficient oxygen and nutrients,
thus promoting cellular quiescence and even necrosis [5].
It has been well documented that solid tumors commonly possess elevated interstitial fluid
pressure (IFP) in comparison to non-cancerous tissue, where the IFP is regulated to optimize fluid flow and
nutrient transport from blood vessels to surrounding cells [2]. Whereas in normal tissue the IFP is slightly
negative (-1 to -3 mm Hg), in solid tumors it can range as high as 10 to 30 mm Hg [6]. For example, the
IFP of implanted A549 orthotopic solid tumors in mice were monitored in correlation with tumor size. As
the tumor volume increased to 2000 mm3, IFP also increased from 2 mm Hg to 4 mm Hg, with other cell
lines exhibiting higher increases [7]. There are three factors that influence IFP in solid tumors, including:
decreased function of blood vessels and lymphatics residing within the tumor microenvironment, osmotic
forces that draw solute into the tissue, and contraction of the tumor stroma [1]. As the factors are
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synergistic, they can promote high solid tumor IFPs s [1]. Numerous studies have analyzed how increased
IFP affects the therapeutic efficacy of drugs, with most studies showing a positive correlation between
increased IFP and poor prognosis [8].
As the cells further away from vasculature become quiescent, a gradient of decreasing cell
proliferation with increased distance from blood vessels will develop [9]. Quiescent cells have shown
increased incidence of resistance to both chemotherapeutics and radiotherapy [10, 11]. Reasons include:
(A) hypoxic cells are usually quiescent not allowing for cycle-dependent chemotherapeutics to be effective,
(B) chemotherapeutics may be inactive in acidic or hypoxic microenvironments, and (C) cells may receive
sub-optimal drug concentrations simply attributed to the distance from the nearest blood supply [4].
The acidic microenvironment of solid tumors can hinder the delivery of chemotherapeutics in
multiple ways [12]. The low pH found in solid tumors is attributed to the build-up of metabolites such as
lactic acid and carbonic acid in the extracellular space. As healthy non-cancerous cells excrete metabolites
from the cellular cytoplasm to the interstitial space, surrounding vasculature and lymphatic ducts will
eliminate the metabolites from the tissue. In cancerous tissue, insufficient vasculature and lymphatic
processes hinder metabolite elimination, leading to their accumulation and resulting in acidic
microenvironments. In accordance with the theory of ion trapping, drugs must be in an uncharged state in
order to cross cellular membranes. Drugs such as doxorubicin are weak bases, which will become ionized
in acidic environments, thus being unable to cross the cell membrane. As the amount of drug entering the
cell decreases, the potential therapeutic action will also diminish [13]. Thus, the acidity of the
microenvironment can significantly impact therapeutic outcomes.
Solid tumors can possess significantly more ECM proteins in comparison to non-cancerous tissue,
resulting in decreased diffusivity of various nutrients and drugs. The ECM is the tissue outside of the cells
that provides structural and biochemical support for the cellular structure. It is responsible for cell adhesion,
cell-to-cell communication, and structural integrity with various proteins (e.g. proteoglycans, collagen,
hyaluronic acid) and can have a large impact on drug delivery as the composition and quantity of ECM can
drastically hinder the movement of both medium and large molecular weight proteins [4] due to size and
charge constraints. For example, collagen possesses a slightly positive charge which may attract anionic
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nanoparticles or drugs, thus decreasing their delivery to malignant tumor cells residing further away from
vasculature [14].
Besides limitations exhibited by the solid tumor, certain chemotherapeutic drugs have poor
pharmacokinetic properties that can also limit their effectiveness. For example, certain hydrophobic drugs
(e.g. paclitaxel) are difficult to use clinically due to deficient water solubility and high plasma protein
binding [15]. Many compounds have been eliminated as potential drug candidates due to their unsuitable
physiochemical properties. To overcome these issues, nanoparticles have been utilized as drug carrier
molecules. Nanoparticles are candidates for the delivery of various compounds including
chemotherapeutics, miRNAs, and imaging agents. For example, paclitaxel is currently available as a nanobased therapeutic albumin-bound drug (Abraxane) for the treatment of lung cancer [16].
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Delivering Nanoparticles to Solid Tumors
Interest arose in the use of nanoparticles as potential drug carriers because they could be combined
with previously developed biologically active compounds to improve drug delivery to tumors at increased
concentrations in comparison to free drug. Properties of nanoparticles that make them candidates for
therapeutic applications, include: (1) high tunability allowing for modification of properties such as shape,
size, and surface charge, (2) ability to specifically target cancer cells, (3) ability to sporadically accumulate
in tumor tissue via passive targeting, (4) ability to overcome physiochemical limitations of the drug itself,
(5) controllable drug release profiles which can be modified for various cancers or treatment regimens, (6)
ability to act as theranostic agents or the simultaneous delivery of diagnostic molecules and therapeutic
agents for the concurrent imaging and treatment of disease, (7) ability to carry multiple drugs, and (8)
ability to bypass intrinsic cellular resistance mechanisms for entry into cells, such as P-glycoprotein. Each
of these properties will be discussed in more detail below.
(1) Nanoparticles are highly tunable, which makes them optimal for appropriate applications in
medicine. Properties including conformational shape, maximum absorbance, surface charge, and
hydrodynamic size can be chemically modified to enhance their efficacy. Conformational shape can have a
crucial impact on cell uptake in vivo, as spherical nanoparticles have been shown to accumulate in tumor
tissue better than rod-shaped nanoparticles. In 2013, Kolhar et al. showed that rod-shaped nanoparticles
exhibited higher specific accumulation in lung endothelium in comparison to spherical-shaped particles
[17]. The maximum absorbance is another modifiable property of nanoparticles, which can be chemically
altered for purposes such as photoacoustic imaging or photothermal therapy. Investigators were able to
monitor gold nanoparticles with an absorption peak around 780 nm as they circulated throughout systemic
circulation using photoacoustic imaging [18]. Ren et al. was able to synthesize paclitaxel-loaded gold
nanorods with a maximum absorbance near 780 nm and showed the feasibility of using these nanoparticles
for both photothermal and chemotherapy efficacy in treating lung cancer [19].
Surface charge also has a large impact on the travel of nanoparticles within circulation and their
diffusion through tissue. Cationic nanoparticles accumulate in tumor vasculature due to electrostatic
interactions, but the cationic charge must be minimal for nanoparticles to extravasate from blood vessels
[20, 21]. It has been shown that neutral charged nanoparticles diffuse rapidly within tumor tissue in
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comparison to charged nanoparticles which may react with extracellular proteins such as hyaluronan or
collagen [14, 22]. The effect of nanoparticle size on tissue distribution has been extensively studied.
Smaller nanoparticles (10-100 nm) exhibit enhanced diffusivity in tumor tissue as compared to larger
nanoparticles, while larger nanoparticles (100-400 nm) are significantly sequestered due to the EPR effect.
For example, liposomes ranging in size from 100-200 nm displayed enhanced tumor accumulation in vivo,
as compared to smaller liposomes (<100 nm) and larger nanoparticles (>200 nm) [23]. Further studies have
analyzed the diffusion of even smaller nanoparticles in tumor tissue, such as Huang et al. who examined
the relationship of ultra-small gold nanoparticles and tumor accumulation using nanoparticles ranging in
size from 2-15 nm. It was shown that 2 and 6 nm nanoparticles accumulate in tumor tissue after intravenous
injection in higher concentrations than slightly larger nanoparticles (15 nm). They further analyzed the
localization of these nanoparticles within individual cancer cells and the microenvironment of the tumor,
illustrating that both 2 and 6 nm particles were distributed throughout the cytoplasm and nucleus of cancer
cells, while larger nanoparticles were only found within the cytoplasm where they formed aggregates [24].
(2) The process of functionalizing nanoparticles refers to the chemical addition of various surface
modifications, such as proteins, peptides, antibodies, or other compounds that can be used to enhance the
delivery of nanoparticles to the tissue of interest. By specifically targeting cancer cells, systemic off target
toxicity that is commonly associated with current chemotherapeutics can be minimized. This process has
been termed “active targeting.” Previous studies have targeted nanoparticles to cell surface receptors
commonly up-regulated in cancer cells, such as EGFR [25-28]. Kao et al. recently demonstrated that gold
nanoparticles targeted to EGFR in A549 cells exhibited higher radioactivity retention in the tumor after
intravenous injection, as compared to non-targeted nanoparticles [25]. Additional groups such as Peng et al.
developed EGFR-targeted heparin nanoparticles loaded with cisplatin, which were shown to significantly
increase the intracellular concentration of drug in H292 NSCLC cells as compared to cisplatin alone. These
nanoparticles showed enhanced pharmacokinetics and bio-distribution through systemic circulation
improving antitumor activity without weight loss or associated nephrotoxicity [28]. As nanoparticles
possess high surface area to volume ratio due to their small size and shape, studies have shown the
feasibility of attaching multiple targeting ligands onto a single nanoparticle, thus increasing the odds of
cellular interactions with the targeted tissue. For example, Rangger et al. developed liposomes targeted
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with two peptides: an arginine-glycine-aspartic acid peptide and a neuropeptide. While the additional
surface modification was predicted to increase tumor accumulation of the liposomes, they found no
additional tumor uptake with the dual-targeted liposomes compared to single targeted liposomes [29]. This
study demonstrated an important concept; while adding multiple targeting ligands seems very useful, the
activity of the targeting ligands may not provide a synergistic effect on targeting capabilities and tumor
accumulation.
(3) Irregular vasculature in tumor tissue hinders the delivery of nutrients to some of the cells
residing in the tumor. The same holds true for freely circulating drugs, in which cells distant from
vasculature will receive minimal amounts of chemotherapeutics leading to suboptimal drug concentrations.
Nanoparticle accumulation in tumor tissue is only a small fraction of the loading dose. Previous studies
have shown that most injected nanoparticles will accumulate in the liver (40-50%), spleen (24-40%), lungs,
kidneys, and heart. Only 1-5% of injected nanoparticles will accumulate in the tumor tissue, which can
ultimately lead to therapeutic failure [30]. For this reason, coating nanoparticles with polymers such as
poly(ethylene) glycol (PEG) has been used to enhance the bioavailability. It was shown that nanoparticles
coated with PEG exhibit an increase circulation time in vivo, over 2X that of non-coated nanoparticles [31,
32]. Passive targeting of nanoparticles is based upon the observation that nanoparticles will accumulate in
tissue surrounding the leaky vasculature as a result of wide fenestrations of the endothelial layer and
reduced lymphatic draining [2, 33]. This phenomenon has been termed the enhanced permeability and
retention effect (EPR), which was first described by Hiroshi Maeda in 1985 [34, 35]. Scientists discovered
that increasing the circulation time of nanoparticles in vivo led to higher accumulation in tumor tissue, as
the EPR effect was time-dependent.
(4) The biological effect of a drug is significantly dependent upon its pharmacokinetic properties.
Many chemotherapeutics have substandard pharmacokinetic profiles which limit their travel throughout
systemic circulation, due to factors such as rapid metabolism or elimination. Major issues associated with
poorly water-soluble compounds include: poor bioavailability, lack of dose-response proportionality,
suboptimal dosing, use of harsh excipients, use of basic or acid conditions to enhance solubility,
uncontrollable precipitation after dosing, and noncompliance by the patient due to dosing strategies [36].
The limited pharmacokinetic properties can be overcome by using nanovectors as a delivery mechanism.
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As nanoparticles are synthesized with tunable pharmacokinetic properties, drugs will be delivered to the
tumor tissue based upon the pharmacokinetic properties of the nanoparticle. For example, paclitaxel is one
of the most effective FDA-approved chemotherapeutic drugs due to its anti-cancer activity and relatively
low EC50, yet minimal water solubility and harsh solvents can hinder efficient delivery and increase the risk
of severe toxicity. The nano-based formulation of albumin-bound paclitaxel has shown enhanced
effectiveness, increased survival rates, increased time to disease progress, and decreased systemic toxicity
[37].
(5) Once drugs are loaded onto nanoparticles, their release profiles can be modified for the
treatment of specific diseases. Drug release from nanoparticles is dependent upon several factors including
pH of the surrounding microenvironment, interactions between the drug and nanoparticle (e.g. covalent
linkage or non-covalent linkage), and the physiochemical properties of the nanoparticles. For example, Yin
et al. synthesized curcumin-loaded nanoparticles with three different amphilic methoxy PEG (mPEG)polycaprolactone (PCL) block copolymers varying in chain length. They showed that mPEG10k-PCL30k
had the highest loading efficiency and most sustained drug release profile of the three polymers. Results
from this study illustrated that various alterations in polymer size could have substantial effects on drug
release kinetics, so constructing nanoparticles specifically for certain release profiles is feasible and
worthwhile [38]. Through surface modifications, rapid and slow drug release patterns can be achieved. The
most common method for analyzing drug release kinetics from nanoparticles is by dialysis, along with
analysis by UV-spectroscopy or high performance liquid chromatography (HPLC) [39]. Li et al. loaded
doxorubicin in anionic methoxy PEG-b-poly(L-glutamic acid) nanoscale complexes that exhibited pH
responsive drug release and significantly prolonged blood circulation time in comparison to drug alone in
nude mice with A549 NSCLC xenografts [40]. By prolonging circulation time of the nanoparticle, there
were more opportunities for the nanoparticle to localize in the tumor tissue as it continuously re-circulated
throughout the body while avoiding the healthy tissue.
(6) While loading drugs onto nanoparticles can provide enhanced therapeutic responses, this
concept was extended to loading imaging agents along with drugs. The development of such particles was a
direct result of scientists wishing to visualize the effects of anticancer treatments. New imaging
methodologies along with novel theranostic nanoparticles made this process possible. For example,
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photoacoustic imaging with multispectral optoacoustic tomography (MSOT) has enabled monitoring the
systemic circulation of gold nanoparticles in real-time [41-43]. Magnetic resonance imaging (MRI) has
been most extensively utilized with theranostic nanoparticles. Patel et al. recently developed theranostic
nanoparticles containing multiple modifications including: PEG-coating to increase systemic circulation, a
CREKA peptide for active targeting to lung cancer, and a cytotoxic compound known as c-substituted
diindolymethanes (CIM-C-pPhC6H5) for therapeutic activity. These newly developed nanoparticles
exhibited a 40-fold increased transport in tumor vasculature compared to control nanoparticles [44].
(7) Due to the high surface area to volume ratio, multiple targeting ligands and therapeutic agents
can be loaded onto a single nanoparticle. This is advantageous since chemotherapeutics regimens
commonly consists of two or more drugs in combination. Aratula et al. developed mesoporous silica
nanoparticles with two anti-cancer drugs (cisplatin and doxorubicin) and two siRNA molecules targeted to
MRP1 and BCL2 mRNA to decrease cellular resistance. Using the luteinizing hormone releasing peptide
(LHRH) as an active targeting ligand, they were able to enhance tumor accumulation, as the siRNA
suppressed cellular resistance to the anticancer drugs, and the anti-cancer agents exhibited enhanced
therapeutic effect for the treatment of NSCLC in vivo [45]. Another group, Liu et al., encapsulated both
doxorubicin with paclitaxel and doxorubicin with rapamycin into magnetic mesoporous silica nanoparticle
to demonstrate the feasibility of loading both hydrophobic and hydrophilic drugs onto the same
nanoparticle. The nanoparticles showed high internalization and enhanced efficacy in A549 NSCLC cells
[46]. By loading multiple drugs onto single nanoparticles, patient compliance could be improved as the
number of necessary drug doses could be decreased.
(8) Drug resistance is a critical hindrance to successful chemotherapeutic treatment. Multidrug
resistance (MDR) has been the most extensively studied mechanism in which cancer cells become immune
to multiple chemotherapeutics [47]. There are both cellular and physiological factors that can alter drug
resistance. Cellular responses involved in drug resistance include altered molecular targets, increased drug
metabolism, genetic defects, reduced apoptosis, and up-regulation of efflux pumps [48]. Physiological
mechanisms of drug resistance include cell-cell interactions, increased IFP, acidic microenvironment,
hypoxic or necrotic regions in tissue, and irregular tumor vasculature [48]. Efflux pumps such as Pglycoprotein are commonly associated with increased drug resistance to multiple classes of
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chemotherapeutics including doxorubicin, vinca alkaloids, and taxols [49, 50]. Using nanoparticles, some
mechanisms of drug resistance can be overcome. For example, Cuvier et al. showed that both sensitive and
resistant cells would uptake the same amount of doxorubicin if delivered via nanoparticles [51]. Other
groups have looked to target intracellular apoptotic mechanisms, such as Bcl-2, which is a protein that
inhibits downstream apoptotic pathways and is up-regulated in most solid tumors. To overcome this drug
resistance mechanism, Bcl-2 siRNAs has been encapsulated to decrease drug resistance in vivo [52-54]. For
example, Saad et al. developed liposomes containing two different siRNAs, Bcl2-siRNA and MRP1siRNA, and doxorubicin for use in MDR lung cancer cells. Results showed effective co-delivery of
doxorubicin and siRNAs with up to 95% cell-death induction, with high suppression of cellular resistance
[55].
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Lung Cancer Facts and Statistics
While other cancer cell lines are utilized in this study, lung cancer is the primary focus. Lung
cancer remains a lethal ailment in the United States in spite of recent treatment advances. Treatment
options are disease-dependent, and can include surgical intervention, radiation therapy, chemotherapeutics,
and select targeted therapies. While these modalities have been shown to improve life expectancy and
enhance quality of life, late onset of clinical symptoms frequently yields diagnoses resulting in incurable
advanced disease. Patients with inoperable disease depend entirely on currently available
chemotherapeutics, yet rapid resistance, miniscule therapeutic windows, excessive off-target toxicity, and
substandard pharmacokinetic properties make many of these drugs therapeutically suboptimal. Even for
patients diagnosed at early stages, undergoing chemotherapy and radiation after surgical removal of the
primary tumor commonly causes severe adverse effects related to off-target drug toxicity.
A remarkable shift occurred in the late part of the 20th century as incidences of lung cancer grew
exponentially, eventually surpassing the incidence rates of all other forms of cancer. Along with increased
prevalence, associated deaths transcend all other cancers, rendering lung cancer as the leading cause of
cancer-related death in both men and women in the United States [16, 56]. While incidence and mortality
rates have declined for men since the 1980s, women have only recently begun to see a decline is death
rates. In 2013, estimates show that lung cancer will account for approximately 14% of newly diagnosed
cancers (228,190 cases) and nearly 27% of cancer-related deaths (159,480 deaths) [56]. Compared to other
forms of cancer, lung cancer accounts for twice the deaths associated with breast cancer in women, and
three times that of prostate cancer in men [57]. Overall, recent statistics show that men have a 1 in 13
chance of developing lung cancer throughout their lifetime, while women have slightly better odds of 1 in
16 [56]; these statistics include both smokers and non-smokers. When considering the population of nonsmokers, male smokers are approximately 23 times more likely and female smokers are 13 times more
likely to get lung cancer in their lifetime [56].
Despite major advances in combatting this disease, overall 5-year survival rates for all types of
lung cancer remain at a dismal 16% [56]. While 5-year survival rates for localized disease is nearly 52%,
virtually 70% of patients present with regional or distantly advanced disease, which have 5-year survival
rates of 14% and 1%, respectively [16, 56]. For such patients, current treatment options provide a median
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survival of 10-12 months, indicating that early detection is critical for enhancing survival [16]. The
majority of cancer cases manifest in individuals >59 years of age, as the probability of developing lung
cancer increases proportionately with age. For example, the overall probability of developing lung cancer
while 40-59 years of age is 1 in 120 (0.9%), 60-69 years of age is 1 in 51 (2.1%), and >70 years of age
embodies the highest odds at 1 in 17.5 (5.7%) [58]. As with many other cancers, racial disparity is evinced
as African Americans experience higher incidence and mortality rates from lung cancer; however, recent
data suggest that this trend will diminish within the next 40-50 years as smoking cessation offerings have
increased in African American communities [59]. These statistics highlight the essential need for novel
treatment options to enhance quality of life and increase survival.
Lung cancer is considered the most preventable form of cancer, as positive correlations between
cigarette smoking and increased incidence rates have been studied extensively since the 1950s. The first
acknowledgement that lung cancer could be associated with cigarette smoking came from Sir Richard Doll
and Austin Hill in 1950 [60]. It was not until 1964 that the U.S. Surgeon General declared cigarette
smoking as the causative agent for most incidences of lung cancer, while also declaring that increased risk
of lung cancer was proportional to quantity and duration of exposure [61]. It is estimated that
approximately 80-90% of lung cancer deaths in the U.S. can be directly associated with tobacco use, while
other cases have been attributed to environmental factors (e.g. asbestos) [62, 63]. Studies have shown that
smoking duration has an essential role in estimating potential risk for developing lung cancer, as the risk
diminishes each year the person remains smoke-free. For example, a 65 year old male who quits smoking at
50-54 years old will decrease his relative risk for developing lung cancer by approximately 70% [64].
Overall, it is estimated that tobacco users who continuously smoke throughout their lifetime have 20-fold
greater odds of developing lung cancer compared to individuals who successfully abstain from smoking for
at least one year [64].
While exposure to tobacco smoke accounts for a large portion of lung cancer incidences, there are
several other risk factors for lung cancer such as passive smoking (second-hand smoke or environmental
exposure), asbestos exposure, contact with certain metals (e.g. chromium and arsenic), and radiation [56].
Previous studies showed significant synergistic interactions among risk factors for lung cancer. For
example, smokers who are exposed to asbestos or radiation have much higher odds of developing lung
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cancer than smokers not exposed to asbestos or radiation as the two risk factors are synergistic [65].
Current estimates suggest that ~10% of lung cancer cases can be linked to occupational exposure [66],
making it the most common workplace-associated cancer [67]. Other risk factors such as contact with
certain metals and radiation contribute a small number of incidences each year (<1%) [68]. It is important
to remember that only a small portion of lung cancer cases can be associated with individuals not exposed
to tobacco or other carcinogens.
There are four major types of lung cancer based upon tissue morphology, including
adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and small cell carcinoma. The first three
types have similar prognosis and treatment options, thus encompassing the non-small cell lung cancer
(NSCLC) category. Small cell carcinoma is the only form of lung cancer categorized as small cell lung
cancer (SCLC). NSCLC accounts for approximately 84% of yearly diagnosed cases, while SCLC accounts
for the remainder (15%) [56]. NSCLC is known to have a much slower growth rate and doubling time (i.e.
the time it takes a tumor to double in size) (184 days) as compared to SCLC (86.3 days), [69].
Adenocarcinoma is the most predominant form of lung cancer accounting for nearly 50% of diagnosed
cases, and is known for rapid metastases to other portions of the lung, liver, bone, adrenal glands, kidneys,
and CNS [70]. Adenocarcinomas possess vast amounts of heterogeneous tissue [71]. Currently, an
increased trend in adenocarcinoma has been seen in women and non-smokers, yet it remains most
predominant in males <50 years old and women of all ages [61, 72].
The second most common form of NSCLC is squamous cell carcinoma, which accounts for 30%
of cases diagnosed cases each year. Squamous cell carcinomas tend to involve the central airways and are
known for metastasizing late in the disease process, thus having better prognoses in comparison to
adenocarcinomas [73, 74]. Lastly, nearly 10% of diagnosed NSCLC cases are classified as large cell
carcinoma and are undifferentiated tumors with histological features atypical of other NSCLC types [73].
Small cell carcinomas account for ~15% of all incidences of lung cancer in the United States. This type is
very aggressive, often metastasizing before diagnosis (60-70% of cases) and leading to scarce treatment
options and dismal survival rates [75]. Treatment for patients with limited stage SCLC who undergo
radiation and chemotherapy have a 20-25% cure rate, yet extensive stage SCLC is incurable [76]. The
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overall 5-year survival rate is much lower for SCLC compared to NSCLC, at 6% and 18%, respectively
[56].
Early detection is critical for successful treatment, yet only ~15% of cases are localized at
diagnosis with the other 85% of diagnosed cases being regional or metastatic [77]. Overall, lung cancer is
not easy to diagnose early due to the late onset of associated symptoms, along with other factors including
concurrent respiratory problems that may mask cancer-related symptoms. The most common symptoms
associated with lung cancer include cough, dyspnea, chest pain, sputum production, and hemoptysis [73]. It
is not uncommon for physicians to overlook these symptoms in patients with histories of tobacco use, as
these symptoms are often associated with on-going chronic pulmonary and cardiovascular disease.
Advanced disease can cause other non-pulmonary symptoms such as neurological deficits, liver
dysfunction, or bone pain, and these symptoms may be difficult to diagnosis early [73].
Common methods for detecting lung cancer include chest x-rays, computed tomography (CT)
scan, and positron emission tomography (PET). Historically, studies have shown that chest radiography and
sputum cytology do not reduce lung cancer mortality in comparison to the usual care provided by primary
care physicians [78]. While integrated CT-PET has shown promise in comparison to either CT or PET
alone in staging NSCLC [79, 80], there has been renewed interest in CT screening for at-risk patients with
a 20% survival improvement over chest x-rays [81]. If needed, physicians may request further tests such as
magnetic resonance imaging (MRI), bronchoscopy, or needle biopsy [82]. Upon surgical resection,
pathological examination of tumor biopsy is performed to confirm diagnosis and determine the stage of the
disease.
Staging of NSCLC is performed using the TNM staging classification from the World Health
Organization. The classification scheme is based upon the primary tumor size and extent (T), regional
lymph node involvement (N), and presence or absence of distant metastases (M) [83, 84]. Like most other
cancers, there is a simpler four stage grouping system which states that stage I refers to tumors confined to
the lung without lymphatic spread, stage II refers to large tumors with ipsilateral peribronchial or hilar
lymph node involvement, stage III refers to the inclusion of other lymph node and regional involvement,
and stage IV refers to tumors with distant metastases [85].Staging of SCLC is performed using a two-stage
method by the Veterans Administration Lung Cancer Study Group, known simply as limited and extensive.
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In this grouping system, limited stage is defined as being confined to the primary tumor or surrounding
lymph nodes, while extensive stage is not.
Currently available treatment options include surgical intervention, radiation therapy,
chemotherapy, and select targeted therapies. Surgical resection of the tumor remains the most effective
treatment, yet is not feasible in many cases. In these circumstances, chemotherapy, radiotherapy, and
targeted therapies have been shown to increase survival rates and improve quality of life. While
chemotherapeutics can be life-saving, their toxicity can evoke adverse effects such as arthralgia, pyrexia,
rigors, hematuria, convulsions with the platinum-containing chemotherapeutic cisplatin, changes in color
vision, and unusual lethargy [86]. While adverse effects caused by these chemotherapeutics can be
debilitating, they remain in clinical use due to a lack of better alternatives.
If left untreated, most patients with NSCLC will die within one year of diagnosis. The first line
treatment for stage I and II NSCLC is surgery, either lobectomy or pneumonectomy, depending upon stage
and lymph node involvement. For those individuals who undergo surgery, 60-70% of patients with stage 1
and 40-50% of patients with stage II NSCLC will survive for at least 5 years after surgery with no sign of
recurrence [87]. Adjuvant therapy using chemotherapeutics or radiotherapy in early stage resectable
NSCLC has been debated, yet several large studies have shown benefits in survival. For example, the
International Adjuvant Lung Cancer Trial (IALT) showed a 17% improvement in disease-free survival with
a 4% increase in overall survival for patients receiving platinum-based adjuvant therapy in comparison to
patients receiving no adjuvant therapy [88].
NSCLC patients who present with advanced; non-resectable disease at the time of diagnosis
depends on chemotherapy as the first line of treatment. Chemotherapy can normally provide an extra 2-4
months of life expectancy with 10% of patients surviving 12 months [87, 89]. First line chemotherapy
treatment for NSCLC includes a doublet combination of a platinum-containing compound (cisplatin or
carboplatin) with an additional non-platinum containing compound, such as gemcitabine, paclitaxel,
docetaxel, or vinorelbine [90]. First line treatment is normally administered for 4-6 cycles in patients
benefiting from the therapy, after which second line treatment will be administered. Second line
chemotherapy for NSCLC includes docetaxel, pemetrexed, and erlotinib, yet there is no consensus
regarding the optimal second-line treatment [91]. Agents such as erlotinib and gefitinib depended upon the
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over-expression of epidermal growth factor receptor (EGFR) by lung cancer cells, by acting as tyrosine
kinase inhibitors. Both of these drugs have shown antitumor activity for patients with advanced recurrent
NSCLC, along with low toxicity and enhanced quality of life [92, 93].
SCLC is more responsive to chemotherapy and radiotherapy in comparison to other forms of lung
cancer [76]. While early stage NSCLC patients will undergo surgery for tumor resection, SCLC tumors are
rarely removed due to aggressive growth rates [94]. Combination therapy using radiotherapy with
chemotherapy has increased median survival rates for both limited and extensive SCLC by 14-20 months
and 9-11 months, respectively in comparison to chemotherapy alone [94]. Since SCLC tumors are normally
very radiosensitive, radiotherapy is used in combination with chemotherapeutics as first line treatment. As
with NSCLC, doublet administration of chemotherapeutics is superior to single drug administration. For
SCLC, there are fewer chemotherapeutics available; first line agents include cisplatin, carboplatin,
etoposide, irinotecan, and topotecan. The most common combinations are cisplatin with etoposide,
carboplatin with etoposide, cisplatin with irinotecan, and carboplatin with irinotecan [94]. Second line
treatment of SCLC includes the agents ifosfamide, paclitaxel, docetaxel, and gemcitabine, with studies
showing that patients who relapse after first line treatment have a mean survival of 4-5 months [94].
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Nanoparticles for Lung Cancer
The term “nanomedicine” refers to the use of nanoparticles, typically 10-1000 nm in size, for the
treatment of various diseases including lung cancer. Nanotherapeutics can enhance the delivery of vital
chemotherapeutics and other agents to solid tumors by passively and actively targeting tumor tissue
compared to freely circulating drug, thus increasing the drug concentration within cancerous tissue. Once in
the target vasculature, nanoparticles accumulate in the tumor tissue due to a phenomenon known as EPR
effect. In particular, in the treatment of lung cancer, nanoparticle delivery has been extensively studied
using two routes of administration, inhalation and intravenous. Inhalation minimizes potential adverse
effects as the particles are delivered mainly to the lung tissue.
The field of nanotherapeutics has grown exponentially since the mid 1900’s. While much progress
has been made, the use of nanoparticles in vivo still invokes unanswered concerns about potential toxicity
and therapeutic efficacy. Although nanoparticles may be candidates for improved cancer therapy, more
definitive studies regarding effective dose requirements and potential toxicity concerns are required.
The numerous types of nanoparticles that have been synthesized can ultimately be divided into two
categories, organic and inorganic nanoparticles.
Organic nanoparticles are those containing carbon residues such as carbon nanotubes, quantum
dots, dendrimers, liposomes, and polymeric nanoparticles, as shown in Figure 2. Inorganic nanoparticles
are particles containing no carbon residues and include magnetic nanoparticles, metallic nanoparticles,
nanoshells, and ceramic nanoparticles as seen in Figure 3. Each type of nanoparticle will be discussed in
detail illustrating their applications within the past five years in the diagnosis and treatment of lung cancer.
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Figure 2. Classification of Organic Nanoparticles. Organic nanoparticles contain carbon residues within
their structure and can be divided into five categories: carbon nanotubes, quantum dots, dendrimers,
liposomes, and polymeric nanoparticles. Carbon nanotubes contain numerous 6-carbon rings that align next
to each other and fold over to make a tube structure, capable of traversing cells without disturbing cell
membranes. Quantum dots are small nanoparticles with cadmium cores and metallic shells shown to be
effective imaging agents as they are brighter and more stable than most organic dyes. Dendrimers are
branched macromolecules that can be precisely controlled during synthesis and capable of carrying large
drug loads. Liposomes are closed spherical phospholipid bilayers that are non-toxic and biodegradable in
vivo. Polymeric nanoparticles are colloidal particles that are modified with biodegradable polymer matrices
to enhance circulation time and overall drug delivery.
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Figure 3. Classification of Inorganic Nanoparticles. Inorganic nanoparticles do not contain any carbon
residues within their structure. Inorganic nanoparticles can be divided into four groups including magnetic
nanoparticles, metallic nanoparticles, nanoshells, and ceramic nanoparticles. Magnetic nanoparticles have
an inner core, most commonly of iron oxide, with an outer of shell of silica or other ceramic molecules.
These nanoparticles can potentially be used for magnetic hyperthermia, a method of destroying tumor cells
using heat. Metallic nanoparticles are composed of a solid metal such as gold or silver. Gold nanoparticles
have been used extensively in research and can be functionalized with various targeting ligands or loaded
with drugs for therapeutic action. Nanoshells consist of two layers similar to magnetic nanoparticles. For
silica-gold nanoshells, there is outer layer of gold that surrounds a hollow silica sphere. Nanoshells are
highly tunable as the thickness of the layer of gold surrounding the silica is modified. Ceramic
nanoparticles are made from biocompatible materials such as silica or titania and exhibit enhanced
biological stability and water solubility.
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Organic Nanoparticles for Lung Cancer
Carbon nanotubes (CNTs) have been studied in several biological applications including targeted
delivery of vaccines, genes, siRNA’s, and chemotherapeutics to tumors. Research has shown that CNTs
transverse cell membranes without perturbing them, thus CNTs have the ability to delivery drugs into cells
[95-97]. CNTs are produced by rolling up one or multiple layers of graphite sheets, which align as
cylindrical tubes having diameters within the nanometer range [98]. They are noted for possessing strong
material strength, along with high electrical and thermal conductivity due to their small size and mass [99].
The large surface area to volume ratio that is exposed to the outside environment makes them optimal for
biological modification allowing for tumor-specific targeting, drug loading, and fluorescent tracking [100].
While the use of CNTs in lung cancer is feasible, many groups have shown that long-term exposure of
CNTs can cause severe toxicity. For example, it was shown that CNTs can induce malignant
transformation, tumorigenesis, and mitotic disruption of lung cells [101, 102]. Similarly, a study by
Lohcharoenkal et al. showed a positive correlation between CNT exposure and mesothelioma. This group
was further able to assess the mechanism of toxicity, which was linked to matrix metalloproteinase-2
(MMP-2), an enzyme involved in the breakdown of ECM [103].
Applications for CNTs in treating lung cancer have been explored in the last five years with
positive results. Das et al. modified CNTs with the Technitium-99m radionucletoide, an Alexa-fluor
fluorochrome, folic acid as a targeting molecule, and methotrexate as an active anticancer agent. This study
showed a 19-fold tumor specific accumulation increase of the multi-functionalized CNTs in comparison to
drug alone, proving that multi-functional nanoparticles could display better benefits in comparison to
previously designed nanoparticles [104]. To further explore the use of multiple surface modifications, Datir
et al. functionalized CNTs with hyaluronic acid and the anticancer agent doxorubicin, along with the same
radionucleotide and fluorochrome as Das et al. for use in the A549 cell line. This study showed an increase
in efficacy by 3.2-fold in comparison to drug alone with pH-specific doxorubicin release [105]. The
potential of CNTs acting as co-therapeutic agents for various chemotherapeutics was also demonstrated by
Arya et al. through the utilization of graphene oxide CNTs for potentiating the efficacy of paclitaxel [106].
Minati et al. developed multi-functional carbon nanotube/gold hybrids that encapsulated doxorubicin for
the treatment of A549 lung cancer cells. Results from this study showed that nanoparticles exhibited a large
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absorption band in the NIR-region making it an ideal imaging agent, along with enhanced cellular uptake of
doxorubicin [107]. Further studies have analyzed the use and possible toxicity associated with carbon
nanotubes in lung cancer including [108-114].
Quantum Dots (QD’s) have semiconductor properties, also known as quantum-confinement,
providing capability to emit fluorescence from the visible to near infrared wavelength [115]. Along with
fluorescence properties, their small size makes them viable candidates for diagnostic purposes as they can
remain in circulation for extended periods of time. QD’s are synthesized from two atoms from the II/VI or
III/V group of elements in the periodic table [116-119]. Some of the most widely employed quantum dots
include Cd/Se consisting of a Cd/Se core with a ZnS shell, proving a wavelength around 470-655nm [120].
QD’s can be made biocompatible with increased water solubility, core durability, and suspension
characteristics by adding various surface modifications [121]. While QD’s have the ability to function as
drug carrier molecules, their small size and quantum-confinement properties have mainly promoted their
use as imaging agents.
Currently, applications of QD’s in photodynamic therapy have shown promise as a novel
treatment method, in which light is used to increase the potency and therapeutic efficacy of the particles.
For example, it was shown that UV-B irradiation was the most effective method for increasing the
therapeutic efficacy of QD’s in A549 cell lines by amplifying both apoptotic and necrotic pathways [122].
Another group functionalized QD’s with two antibodies for the detection of micro-metastases of lung
cancer using patient blood samples, displaying the capability of detecting lung cancer using peripheral
blood. The test was shown to be reliable with a positive detection rate of 81% (21 out of 26 lung cancer
samples) and no false positives [123]. Furthermore, recent studies have demonstrated that QD’s possess
enhanced photostability and imaging capabilities as compared to traditional organic dyes. For example, the
influence of paclitaxel on endocytotic trafficking in live A549 cells was studied by labeling QD’s with
epidermal growth factor (EGF). By analyzing the endocytosis and post-endocytotic trafficking of the
EGFR, it was shown that cells treated with cisplatin have shortened endosomal trafficking pathways and a
30% decrease in directed motion [124]. Related studies have been performed on the use of QD’s for the
diagnosis of lung cancer [125-129]. Overall, QD’s have displayed promise as imaging agents for the
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detection of tumor, yet limitations such as toxicity, specificity, and sensitivity must be further evaluated
before clinical application.
Dendrimers are highly branched 3D synthetic polymeric nanoparticles that extend from a center
core from which multiple generations of monomers attach. Dendrimers can range in size from 2-20 nm, and
their synthesis must be carefully controlled to ensure the addition of one monomer layer at a time [130].
Their synthesis can be completed by two methods: (1) either growth from the inner to outer regions, also
known as divergent synthesis, (2) or from the outside inward to the core, known as convergent synthesis
[130]. Multiple branches (i.e. monomers) can be added to the core and each set of branches is known as a
generation. Dendrimers have many properties that make them suitable nanoparticles for biological purposes
including their small size that is similar to that of proteins and DNA, numerous active surface groups
capable of bio-conjugation, an interior open space that can be used for drug loading, minimal
immunogenicity, and the ability to modify their excretion from the body through size and surface charge
alterations [131-133].
Movassaghian et al. developed dendrosomes with a non-cationic liposomal shell containing an
antisense oligonucleotide that increased the suppression of the target gene, protein kinase C (PKC)-alpha in
A549 cells with high encapsulation efficiency and no visible toxicity [134]. Wang et al. further
functionalized dendrimers by synthesizing folic acid-modified dendrimer-entrapped gold nanoparticles for
use as CT imaging agents in lung cancer. These novel dendrimers showed enhanced biocompatibility with
no alterations on cell morphology or viability, demonstrating the potential use of dendrimers as imaging
agents with low toxicity [135]. Dendrimers have also been conjugated to various proteins or peptides in
hopes to increase the therapeutic efficacy of the protein or peptide. For example, after discovering a novel
NSCLC-targeting peptide known as lung cancer targeting peptide (LCTP), Liu et al. conjugated the peptide
to acetylated polyamidoamine (PAMAM) dendrimers. It was concluded that although the dendrimerpeptide conjugate was successfully targeted to the NSCLC tumors, more studies were needed for analyzing
its efficacy as a drug carrier molecule [136]. The addition of cisplatin onto dendrimers has been studied by
many groups, including Malik et al. who conjugated cisplatin through the sodium carboxylate surface of
PAMAM dendrimers. The success of this formulation was studied in B16F10 tumor mice, and further
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application of this formulation could be applied for lung cancer [137]. Additional studies using dendrimers
for studying lung cancer have been performed by [138-141].
Liposomes consist of closed spherical assemblies of amphiphilic phospholipid bilayers, capable of
encapsulating drugs or other molecules within an inner aqueous core. Liposomes are the most extensively
studied type of nanoparticle for the treatment of most cancers due to their ease of synthesis, minimal
toxicity, and biodegradability. Many groups have successfully targeted liposomes containing two common
anticancer agents used for the treatment of lung cancer, cisplatin or paclitaxel, to lung tissue [142-144]. For
example, Zhou et al. loaded paclitaxel onto liposomes with a mitochondrial targeting molecule for the
treatment of drug-resistant lung cancer. Using the A549/cDDP xenograft tumor model, targeted paclitaxel
liposomes experienced significantly enhanced uptake into the mitochondria of the lung cancer cells,
resulting in enhanced apoptosis by acting on the mitochondrial signaling pathways [145]. A similar study
by Li et al. developed lonidamine liposomes in combination with epirubicin liposomes for the con-current
treatment of drug resistant lung cancer. They showed that lonidamine liposomes in combination with an
anticancer agent can enhance the response of drug resistant lung cancer through action on the mitochondrial
signaling pathway [146]. Clinically, there are stage III trails analyzing the use of liposomal cisplatin in
combination with paclitaxel for a first line treatment of NSCLC with reduced systemic toxicity and
increased systemic drug circulation time. There were no significant differences between group (A)
liposomal cisplatin in combination with paclitaxel and (B) cisplatin in combination with paclitaxel, yet
there was significant decreased nephrotoxicity, leucopenia, neuropathy, nausea, vomiting, and fatigue
[147]. There are multiple clinical trials using liposomal forms of cisplatin for the treatment of NSCLC,
including Lipoplatin and SPI-77 [148-152].
Doxorubicin is another anticancer drug that has been successfully encapsulated using liposomes
that have shown greater efficacy in the treatment of lung cancer compared to freely circulating drug [153156]. Liposomal doxorubicin in combination with liposomal tumor necrosis factor-related apoptosisinducing ligand (TRAIL) was shown to have a stronger antitumor effect when used together, as
doxorubicin sensitizes cells to TRAIL-induced apoptosis [157]. Saad et al. designed liposomes for the codelivery of doxorubicin and siRNA targeted to suppressors of pump and non-pump cellular resistance
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mechanisms. The study revealed suppression of cellular resistance by the siRNA and increased therapeutic
efficacy due to the doxorubicin [55].
Some groups are analyzing new methods for sensitizing lung cancer cells to current
chemotherapeutics such as cisplatin. For example, Ou et al. developed a liposomal form of a novel tumor
suppressor gene, LKB1, in combination with low-dose cisplatin to decrease the number of lung metastatic
tumor nodules in vivo. The use of siRNA as a therapeutic treatment in lung cancer has recently been studied
by multiple groups [55, 158], including Taetz et al. who created cationic hyaluronic-modified liposomes for
the targeted delivery of anti-telomerase siRNA to CD44 receptor-expressing A549 lung cancer cells [159].
There are many additional groups who have used liposomes for both treatment and diagnostic purposes in
lung cancer [156, 160-164].
Polymeric Nanoparticles are colloidal particles of biodegradable polymer matrices that can range
in size from 10-1000 nm. Current uses of polymeric nanoparticles in medicine include delivery of plasmic
DNA, proteins, peptides, water-insoluble drugs, contrasts agents, and other compounds to targeted tissue.
The most commonly used polymers used in lung cancer nanotherapeutics include polylactic acid (PLA)
[165-167], poly(lactide-co-glycoside) (PLGA) [168-170], poly(ethylene glycol) (PEG) [171-176],
poly(ethyleneimine) (PEI) [177-181], chitosan [182-186], and gelatin [187-190]. Nguyen et al. developed
conjugates that coupled cell penetrating peptides (CPP) to PEI, through a PEG linker. Overall, the addition
of PEG and coupling of CPPs to PEI enhanced the bioactivity of the particles after intra-tracheal delivery
[191]. Similarly, Koshkina et al. analyzed the biodistribution of human p53 plasmid with PEI in vivo
through inhalation, which showed increased lung accumulation that lasted for at least 24 hours [192]. While
PEI functions as a gene-delivery polymer, its toxic nature makes it unsuitable for clinical applications. To
overcome toxicity, Hong et al. developed a novel biocompatible polymer, glycerol triacrylate-spermine
(GT-SPE) for the delivery of gene therapy in lung cancer. The particles possessed an average size of 121
nm with a strong anionic charge, as the particles protected the DNA from nucleases and decreased
proliferation and angiogenesis markers in a murine model [193].
Polymeric nanoparticles have been utilized for photodynamic therapy, the process in which a
photosensitizer produces singlet oxygen and other reaction oxygen species that lead to peroxidation and
ultimately to cellular death. Fadel et al. developed biodegradable copolymer PLGA nanoparticles for the
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delivery of zinc (II) phthalocyanine (ZnPc), a photosensitizer for photodynamic therapy. The PLGA
nanoparticles encapsulating ZnPc showed enhanced tumor regression as compared to freely circulating
ZnPc, demonstrating that polymers can assist in delivering nanoparticles to regions of interest [194]. Jung
et al. prepared polymeric nanoparticles using polylactic acid and an amphilic block copolymer (mPEGPLA) for the delivery of paclitaxel in A549 xenograft mice. The polymeric nanoparticles exhibited
enhanced anticancer and radiotherapeutic efficacy in vivo by intravenous injection of the paclitaxel loaded
nanoparticles [195]. The feasibility of delivering biodegradable polymeric nanoparticles via inhalation for
drug delivery was studied by Beck-Broichsitter et al. using 5-(6)-carboxyfluorescein entrapped in
biocompatible, fast degrading, branched polyester nanoparticles. The nanoparticles were delivered to an
isolated rabbit lung model, and displayed rapid release kinetics with 90% of drug being released during the
first fifty minutes along with encapsulation efficiencies ~60%. Overall, their approach showed that these
new polymeric nanoparticles were excellent candidates for the pulmonary delivery of nanomedicine
through inhalation [196]. Recently, Anselmo et al. attached PLGA nanoparticles to red blood cells (RBC)
to decrease their uptake in the liver and spleen resulting in increased tumor accumulation. While the
nanoparticles would travel throughout circulation, they would eventually mechanically transfer the
nanoparticles from the RBC surface to the lung endothelium [197].
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Inorganic Nanoparticles for Lung Cancer
Magnetic nanoparticles are biocompatible, non-toxic, chemically stable particles that vary in size
from 5-200 nm and possess magnetic properties that can be utilized for the enhancement of therapeutic
efficacy. The applications of magnetic nanoparticles in cancer therapy have included thermotherapy,
targeted delivery of drugs, magnetic cell separation, and imaging agents (e.g. MRI). The most commonly
investigated magnetic nanoparticle is comprised of an iron-oxide core, Fe3O4. While thermotherapy has
shown promise in decreasing tumor size, inadequate intra-tumoral accumulation of nanoparticles often
results in sub-lethal temperature increase and inadequate therapeutic response. To enhance the delivery of
superparamagnetic iron oxide (SPIO) nanoparticles to NSCLC in vivo tumors, Sadhuka et al. actively
targeted the nanoparticles to EGFR resulting in superior intra-tumoral particle accumulation and significant
inhibition of the lung tumor growth [198]. Concurrent delivery of multiple drugs on a single nanoparticle
provides additional benefit in comparison to single drug-loaded nanoparticles and to freely circulating drug,
as most cases of lung cancer will be treated with a regimen of two or more drugs simultaneously. Liu et al.
synthesized two types of magnetic mesoporous silica nanoparticles co-loaded with either doxorubicinpaclitaxel or doxorubicin-rapamycin. Using A549 cells, the group showed increased efficacy of the dualdrug loaded nanoparticle in comparison to single drug loaded nanoparticles [46]. To further study the
applications of magnetic nanoparticles, Guthi et al. developed multi-functional micelles that entrapped
SPIO nanoparticles containing doxorubicin for the concurrent imaging and treatment of lung cancer. The
SPIO-loaded nanoparticles were targeted using a lung cancer-targeting peptide, which resulted in a 3-fold
increase of SPIO loaded micelles in comparison to control untargeted micelles, thus showing the potential
of “smart” targeted, image-guided treatments for lung cancer [199].
The application of magnetic nanoparticles for purposes such as magnetic hyperthermia has been of
interest recently due to the non-invasive approach and efficiency of tumor ablation. The process of
magnetic hyperthermia occurs when SPIO nanoparticles are exposed to an alternating magnetic field,
causing the nanoparticles to release heat within the cell resulting in cell death. For this method to be
efficacious in practice, an adequate number of injected nanoparticles must be able to reach the malignant
cancerous cell residing within solid tumors. To overcome this problem, Sadhukha et al. synthesized
inhalable SPIO nanoparticles targeted to the EGFR, which resulted in an increase of nanoparticle
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accumulation in the tumor adequate for significant inhibition of lung tumor growth after magnetic
hyperthermia [198]. Similar studies have utilized magnetic nanoparticles for the treatment and imaging of
lung cancer [200-205].
Metallic Nanoparticles are synthesized from various metals including gold [19, 206-210], silver
[211-214], copper [215-217], palladium [218], ruthenium [219], and nickel [220-222]. These nanoparticles
have been proven to be multi-functional, as they can be utilized in numerous applications including drug
delivery and in vivo imaging, such as photoacoustic imaging. On the contrary, poor biocompatibility and
uncertain fate in vivo has hindered their use clinically [223]. Wang et al. showed that gold nanoparticles
coated with 1-stearoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) were readily uptaken into A549
cells, yet they induced the formation of lamellar bodies which could export the nanoparticles out of the cell,
thus acting as a cellular resistance mechanism [224]. In Chapter 2, England et al. analyzes the diffusion of
three types of citrate gold nanoparticles in 3D cell cultures of A549 cells. Nanoparticles with multiple
layers, including PEG, phosphatidylcholine (PC), or PC with high density lipoprotein (HDL) were
developed. From analyzing the diffusion patterns of these coated nanoparticles in 3D cell cultures, they
show that nanoparticles coated with both PC and HDL exhibited enhanced tissue penetration in comparison
to PEGylated or PC-only coated nanoparticles. While PEG is the primary polymer used for enhancing the
circulation time of nanoparticles, this study suggests that the multi-layering of gold nanoparticles may
augment transport within solid tumors [225]. Some groups have attempted to use gold nanoparticles to
diagnose lung cancer using non-invasive approaches. Recently, gold nanoparticles have been shown to be
effective sensors in diagnosing lung cancer in exhaled breath by detecting high concentrations of several
volatile organic compounds [226] and through histological classification by binding to biomarkers of
distinct lung cancer types [227].
As metallic nanoparticles have been associated with possible toxicity concerns, multiple groups
are searching for ecofriendly and nontoxic methods for synthesizing nanoparticles. As the manufacturing of
nanoparticles can pose health concerns for workers, finding better methods for creating nontoxic
nanoparticles is of particular interest. For example, Bhat et al. developed a green chemistry approach to
synthesize gold nanoparticles with the mushroom Pleurotus florida through a photo-irradiation method.
The bio-functionalized nanoparticles showed enhanced anticancer properties in A549 cells, as well as four
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other cancer cell lines [228]. Many other metals been have studied for their potential for biological
purposes, yet most have displayed toxicity in vivo. Nickel nanoparticles are of particular interest due to
their use in modern industries for purposes such as sensors and catalysts. A link between nickel
nanoparticles and reduced mitochondrial function was recently discovered. In addition, nickel nanoparticles
resulted in leakage of lactate dehydrogenase in a dose and time-dependent manner in A549 cells,
suggesting the metallic nanoparticles are toxic to human lung epithelial cells [229].
Nanoshells are synthesized using a template-mediated method with an inner core composed of
various materials including silica, polystyrene, poly (lactic-co-glycolic) acid, and Fe3O4 with outer metallic
shells. For example, silica-gold nanoshells are composed a dielectric silica core with an outer metallic shell
of gold, and have been studied extensively for applications in lung cancer [230, 231]. They are optically
tunable for specific applications, as the maximum wavelength and hydrodynamic size can be altered
chemically by altering the thickness of the outer metallic shell. Interestingly, nanoshells can be optimized
to exhibit maximum absorbance values in the NIR-spectral range, making them candidates for both multimodality imaging and photothermal therapy. The Stöber process is used to synthesize silica gold-nanoshells
through functionalization of organosilane molecules such as aminopropyltriethoxysilane (APTES) [232].
After formation of the silica cores, ultra-small gold nanoparticles with diameters ~1 nm are covalently
attached to the core creating a shell of gold around the silica core [233]. After this process, nanoshells can
be functionalized using various chemical entities such as polymers, lipids, or targeting ligands. England et
al. functionalized silica gold nanoshells with three different surface entities to compare physiochemical
characteristics and tissue diffusivity in A549 3D cell culture. By applying different surface modifications,
the size of the nanoshells ranged from 145-160 nm and the wavelength fluctuated from 820 to 860 nm,
showing their highly tunable properties [225].
Using lasers corresponding to the maximum wavelengths of these nanoparticles, photothermal
therapy can be used to excite the particles resulting in increased temperatures as the nanoparticles release
vibrational energy in the form of heat in the surrounding tissue, promoting cell death. In the process of
photothermal therapy, electromagnetic radiation from the laser is absorbed by the nanoparticles and
transformed into heat, resulting in irreversible damage to the target tissue and triggering cell death [234].
The uniqueness of this treatment is its minimal invasiveness, as laser light can travel through skin tissue
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with minimal transfer of energy. While most photothermal therapy has been used with subcutaneous
tumors, Bagley et al. recently showed the feasibility of photothermal therapy for intraperitoneal tumors by
using small implanted NIR sources, which may also have implications for lung cancer [235].
Previous studies have shown that nanoshells are more effective at photothermal therapy than other
types of theranostic nanoparticles such as gold nanorods. For example Cheng et al. showed that silica-gold
nanoshells that underwent laser activated photothermal therapy experienced an increase in temperature of
the environment by 25˚ C, while gold nanorods only exhibited a 10˚ C increase in temperature at 7 minutes
of laser irradiation (30 V cm-2). From this study, it was concluded that silica-gold nanoshells required the
lower nanoparticle accumulation in the tissue to induce cell damage, thus making them optimal candidates
for future studies [230, 236]. While photothermal therapy is currently not available for human use, some
groups have recently shown its feasibility [237]. Liu et al. used gold nanoshells with carboxylated
polystyrene spheres for photothermal therapy in Lewis lung carcinoma mice, which resulted in an average
tumor inhibition rate of over 55% in comparison to controls [231]. Clinical trials using silica-gold
nanoshells for photothermal therapy have only recently begun in cancers such as melanoma and head-andneck cancers. There is currently an ongoing clinical trial using gold nanoshells for photothermal therapy in
human head and neck cancer (Nanospectral Biosciences, Inc.) [238], and it has recently been declared that
the first clinical trial for gold nanoshells in the treatment of lung cancer will be carried out in the United
States [239].
Ceramic Nanoparticles are synthesized from ceramic chemicals such as hydroxyapatitie [240],
silica [241-244], nitrides (e.g. boron nitride) [245], and oxides (e.g. zinc, titanium, iron oxide, manganese)
[246-250]. Currently, hollow mesoporous nanospheres are of particular interest due to their high drug
loading efficiency and minimal toxicity in vivo. Drugs such as bortezomib, the first clinically approved
proteasome inhibitor, experienced limited efficacy due to its poor water-solubility and stability. Using
hollow mesoporous silica nanospheres containing bortezomib, Shen et al. showed improved anti-tumor
efficacy in comparison to drug alone in an NSCLC cell line with a 42% decrease in IC50 from the
bortezomib- loaded nanoparticles [242]. Other groups have also shown effective drug loading capabilities,
including Huang et al. who demonstrated the potential use of mesoporous nanoparticles are imaging agents
for MRI and pH-controlled drug release [243]. Ashokan et al. also studied the applications of ceramic
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nanoparticles for imaging purposes (MRI, X-ray, NIR fluorescence) by using hydroxyapatite nanocrystals,
which exhibited selective accumulation in cancer cells through targeting of the folate receptor [240].
EGFR targeting has been of great interest due to its overexpression in most cancer cell lines [251253]. Sundarraj et al. recently targeted mesoporous silica nanoparticles to EGFR overexpressing NSCLC
cells, with an anticancer agent pryyolidine-2. Using EGFR as the targeting agents, the nanoparticles
showed enhanced accumulation in the NSCLC cells with enhanced therapeutic efficacy [254]. Some types
of nanoparticles can be combined with the goal of enhancing their therapeutic efficacy in vivo, such as
polymeric micelles and mesoporous silica nanoparticles. For example, Yuan et al. studied cellular uptake
and cytotoxicity of doxorubicin-loaded stearic acid-g-chitosan nanoparticles in A549 cells demonstrating
faster cellular uptake with increased silica ratio [255]. Despite the advantages of ceramic nanoparticles in
drug delivery and cancer therapy, questions have been raised about the potential toxic effects. Another type
of ceramic nanoparticle, titanium dioxide, has been shown to induce genotoxicity and apoptosis in A549
cells [256, 257]. To explore the potential toxicity of silica nanoparticles, Ahamed investigated the induction
of cytotoxicity, oxidative stress, and apoptosis caused by silica gold nanoparticles in NSCLC, showing a
dose-dependent cytotoxicity in A549 cells, along with induction of oxidative stress in a dose-dependent
manner [244].
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Nanotoxicology
Administration of nanoparticles to the lungs can be accomplished through systemic circulation
(e.g. intravenous injection) or pulmonary inhalation. Systemic circulation can result in systemic toxicity as
the nanoparticles distribute within other tissues and organ systems, while inhalation provides a direct route
to the lungs [258]. Both intentional administration of nanoparticles for medicinal purposes and
occupational exposure as a result of inhaling aerosols released during the production process of various
nano-materials can result in toxicity. As there are no universal parameter sets required for synthesis and
study of nanoparticles, it is difficult to directly compare the associated toxicity of nanoparticles. Recent
reports suggests that certain characterization processes should be completed for each type of nanoparticle
synthesized, including information regarding size distribution, shape, composition, agglomeration status,
dissolution, purity, surface area, and surface modifications [259]. If each type of nanoparticle synthesized
were characterized by a set of standards, direct comparisons of toxicity could be made providing enhanced
insight into treatments for nanoparticle overdose and accidental exposure.
Numerous studies have analyzed the toxicities associated with both systemically distributed and
inhalable nanoparticle therapies [260-266]. Park et al. studied the toxicity of various inhalable metallic
nanoparticles (i.e. titanium oxide, gold, alumina, zinc, and nickel) by analyzing the apoptotic and
morphological damages caused by the nanoparticles in A549 cells. They showed a dose-dependent toxicity
with zinc nanoparticles having the most apoptotic effect and titanium oxide nanoparticles exhibiting the
most morphological damage [267]. Another study further analyzed the toxic effects of metallic oxide
nanoparticles in comparison to multi-walled carbon nanotubes (MWCNT). Results from this study showed
that copper oxide nanoparticles displayed the most toxicity regarding cytotoxicity and DNA damage. In the
study, zinc oxide nanoparticles showed significant adverse effects on cell viability, yet iron oxide
nanoparticles showed minimal toxicity [268].
Nanoparticles delivered via inhalation will distribute throughout the airways with size-dependent
deposition patterns, with particles <10 nm depositing primarily in the tracheobronchial regions, particles
20-30 nm depositing in the alveolar regions, and particles 30-100 nm depositing within all regions of the
lung [269]. Currently, there is a lack of research analyzing the potential toxic effects of nanoparticles in
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human lungs, although some groups have studied the deposition patterns of inhaled nanoparticles using
computational models [270-272].
The most common toxicity associated with the use of inhaled nanoparticles in vivo is pulmonary
fibrosis, or an increased amount of collagen within the lung tissue. Currently, carbon nanotubes have been
the most common nanoparticle studied in reference to potential toxicity. Mitchell et al. analyzed the
toxicity of inhaled MWCNT, showing that they did not result in significant lung inflammation or tissue
damage after 7 days (6 hour exposure/day), yet higher concentrations of the MWCNTs did cause nonmonotonic system immunosuppression after 14 days, which was primarily characterized by a reduction in
T-cell dependent antibody as well as T-cell proliferation [273]. Other studies have identified nanoparticles
as potential toxic entities through in vitro cytotoxicity testing. For example, Vandebriel and De Jong
recently summarized the mammalian cellular toxicity of zinc oxide nanoparticles by showing that their
primary toxicity was due to low solubility of nanoparticles and the decreased contractility of airway smooth
muscle in the lungs. Other common toxicities were also evaluated including cytotoxicity, oxidative stress,
intracellular calcium flux, decreased mitochondrial membrane potential, and numerous immune reactions
[274].
While all nanoparticles exhibit some degree of toxicity in a dose-dependent manner, metallic
nanoparticles have shown increased risk as their structure is prone to agglomeration. As more people are
exposed to metallic nanoparticles in industrial plants, there is a growing concern about the potential
systemic toxicities associated with chronic exposure to metallic nanoparticles. Yu et al. studied the effects
of metallic nanoparticles in vivo, where rats were treated with 2×106 nanoparticles per cm3 by inhalation for
6 hours per day for 15 days. Exposure for five days resulted in accumulation of gold within the lungs and
by day 15, nanoparticles were detected in the esophagus, tongue, kidneys, aorta, spleen, heart, and blood.
There was also down-regulation of genes related to muscle function in the lungs, displaying potential lung
toxicity [275]. The location of nanoparticle accumulation in vivo can directly correlate with toxicity, as
certain organs, such as the liver and spleen, will accumulate more nanoparticles than other organ systems.
Toxicity testing focuses on these particular sites [276]. Additional studies have been performed analyzing
possible links between nanoparticle size and toxicity. For example, Chen et al. showed that gold
nanoparticles ranging in size from 8-37 nm caused severe sickness in mice that received repeated

32

intraparental injections [277]. Ferin et al. studied the retention of ultrafine nanoparticles inhaled by rats
exposed for 12 weeks resulting in acute inflammatory response in the lungs [278]. In addition, Geys et al.
studied the dose-dependent toxicity of nanoparticles using carboxyl-coated quantum dots that caused
vascular thrombosis [279].
Overall, several factors must be considered when analyzing the toxicity of nanoparticles. First,
while nanoparticles may display toxicity in cell lines (i.e. in vitro), one should recognize that toxicity in
vitro does not always correlate with toxicity in vivo as the animal model is more complex than cell cultures.
For example, while fullerenes were highly toxic in vitro, the in vivo finding showed no adverse effects in
the lung tissue at 3 months post-exposure to the highest concentration of fullerenes available [280]. In
another study, Sayes et al. tested five different nanoparticles for toxicities including carbonyl iron,
crystalline silica, amorphous silica, and zinc oxide nanoparticles. It was demonstrated that toxicity between
in vitro and in vivo should not be correlated without experimental results, as nanoparticles showing toxicity
in vitro did not show toxicity in vivo and vice versa [281]. Another factor that can influence the toxicity
profile of nanoparticles is surface modifications. Even simple surface alterations or modifications can result
in significant changes in toxicity. This supports the need for a set of characterization standards by which
nanoparticles can be assessed. In conclusion, the toxicity of nanoparticles is highly dependent upon the type
of particle being employed and should not be estimated based upon in vitro results alone. While in vitro
toxicity may indicate the potential for in vivo toxicity, little correlation has been established between cell
culture and animal models. Additional studies are needed to determine the possible toxicities associated
with nanoparticle usage and to determine optimal treatment strategies.
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Hypotheses and Aims
Nanotherapeutics provide an alternative method for delivering chemotherapeutics to solid
tumors, yet the transport of nanoparticles in vivo is not fully understood. After systemic injection of
nanoparticles, a large portion of injected dose will become sequestered by macrophages of the liver and
spleen resulting in a diminished treatment. Once nanoparticles localize the tumor, they must extravasate
from the irregular vasculature and diffuse throughout the tissue reaching all malignant cells. Currently,
there is little research regarding the movement of nanoparticles throughout tumor tissue.
We will examine the potential use of two and three layer gold nanoparticles for treating cancerous
solid tumors by investigating their diffusivity properties, drug loading and release capabilities, and their
efficiency at causing cell death. We hypothesize that smaller nanoparticles with enhanced diffusivity
properties, such as colloidal gold nanoparticles, will be more efficacious in the treatment of solid tumors.

Aim 1: Design two and three layer gold nanoparticles and examine the diffusivity of these particles in 3D
cell cultures. Hypothesis: Two and three layer gold nanoparticles will diffuse further than previously
developed PEGylated nanoparticles because the physiochemical properties of the layered nanoparticles.
a)

Synthesize two and three layer colloidal gold nanoparticles and silica gold nanoshells and
characterize particles to ensure presence of surface moieties.

b) Determine the accumulation of nanoparticles in 3D cell cultures of human lung, pancreas, and
liver cell lines.
c)

Compare the diffusivity of two and three layer nanoparticles to the diffusivity of previously
developed PEGylated nanoparticles in 3D cell cultures.

Aim 2: Examine the biodistribution and diffusivity of PC-coated two layer citrate gold nanoparticles and
silica gold nanoshells in vivo. Hypothesis: We hypothesize that size-dependent localization of nanoparticles
will occur, with smaller citrate gold nanoparticles accumulating at higher concentrations and diffusing
further from vasculature in the orthotopic pancreatic tumor in comparison to the larger silica gold
nanoshells, as they have been shown to be hindered due to their large size.
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a)

Compare the accumulation of two layer colloidal gold nanoparticles and silica gold nanoshells in
the liver, spleen, and pancreatic tumor.

b) Analyze the diffusivity of two layer citrate gold nanoparticles and silica gold nanoshells from
nearest extravasation sites in liver, spleen, and pancreatic tumor sections.

Aim 3: Analyze the drug loading capabilities and release kinetics of two and three layer colloidal gold
nanoparticles. Hypothesis: We hypothesize the hydrophobic region between the first and second layer of the
nanoparticles is optimal for loading of hydrophobic compounds, including paclitaxel. For this reason, the
loading efficiency of paclitaxel will be high with a controlled release pattern.
a)

Synthesize two and three layer colloidal gold nanoparticles loaded with cisplatin or paclitaxel.

b) Determine the loading efficiency of paclitaxel and cisplatin onto each type of particle.
c)

Analyze the drug release patterns to determine the best model to describe the release of drug from
each type of nanoparticle.

Aim 4: Compare the efficacy of two and three layer nanoparticles loaded with cisplatin or paclitaxel to free
drug using 3D cell culture models of lung cancer. Hypothesis: We hypothesize that drug loaded
nanoparticles will show similar efficacy at causing cell death as free drug because layered nanoparticles
release drug while diffusing throughout tissue.
a)

Examine the efficacy of free cisplatin and paclitaxel in monolayer cell cultures.

b) Compare the drug dosages required for cell death in monolayer cell cultures and 3D cell cultures.
c)

Analyze the efficacy of cisplatin or paclitaxel-loaded two and three layer nanoparticles in 3D cell
cultures.
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CHAPTER II
ENHANCED PENETRATION INTO 3D CELL CULTURES USING TWO- AND THREE LAYERED
NANOPARTICLES

Background
Microenvironment of Solid Tumors
In addition to excessive cellular proliferation, solid tumors typically elicit irregular angiogenesis
resulting in structurally abnormal and leaky vascular structures. The passive mechanism of nanoparticle
accumulation (EPR effect) takes advantage of this situation by enabling systemically administered
nanoparticles sized 10–400 nm to preferentially extravasate from the vasculature into the interstitial space
of solid tumors [282, 283]. Additional factors contributing to nanoparticle pharmacodynamics and
cytotoxicity include size, surface charge and morphology [284, 285]. These properties are typically tailored
to design systems that exhibit optimal tumor tissue uptake. Drugs delivered via nanoparticles can thus
increase treatment effectiveness while reducing systemic toxicity.
In particular, gold nanoparticles have shown promise in cancer treatment. Bulk gold itself is an
inert material, though nanoparticles smaller than 5nm in diameter have documented cytotoxic properties
[286, 287]. Larger particles have demonstrated little cytotoxicity, depending on the surface charge. Cationic
particles can be more cytotoxic at lower concentrations compared to anionic nanoparticles, which has been
attributed to electrostatic interactions of the positively-charged particles with negatively-charged cell
membranes [288]. Surface coatings of poly-(ethylene glycol) (PEG) can effectively hide the nanoparticles
from the immune system, further lowering systemic toxicity [284, 287].
However, heterogeneity in blood flow due to irregular angiogenesis and vascular remodeling at the
tumor site promote tissue hypoxia and thus cell quiescence, presenting a physical barrier to cell-cycle
dependent chemotherapeutics delivered by nanocarriers [289-291]. Inadequate vascularization leads to
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further impediments that hinder optimal treatment, including insufficient drug dosages due to abnormally
long inter-vascular diffusion distances, as well as disturbed convection and diffusion of molecules (such as
glucose, oxygen) and nanoparticles in the interstitium [289, 292-294], as has recently been explored
through intravital microscopy and mathematical modeling [292, 295]. Cancerous tissue can contain almost
twice the volume of interstitial space compared to normal tissue [289, 294]; an abundance of ECM proteins
along with an increased interstitial pressure may further inhibit nanoparticle delivery and drug diffusion in
under-vascularized tumor regions [289, 294, 296]. These physical barriers, coupled with intrinsic resistance
mechanisms at the cell-scale, often cause cancer drug therapies to fail. Recently, engineering and physicsbased approaches are being applied to help tackle these challenges in cancer treatment [297].
Estimates of nanoparticle distribution in 3D tissue have been previously obtained in collagen gels
[298] as well as in 3D cell culture [24, 299]. Gold nanoparticle accumulation was shown to be size
dependent, suggesting that particles ~20 nm or smaller had superior penetration abilities compared to larger
particles [299]. For example, particles < 10 nm were able to better penetrate breast cancer tumor spheroids
representing avascular tumor tissue than larger particles, which has also been confirmed in vivo [24]. It has
been shown that while larger polymeric micelles distribute within hypervascularized tumors, only sub-100
nm particles were able to meaningfully penetrate hypoxic tumors [300]. However, smaller particles (< 50
nm) are not as useful for drug delivery compared to larger nanoparticles, since they are typically unaffected
by the EPR effect and are thus less targeted [24]. Previous studies have shown cellular uptake of both
smaller citrate gold nanoparticles and larger silica gold nanoshells, with enhanced cellular uptake of the
smaller particles [301-303].
Purpose of Study
In this study we examine the uptake of functionalized silica gold nanoshells into a 3D cell culture
(spheroid) model as a first step to represent avascular liver, lung, and pancreatic tumor tissue. In addition to
the nanoshells, citrate-gold nanoparticles were investigated for comparison. Cells aggregate in 3D culture
to create avascular nodules with the production of ECM components and the establishment of diffusion
gradients of oxygen, glucose, and nanoparticles [290]. Experiments with 3D cell cultures have previously
helped to analyze the effect of under-vascularization on particle and drug delivery [299, 304]. Here, particle
surfaces were functionalized by a process consisting of either two- or three-layers to optimize uptake into
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tumor tissue. Two-layer particles were synthesized with an inner layer of alkanethiol and an outer layer of
PC, a type of phospholipid that is a major component of biological membranes [305]. In order to further
optimize tumor uptake, active targeting was promoted by adding a layer of HDL, since the HDL receptor is
mainly expressed by liver and cancer cells, thus creating a three-layered particle. Size, zeta potential, and
morphology were optimized, and the uptake and distribution were compared to the performance of
PEGylated nanoparticles.
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Methods
Synthesis of Citrate Gold Nanoparticles
Particles were synthesized using the method in which gold chloroauric acid is reduced by
trisodium citrate [306]. In this process, 2.2-2.4 mL 1% wt/v citrate (Fischer Scientific) and 200 mL 0.01%
wt/v HAuCl4 (Alfa Aesar, MA) are mixed and heated to boiling, which promotes the reaction of sodium
citrate to citric acid. Once the reaction is completed, the solution is concentrated using a rotovapor (Buchi
Rotovapor System) to ~20 mL before the addition of layering to the particles.
Synthesis of Silica Gold Nanoshells
Particles have an inner core composed of silica with an outer coating of gold. Synthesis follows
the Stöber method [232, 307, 308], which consists of four stages: production of small gold seeds,
fabrication of monodispersed silica cores, attachment of gold to the seeds, and gold shell growth. The gold
colloid solution is created using the recipe from Duff et al [309]. Growth of the silica cores requires the
combination of 7.5 mL tetraethyl-orthosilicate (Sigma Aldrich), 225 mL absolute ethanol (Decon Labs),
and 12.5-13.5 mL ammonia (Sigma Aldrich) [310]. Ammonia is adjusted to achieve silica core sizes 110
+/-5 nm. After removal of the paraffin cover and evaporation of the ammonia, the cores are coated with 34% aminopropyltriethoxysilane (APTES) (Sigma Aldrich). Once the seeds are washed, the 10% gold
solution (THPC) is added. After reaction time, the seeds are washed and redispered in DI water. The seeds
are diluted to 0.3-0.5 OD (optical density) at 530 nm (Varian Cary 50Bio UV-Visible Spectrometer). A
sweep of the seeds is performed to optimize the chemical ratio between them, K 2CO3-HAuCl4, and
formaldehyde (Fisher Scientific).
Particle Functionalization
The first layer applied to the citrate gold particles was Hexadecathiol (Sigma Aldrich) dissolved in
ethanol [311]. While stirring, 20 mL pure ethanol (Decon Labs) was placed in a breaker with 60 μL 1Hexadecathiol being added secondly. The nanoparticles were added to the sample slowly over the next few
minutes. The sample was first agitated for 20 minutes, then placed for 12 hours on an orbital rocker
(Boekel Scientific). The sample was spun down and the pellet was washed twice and resuspended in
chloroform (Sigma Aldrich). The second functionalization was the addition of the PC. The stock solution
was made by diluting PC in chloroform, and 100 μL were added to the particles after the thiol layer and
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allowed to set overnight on an orbital rocker. The solutions were transferred to glass tubes and the
chloroform evaporated at ambient temperature. This process completed the two-layered particles, referred
to as CAU/TL/PC (citrate gold/thiol/phosphatidylcholine) and NS/TL/PC
(nanoshell/thiol/phosphatidylcholine). The three-layered particles, referred to as CAU/TL/PC/LP and
NS/TL/PC/LP, were created by optimizing the ratio of high-density-lipoprotein (HDL) to nanoparticle
optical density, and allowed to react overnight.
PEGylation is considered a common form of surface modification for delivering nanoparticles into
cancerous tissue, thus we created PEGylated nanoparticles (C AU/PEG, citrate gold/pegylated, and NS/PEG,
gold nanoshell/pegylated) to compare the efficacy of the synthesized two- and three layer nanoparticles. To
prepare PEGylated nanoparticles, 2000 MW PEG was added at a molar ratio of 2500:1. The solution was
allowed to react overnight on the rocker. Excess PEG was removed by centrifuging the particles at 13,000G
for 20 minutes. The pellet was resuspended in PBS. It is well documented that pegylated particles will stay
in circulation longer than non-pegylated particles [312]. To create the pegylated particles, both citrate gold
nanoparticles and silica gold nanoshells were incubated with 2000 MW poly(ethylene)glycol overnight and
then centrifuged to separate the particles.
Particle Characterization
Nanoparticle identity was verified as follows. (i) Maximum absorption wavelengths were
obtained using the Varian Cary 50 Bio UV-Visible Spectrometer. (ii) Size and zeta potential measurements
were obtained using the ZetaSizer Nanoseries ZS90 (Malvera Instruments). (iii) Shape and size were
determined using a Zeiss Supra 35VP scanning electron microscope (SEM). (iv) Presence of lipids on the
particle cores was confirmed using a Fourier transform infrared (FTIR) instrument (Perkin Elmer Spectrum
BX) and through visual analysis using the SEM.
Cell Culture and Particle Experiments
Human lung adenocarcinoma (A-549) and liver hepatocellular carcinoma (HEPG2) cells were
maintained in Dulbecco’s modified Eagle’s medium (Sigma) with 10% fetal bovine serum and 1%
penicillin-streptomycin-glutamine solution in a humidified atmosphere of 5% CO2 at 37˚C. Pancreatic
adenocarcinoma (S2VP10) cells were maintained with RPMI 1640 medium (Cellgro) in similar conditions.
All cells were grown to 80% confluence before 3D cell culture formation. Using 24 well ultra-low
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attachment plates (Corning), 100K cells were placed in each well and lightly shaken for ~15 min. Tumor
spheroid formation occurred by self-aggregation after 7-14 days of incubation. Spheroids typically
measured between 0.5 and 2 mm in diameter, though the S2VP10 cells produced smaller, grape-like
structures. Spheroids were incubated with 40 μL particles at 25 OD for 6 hours before being washed with
PBS.
3D Cell cultures were placed in cryomolds made of tissue freezing medium. Samples were
allowed to set for two hours, and then sectioned at 5µm using a Leica CM1860 Cryostat. Sectioned
spheroids were then fixed onto Superfrost Plus microscope slides (Fisher Scientific). Successful fixation
was determined via bright-field microscopy. Excess media was removed by soaking with 30% Neutral
Buffered Formalin for 1 min. Slides were washed in DI water prior to analysis. All experiments were done
in triplicate.
Silver Enhancement Stain
Slides were placed in cold acetone (Fischer Scientific) for 30 sec., then allowed to dry for 1 min.
Slides were placed in 10% formalin buffer (Sigma Aldrich) for 3 min., then washed 2x with DI water and
allowed to dry for 5 min. The silver enhancement solution was prepared by mixing 1 mL/slide Silver
Enhancement Stain A along with 1 mL/slide Silver Enhancement Stain B (Sigma Aldrich). The two
solutions were mixed in a 50 mL tube and vortexed for 10-15 sec. The combined solution (2 mL) was
added to each slide and allowed to react for 6 min. After the reaction time, the solution was washed off 2x
using DI water. Slides were analyzed using NIS Elements AR and an Accuscope 3032 inverted light
microscope. ROI intensity measurements were recorded for both stained and unstained samples.
Particle Detection using Hyperspectral Imaging
The CytoViva Hyperspectral Imaging System was used to located nanoparticles within sections of
3D cell cultures. A DAGE camera with the dark field microscope was used to obtain images highlighting
the nanoparticles. Particle presence was confirmed using hyperspectral imaging, with data analysis
performed using ENVI 4.8 and ImageJ. Using the software, linear [0-255] enhancement was applied and
the z-profile library was used to detect single nanoparticles within 3D cell cultures. Regions of interest
(ROIs) were determined and particles within these regions were counted to determine concentration in
various tumor areas. The number of particles decreased from the periphery towards the center; accordingly,
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measurements from 10 to 50 µm from the tumor periphery were taken to determine spatial distribution of
particles into the tumor spheroids.
Statistical Analysis
Analyses used the two-tailed Student’s t test with significant values being less than 0.05.
Statistically significant differences are illustrated with an (*) in the Results.
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Results
Nanoparticle Characterization
Silica gold nanoshell and citrate gold particles were layered with either two- or three- layers
(Figure 4) to promote enhanced penetration into 3D cell cultures of various cancer cell lines, while
comparing their penetration and diffusion capabilities to previously designed PEGylated nanoparticles.
Nanoparticles were characterized with UV-Visible (UV-Vis) absorbance spectroscopy, zeta potential
analysis, dynamic light scattering (DLS), SEM, and FTIR to ensure proper particle formation and
modification.

Figure 4. Illustration of Functionalized Gold Nanoshells. Six types of nanoparticles were developed
including citrate gold particles and silica gold nanoshells. Particles were modified to form PEGylated, two
layer, and three layer particles.
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Optical and charge measurements (Figure 5) indicated that the surface modifications were
successful. Prepared citrate-gold nanoparticles (Figure 5A) had a peak absorbance between 533-541 nm
(Table 1), which is consistent with previous work [313]. Silica-gold nanoshells (Figure 5B) exhibited peak
absorbance between 820-860 nm (Table 1), which is typical for nanoshells having 110 nm diameter silica
cores and a ~15 nm gold coating [314]. The spectra displayed minute amounts of noise at higher
wavelengths, which is expected for silica gold nanoshells [315]. Nanoshells demonstrated ideal optical
properties for near-infrared (NIR) application [316, 317], though such experiments were not included in the
scope of this work.

Figure 5. Characterization of Gold Nanoparticles by UV-Visible Spectrometry and Zeta Potential Analysis.
Wavelengths for each particle are presented with PEGylated particles (dotted line), two layer (dashed and
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dotted line), and three layer (dashed line). (A) Spectrum of citrate gold nanoparticles indicates a maximum
absorption ranging from ~533-541 nm. (B) Spectrum of silica gold nanoshells suggests a maximum
absorption at ~820-860 nm. For verification of surface modifications, zeta potential analysis is shown
below the spectra as an indication of surface charge. (C) PEGylated citrate gold nanoparticles had a zeta
potential of -9 mV, two layer citrate gold nanoparticles had -20 mV, and three layer citrate gold
nanoparticles had -2 mV. (D) A zeta potential of -18 mV was found for PEGylated silica gold nanoshells,
for two layer silica gold nanoshells it was -29 mV, and for three layer nanoshells it was -6.8 mV.

Table 1
Determination of Nanoparticle Size and Wavelength

Nanoparticle Penetration in 3D Cell Cultures
In order to verify particle surface modifications, the zeta potential was measured (Figure 5C).
Modification with PC and thiol resulted in more highly negatively charged particles compared to
PEGylated particles. Conversely, HDL caused the zeta potential to become more positively charged when
compared to PEGylated particles, but still yields slightly negatively charged particles. PEGylated citrate
gold nanoparticles exhibited a zeta potential of -9 mV, while the two-layer citrate gold nanoparticles had a
zeta potential of -20 mV and the three-layer citrate gold nanoparticles had -2 mV. Gold nanoshells
generally exhibited higher surface charge than citrate gold nanoparticles, which is consistent with the larger
size of the nanoshells. PEGylated nanoshells had a zeta potential of -18 mV, two-layer nanoshells
measured a zeta potential of -29 mV, and three-layer nanoshells had a zeta potential of -6.8 mV. These
results were in agreement with previous studies [318-320].
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To ensure the presence of surface modifications, FTIR was performed (Figure 6). PEGylated
nanoparticles exhibited C-O-C stretch of the PEG ether ~1050 cm-1 and vibration ~1350 cm-1, along with CH2 and –CH3 bending vibrations around ~1450 cm-1. This stretch is smaller than previously reported
[321], possibly due to the addition of PEG onto the silica-core nanoshells. Two layer nanoparticles with an
outer layer of PC exhibited PO43- group vibrations between ~820-1000 cm-1, C-O-C stretch ~1100 cm-1,
with the largest band corresponding to the asymmetric and symmetric -CH2 (2880 cm-1) and -CH3 (2950
cm-1) stretch and vibration, respectively. For HDL coated nanoparticles, the asymmetric and symmetric CH2 (2880 cm-1) and -CH3 (2950 cm-1) stretch and vibration are still shown along with C=O from the lipid
ester ~1750 cm-1, amide bonds between 1600-1700 cm-1, and a phospholipid P=O2 stretch ~1250 cm-1. The
two- and three layer exhibited overlap in their spectra due to the layering process of the surface
modifications.

Figure 6. Determination of Surface Functionalizing using FTIR. From bottom to top: PEGylation, two
layer containing dodecathiol and PC, and three layer containing dodecathiol, PC and HDL. PEGylated
nanoparticles exhibited C-O-C stretch of the PEG ether ~1050 cm-1 and vibration ~1350 cm-1, along with CH2 and –CH3 bending vibrations around ~1450 cm-1. Two Layer nanoparticles with an outer layer of PC
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exhibited PO43- group vibrations between ~820-1000 cm-1, C-O-C stretch ~1100 cm-1, with the largest band
corresponding to the asymmetric and symmetric -CH2 (2880 cm-1) and -CH3 (2950 cm-1) stretch and
vibration, respectively. For HDL coated nanoparticles, the asymmetric and symmetric -CH2 (2880 cm-1)
and -CH3 (2950 cm-1) stretch and vibration are still shown along with C=O from the lipid ester ~1750 cm-1,
amide bonds between 1600-1700 cm-1, and a phospholipid P=O2 stretch ~1250 cm-1

SEM was used to determine particle size and morphology (Figure 7). Nanoparticle shape has been
demonstrated to influence particle uptake into tissues [287]. Gold nanoshells, and for the most part citrategold nanoparticles, were spherical, which is desirable to produce optimal optical properties for potential
NIR treatments. PEGylated gold nanoshells had spherical morphology and were ~150-170 nm in diameter.
The influence of hydrodynamic size plays a large role in how nanoparticles will act in vivo. DLS values
were determined for each type of particle with varying sizes similar to those depicted by SEM (Table 1). To
ensure decreased aggregation before DLS analysis, particles were sonicated and mixed thoroughly.

Figure 7. Scanning Electron Images of Functionalized Gold Nanoparticles. Silica gold nanoshells exhibit a
particle size ~150-170 nm in diameter. Citrate gold nanoparticles with an average diameter of ~50 nm were
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much smaller than nanoshells, and appeared to form polydispersed clusters, with the two- and three-layer
citrate gold particles being approximately the same size.

Citrate gold nanoparticles were much smaller than nanoshells (Figure 7), measuring ~50 nm in
diameter. Aggregation was more prevalent with citrate gold nanoparticles, as evidenced by the PEGylated
particles (Figure 7). This aggregation is due to the decreased zeta potential of citrate gold nanoparticles
when compared to the gold nanoshells. Addition of hexadecanethiol and PC is estimated to add ~5-7 nm to
the diameter of the gold nanoparticles due to the size of PC (~2.5-3 nm and –thiol ~2.5 nm)[322, 323],
while HDL is estimated to add ~10 nm due to the size of this molecule [324].
Nanoparticle Penetration in 3D Cell Cultures
In order to determine particle penetration and distribution into 3D cell cultures, region of interest
(ROI) measurements were taken at the periphery and center of the spheroid sections using silver
enhancement staining (Figure 8). This staining is commonly used for nanoparticle detection. We also
evaluated the samples using hyperspectral imaging with dark field microscopy. Results (ROI intensity)
were measured between unstained and stained samples. Differences between the samples were extracted in
order to obtain particle accumulation in the 3D cell cultures.
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Figure 8. Nanoparticle Detection in 3D Cell Cultures through Silver Staining. ROI intensities were
measured for both unstained and stained tissue sections; darker regions denote an increase in ROI intensity.
Top: 20X image of A549 3D cell culture (A) before and (B) after silver staining. Bottom: 20X image of
HEPG2 3D cell culture (C) before and (D) after silver staining.

For all three cell lines, the two- and three layer silica gold nanoshells staining exhibited higher
ROI intensity values than the PEGylated counterpart (Figure 9). For the HEPG2 cells, the two layer
nanoshells presented ROI intensity values that were statistically the same between periphery and interior,
indicating uniform distribution into the tissue. This particle type had an ROI intensity nearly 2x that of the
three layer and 3x that of the PEGylated particles (Figure 9A). The two layer citrate gold particles had a
peripheral ROI intensity that was almost 2x that of the interior, indicating a steep diffusion gradient into the
3D cell culture. In contrast, the three layer citrate gold particles exhibited similar intensities between
periphery and interior at lower values than the silica gold nanoshells, suggesting uniform yet poorer
penetration. The PEGylated particles had higher ROI intensity at the periphery than the interior while
showing the lowest particle uptake. It should be noted that ROI intensity differences for the HEPG2 cell
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line were higher than both the A549 and S2VP10 cell lines, suggesting an increased amount of particles
present in the HEPG2 tumors regardless of particle type.

Figure 9. Accumulation of Gold Nanoparticles in 3D Cell Cultures by Silver Enhancement. ROI intensity
measurements were taken at the periphery (black bars) and in center regions (grey bars) of HEPG2 (liver),
A549 (non-small cell lung cancer), and S2VP10 (pancreatic) 3D cell cultures. Exposure to the various types
of silica gold nanoshells and citrate gold nanoparticles generally exhibited equal or increased amounts of
particles on the spheroid periphery as compared to the interior. All error bars represent standard deviation
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from at least n=3 measurements; asterisk indicates statistically significant difference (p<0.05) determined
by Student’s t-test with α=0.05.

The ROI intensities for the A549 cell line indicated an increased accumulation of two layer
compared to PEGylated silica gold nanoshells (Figure 9B). The two layer particle had higher penetration
but with more of a differential between periphery and tumor interior compared to the three layer case. The
three layer citrate gold particle exhibited higher ROI and more uniform values compared to the other citrate
gold cases.
The S2VP10 cell line presented ~2x the ROI intensity values at the periphery for both two- and
three-layer silica gold nanoshells compared to the PEGylated case (Figure 9C), although the three-layer had
~50% higher values than the two-layer in the interior. Both two- and three-layer silica nanoshell and citrate
gold particles had significantly higher ROI in the interior than the PEGylated particles, indicating increased
particle penetration. The two- and three layer citrate gold particles presented similar ROI intensity values
between periphery and interior compared to the PEGylated case, suggesting a more uniform particle
distribution.
Modified particles within the sectioned tumor spheroids were observable in the images captured
via dark-field microscopy. The particles reflected the light, displaying sharp contrast with the surrounding
tissue, and could be numerically calculated. A representative image is displayed in Figure 10, and arrows
pointing to the small red-orange dots indicate the position of sample particles within the tissue. To ensure
that the particles could be distinguished from the tissue, hyperspectral mapping was used to filter out the
tissue while leaving nanoparticles [325]. Spectral libraries, as shown in Figure 11, were used to locate
nanoparticles within the 3D cell culture. Individual nanoparticles were identified and accumulation within
various spheroid regions was calculated.
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Figure 10. Detection of Nanoparticles in 3D Cell Cultures using Dark Field Microscopy. Nanoparticle
uptake was determined using the CytoViva setup with a dark field microscope to visualize the
nanoparticles, and with hyperspectral imaging to confirm particle identity. (A) 60× image showing
increased particle concentration around periphery of HEPG2 3D cell culture with decreasing particle
numbers towards the interior. (B) 100× image of a549 3D cell culture showing the particles (arrows)
distributed throughout the tissue.
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Figure 11. Hyperspectral Imaging of Nanoparticles using CytoViva Imaging System. Nanoparticles in
solution were placed on slide for analysis using hyperspectral imaging. Individual particles could be
identified using this technique. For further analysis of the particles, individual spectra are presented for the
PEGylated, and two and three layer nanoparticles. Spectra differences are associated with varying surface
modifications.

Particle uptake and penetration from the periphery of the tumor spheroids into interior regions was
analyzed via counts obtained from the hyperspectral dark-field images (Figure 12). In agreement with the
silver staining measurements, the two layer silica gold nanoshells in the HEPG2 tumors and the three layer
citrate gold nanoparticles in the A549 tumors had the best performance in terms of higher uptake and
uniform distribution, while both of these particle types behaved similarly in the S2VP10 tissue with lower
uptake and steeper diffusion gradients. The three-layer particles showed slightly higher uptake into S2VP10
tissue, which could be due to the morphology of these tumors resembling a cluster of grapes, as well as
other cancer-specific interactions with the HDL. Generally, the PEGylated particles exhibited lower uptake
and poorer penetration.
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Figure 12. Nanoparticle Penetration and Distribution in 3D Cell Cultures Measured by Dark Field
Microscopy. Diamonds and dotted line: PEGylated; Squares and dashed/dotted line: two layer; Triangles
and dashed line: three layer. Particle uptake was quantified for citrate gold nanoparticles (left) and silica
gold nanoshells (right) for HEPG2 (liver), A549 (non-small cell lung cancer), and S2VP10 (pancreatic) 3D
cell cultures as a function of distance from the spheroid periphery. The two layer silica gold nanoshells in
the HEPG2 tumors and the three layer citrate gold nanoparticles in the A549 tumors had the best
performance in terms of higher uptake and uniform distribution, while both of these particle types behaved
similarly in the S2VP10 tissue with lower uptake and steeper diffusion gradients. Generally, the PEGylated
particles exhibited lower uptake and poorer penetration. All error bars represent standard deviation from at
least n=3 measurements.
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Comparing the gold nanoshell results across cancer types, the two-layer exhibited an average 50%
higher uptake compared to the three-layer nanoshells. Citrate-gold nanoparticles had approximately 30%
more penetration at the tumor periphery compared to the gold nanoshells, but this was mostly due to the
larger size of the nanoshells, which are 3x the size of the citrate gold particles.
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Discussion
We developed “two-” and “three-layer” nanoshells to compare the penetration and diffusion
capabilities of these particles against PEGylated AuroShells™ in 3D cell cultures. To this end we used PC,
which has previously been employed as a passivating agent for gold nanorods significantly reducing their
cytotoxicity [326]. In addition, PC is the most abundant phospholipid within the body and can be found in
all cell membranes, and is thus expected to be less immunogenic.
In order to form a layer of PC around the gold nanoshells, a hydrophobic layer must also be
created. Thiol groups exhibit strong binding to gold, and can be used to displace other stabilizing ligands
and adsorbed molecules to stabilize the particles. An alkanethiol possesses optimal qualities for this
purpose; the hydrophobic carbon chains will interact with the fatty acids of the PC to form a properly
oriented layer. Here, we theorized that such a two-layer approach would yield better biocompatibility and
thus improved penetration into under-vascularized tumor regions when compared to PEGylated particles.
With the two-layer method, a hydrophobic region is created between the PC and alkanethiol, which could
potentially hold hydrophobic drugs to produce a more potent therapeutic agent. Further, NIR-absorbing
gold nanoshells have proven effective at reducing cell viability significantly in solid tumors due to
hyperthermia when treated with laser radiation [316, 327].
We find that modifying gold nanoshells with an alkanethiol and PC creates a viable two-layer
nanoparticle platform that consistently outperforms the current standard, PEGylated nanoparticles, when
measuring particle accumulation in 3D cell cultures. As such, two-layer nanoshells should be further
considered for potential photothermal and targeted drug delivery therapies. The addition of the PC layer
makes the nanoparticles similar to liposomes, which have been previously used for enhanced delivery of
gold nanoparticles [328]. We hypothesize that the phospholipid similarities increased cellular uptake of
these nanoparticles as compared to PEGylated nanoparticles. We also developed a three-layer system;
experimental evidence suggests that HDL uptake in hepatocytes is upregulated in liver cancers [329].
Adding a layer of HDL around the two-layer particles could potentially allow the particles to penetrate
deeper into liver cancers as the surface modifications make uptake by the hepatocytes more likely rather
than just relying on the EPR effect for passive targeting. The enhanced uptake of HDL in pancreatic and
liver cancer suggests increased cellular uptake of HDL-coated nanoparticles [330, 331]. Surface charge has
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a large effect on how nanoparticles will react in vivo. PEGylated nanoparticles were expected to exhibit
slightly negative values similar to those found in literature. Two layer nanoparticles with PC were expected
to exhibit highly negative zeta potentials from -15to -40 mV due to the negative choline head group, while
the neutral surface charge of HDL would yield particles with neutral surface charges [332]. These
expectations were confirmed as shown in Figure 5.
FTIR confirmed the identity of the nanoparticles by revealing the presence of various bands. For
HDL, bands associated with lipid esters (1700-1800 cm-1) and two distinct amide stretches (~1500-1700
cm-1) were expected along with characteristics from the FTIR of PC (due the layering process of
nanoparticles) [333]. PC coated nanoparticles were expected to have a large peak associated with –CH2 and
–CH3 groups (~3000 cm-1) along with phosphate group vibrations ~900 cm-1 [334]. PEGylated
nanoparticles were expected to exhibit decreased –CH2, –CH3, and –CH out of plane bending intensities.
These particles were also expected to exhibit a PEG ether stretch C-O-C between 1050-1100 cm-1 with the
corresponding vibration band between 1342-1353 cm-1 [335].The bands of the two- and three layer
nanoparticles were stronger than the PEGylated nanoparticles.
The penetration and diffusion capabilities of two-layer and three-layer citrate-gold nanoparticles
into 3D cell cultures was also analyzed, although the application of these particles in cancer therapy is
limited compared to silica-core gold nanoshells. Citrate-gold nanoparticles are much smaller than
nanoshells and do not possess tunable optical properties; they also lack absorption in the NIR range and
thus cannot be used for photothermal ablation therapy. Evaluation of the diffusivity of nanoparticles in 3D
cell cultures was also dependent upon the morphology and stability of the cell cultures. Since HEPG2 3D
cell cultures formed less tightly bound clusters, nanoparticles could enter these cultures better than the
A549 and S2VP10 cell cultures. This could explain the accumulation of more nanoparticles in HEPG2
spheroids in comparison to the other cell lines.
This study focused on evaluating the uptake and distribution of nanoparticles within
avascular/hypoxic regions of solid tumors at varying depths of penetration using 3D cell cultures as an in
vitro model of avascular tumor tissue. By quantifying the amount of particles within specific regions of
tissue, the diffusion of particles can be analyzed and this information combined with mathematical
modeling to better understand effectiveness of these particles for cancer treatment. The results could then
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be utilized to calibrate computational simulations to elucidate the complex dynamics of particles and drug
molecules within solid tumors [292, 296, 336, 337]. The work here represents an initial step to assess the
performance of two- and three-layered nanoparticles in penetrating avascular tissue. We note that 3D cell
culture is a rudimentary model of avascular tumor tissue; also, the reticuloendothelial system (RES) and
other systemic factors may significantly affect nanoparticle performance in vivo.
This study can be continued by examining the efficacy of the two-layer nanoshell system in
photothermal applications and determining its benefits compared to PEGylated nanoshells. In addition,
work is currently in progress to investigate the potential for embedding drugs into the layers of the twolayer nanoshell for chemotherapeutic delivery. A more interesting approach would be to combine the
photothermal treatments with drug delivery. A system could potentially be designed that would release its
drug payload once the particle has been excited through NIR energy, disrupting the layers on the nanoshell.
These steps would provide a logical progression towards developing more efficacious systems for targeted
cancer therapy.
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CHAPTER III
DETECTION OF PHOSPHATIDYLCHOLINE-COATED NANOPARTICLES IN ORTHOTOPIC
PANCREATIC CANCER USING HYPERSPECTRAL IMAGING

Background
Systemic Delivery of Nanoparticles to Tumors
Systemic delivery of nanoparticles to solid tumors can be considered in three distinct stages:
systemic travel while avoiding sequestering by the reticuloendothelial system (RES, mainly the liver and
the spleen), extravasation from intra-tumoral capillaries, and diffusion to reach and penetrate malignant
cells [338, 339]. The compromise of any of the associated processes can lead to suboptimal nanoparticle
uptake within tumor tissue, resulting in diminished therapeutic or diagnostic efficacy. To facilitate systemic
travel, surface modifications have been applied to nanoparticles to enhance passive and active targeting
while minimizing RES sequestering, e.g., coating with the hydrophilic polymer poly(ethylene)-glycol
(PEG) results in prolonged circulation time and diminished RES uptake [340, 341]. Coating with targeting
ligands specific to over-expressed receptors on cancer cells (e.g., high-density lipoprotein receptor
(HDLR)) can further enhance nanoparticle uptake and accumulation at the tumor site [341].
However, the typically irregular tumor vasculature resulting from uncoordinated pro- and antiangiogenic stimuli further hinders nanoparticle passive transport to cellular targets as well as therapeutic
efficacy even if systemic travel and targeted accumulation were successful [342]. Hypo-vascularized
regions of tissue lead to cells invoking survival mechanisms to overcome oxygen and nutrient deprivation
including minimization of metabolism (quiescence) resulting in cell cycle-dependent chemotherapeutic
resistance [343]. In addition to intrinsic and microenvironment-associated resistance mechanisms, cells
distant from vasculature in solid tumors receive suboptimal levels of diffusible substances as transport may
be limited by increased interstitial fluid pressure (IFP), a chaotic and dense ECM, and an acidic
microenvironment [338, 342, 344-346].
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To overcome these transport barriers and successfully deliver nanoparticles more homogeneously
into tumor tissue, nanoparticle size and surface modifications have traditionally been modulated [292].
Studies have described positive correlations between 50 nm nanoparticles and enhanced tumor
accumulation and diffusivity within tumor tissue [347], while larger 100 nm nanoparticles are readily
filtered by the liver and their transport is hindered once at the tumor due to a dense ECM [299, 348]. Very
small (5 nm) gold nanoparticles conjugated with anti-EGFR antibody were shown to successfully target
and treat pancreatic cancer when injected intraperitoneally into mice [349]. Using 3D cell cultures, sizespecific localization of nanoparticles was demonstrated by showing that small nanoparticles (2 and 6 nm)
exhibited superior penetration in comparison to slightly larger (15 nm) nanoparticles [24]. It was also
shown that nanoparticles ~20 nm displayed superior penetration in comparison to even larger nanoparticles
[299].
Previously, we have shown that smaller citrate gold nanoparticles (45-60 nm) display enhanced
tissue diffusivity in comparison to larger silica-gold nanoshells (160-175 nm) [225]. We also evaluated the
effects of surface modifications on passive transport by functionalizing nanoparticles with PC and HDL.
Results showed that both PC-coated and HDL-coated nanoparticles displayed enhanced tissue penetration
compared to PEGylated nanoparticles in 3D cell cultures of human pancreatic, lung, and hepatocellular
cancers [225]. As PEGylation is the most common surface modification, the results demonstrated that such
alternative surface modifications might enhance passive transport through solid tumor tissue.
Detecting Nanoparticles in Tissue
Nanoparticle localization is usually assessed using SEM and transmission electron microscopy
(TEM), yet these methods alone cannot conclusively detect nanoparticles. In combination with other tools
(e.g., energy dispersive X-ray (EDX) microanalysis), elemental analysis can provide further confirmation
of nanoparticle identity [350]. Here, we employ hyperspectral imaging to create libraries of known
nanoparticles and thus enable their detection within tissue samples or individual cells. Recently, the
deposition patterns of cisplatin aerosol therapy in surgically resected stage II lymph nodes from lung cancer
patients was analyzed using hyperspectral imaging [351]. Further, recombinant human epidermal growth
factor was encapsulated into liposomes, from which the morphology and particle distribution was analyzed
using hyperspectral imaging [352]. This imaging has also been utilized in patients for rapid, on-sight
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histological classification of lung cancer [353], demonstrating the flexibility of this technique in biomedical
applications. While nanoparticles can be identified using dark field microscopy alone, the combination of
hyperspectral imaging with dark field microscopy allows for automatic detection of nanoparticles within
the tissue, leading to less humanized error .
Purpose of Study
We examine the uptake and diffusivity of PC-coated citrate gold nanoparticles and silica-gold
nanoshells in tumors of the pancreas. Pancreatic cancer is the fourth most common cause of cancer-related
death in the United States with dismal 5-year relative survival rates of < 6% [56]. Due to the late onset of
clinical symptoms and a paucity of known biomarker candidates, pancreatic cancer prevention and
diagnosis remain difficult, with over 70% of pancreatic cancer cases diagnosed at stage III or IV, when
surgical intervention is generally no longer an option as the disease has spread through metastasis [354].
Current treatment options fail to effectively cure pancreatic tumors and have only provided minimal
increases in survival rates, demonstrating the vital need for novel treatment options. Here, we synthesize
and characterize PC-coated gold nanoparticles using methods outlined previously [225], and tail-vein inject
them into mice bearing orthotopic pancreatic tumors.
An orthotopic model was chosen for these experiments because it provides a more realistic
comparison to the human pancreatic tumors in comparison to subcutaneous models. After allowing for 48
hours of circulation, the animals were euthanized and the organs harvested for histological analysis. Ex
vivo identification and localization of nanoparticles in the liver, spleen, and pancreatic tumor tissues were
determined using hyperspectral imaging of histology sections. Results were compared to previous work in
which uptake of these nanoparticles was assessed in 3D cell culture [225].

Methods
Synthesis of Gold Nanoparticles
As previously described [225], nanoparticles were synthesized using the method in which gold
chloroauric acid is reduced by trisodium citrate [306]. In this process, 2.2–2.4 mL 1% weight/volume
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(wt/v) sodium citrate (Fisher Scientific, Waltham, MA, USA) and 200 mL 0.01% wt/v HAuCl 4 (Alfa
Aesar, Ward Hill, MA, USA) are mixed and heated to boiling, which promotes the reaction of sodium
citrate to citric acid. Temperature and final concentration of the gold salt allows particles of varying sizes.
Once the reaction is completed, the solution is concentrated using a rotovapor (Buchi Rotovapor System,
BÜCHI Labortechnik AG, Flawil, Switzerland) to ~20 mL before the addition of layering to the particles.
The silica gold nanoparticles have an inner core composed of silica with an outer coating of gold.
Synthesis consists of four stages: production of a colloid of small gold particles (2-4 nm) through reduction
and aging of gold colloid produced by the recipe of Vogel et al. [355], fabrication of monodispersed silica
cores from the Stöber method [232, 308], attachment the seeds to the silica surface, and finally gold shell
growth via reduction of additional gold. The gold colloid solution is created utilizing the THPC
(Tetrakis(hydroxymethyl)phosphonium chloride) method [316]. Growth of the silica cores requires the
combination of 7.5 mL tetraethyl-orthosilicate (TEOS, Sigma Aldrich, St Louis, MO, USA), 225 mL
absolute ethanol (Decon Labs, King of Prussia, PA, USA), and 12.5–13.5 mL ammonia (Sigma Aldrich).
Ammonia is adjusted to achieve silica core sizes 110 ± 5 nm. After removal of the paraffin cover and
evaporation of the ammonia, the cores are coated with 3%–4% aminopropyltriethoxysilane (APTES; Sigma
Aldrich). This allows for slightly positive cores for deposition of small colloidal gold particles, thus
forming what is hence called a seed particle.
The seeds are then washed and a 10% gold solution is added to complete the shell. After reaction
time, the seeds are washed and re-dispersed in DI water. The seeds are diluted to 0.3–0.5 optical density
(OD) at 530 nm (Varian Cary 50 Bio UV-Visible Spectrometer, McKinley Scientific, Sparta, NJ, USA). A
sweep of the seeds is performed to optimize the chemical ratio between them, K 2CO3-HAuCl4, and
formaldehyde (Fisher Scientific). Limiting the concentration of gold in the final reduction step controls the
thickness of the gold shell.
Functionalization of Nanoparticles
The first layer applied to the citrate gold nanoparticles and silica-gold nanoshells was 1Hexadecanethiol (Sigma Aldrich) dissolved in ethanol. While stirring, 20 mL pure ethanol (Decon Labs)
was placed in a beaker with 60 μL 1-Hexadecanethiol being added secondly. The nanoparticles were added
to the sample slowly over the next few minutes. The sample was first agitated via shaking and sonication
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for 60 minutes, and then placed for 12 hours on an orbital rocker (Boekel Scientific, Feasterville, PA, USA)
overnight. The sample was spun down, and the pellet was washed twice and resuspended in chloroform
(Sigma Aldrich). The second functionalization was the addition of the PC. The stock solution was made by
diluting PC in chloroform, and 100 μL were added to the particles after the thiol layer and allowed to set
overnight on an orbital rocker. The solutions were transferred to glass tubes and the chloroform evaporated
at ambient temperature. After removal of chloroform, PC-coated citrate gold nanoparticles and silica-gold
nanoshells were reconstituted in ddH2O to 2 OD.
Nanoparticle Characterization
Nanoparticle maximum absorption wavelengths were obtained using the Varian Cary 50 Bio UVVisible Spectrometer (McKinley Scientific). Nanoparticle size and zeta potential measurements were
obtained using the Zeta-Sizer Nanoseries ZS90 (Malvern Instruments, Worcestshire, UK). Hydrodynamic
size in solution based upon Brownian motion was measured using DLS (dynamic light scattering). Shape
and size were also previously determined using SEM, with the presence of lipids on the particle cores
confirmed using a FTIR spectroscopy (England et al. 2013).
Cell Culture Experiments
The highly metastatic pancreatic adenocarcinoma cell line, S2VP10 cells expressing luciferase,
was obtained from Dr. Michael Hollingsworth (University of Nebraska). Cells were grown in DMEM with
10% FBS and 1% L-glutamine at 37 ̊C in a humidified incubator.
Human Pancreatic Cancer Orthotopic Xenograft Mouse Model
Adherence to the University of Louisville Institutional Care and Use Committee (IAUCUC)
approved protocol was upheld for the in vivo experiments. Severe combined immunodeficiency (SCID)
female mice (Harlan, Indianapolis, IN) received orthotopic pancreatic injections of S2VP10 metastatic
pancreatic adenocarcinoma cells expressing luciferase, resulting in pancreatic tumors within 7 days. The
procedure for orthotopic pancreatic cell implantation was previously described (McNally et al. 2010).
Briefly, mice were anesthetized with isoflurane (≤4% isoflurane for induction and ~1.5% maintenance
dose) at 100% O2. The left upper abdominal quadrant of the animals was sterilized before making a 1-cm
incision. The pancreas was localized using forceps, and the tail of the organ was injected with 1.5×105
cells/30 µL S2VP10 cells expressing luciferase using a 28-gage needle. Peritoneal leakage of cell solution
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from pancreatic injection site was minimized by applying a sterile cotton tip applicator for 30 seconds.
Organs were returned to normal anatomical position prior to closing the skin and peritoneum using 5-0
Nylon sutures. Animals recovered in a warm area and received liquid acetaminophen for 24 hours postsurgery. Growth of the tumor was monitored using the AMI-1000X bioluminescence imaging system
(Spectral Imaging Instruments, Tucson, AZ). 2.5 mg luciferin was given via intraparenteral injection to
each mouse 10 minutes prior to imaging.
An intravenous (tail vein) injection of 200 µL 2 OD nanoparticle solutions was given to the mice
nine days after tumor cell implantation. As there were five mice in each group, the first group received an
injection of PC-coated citrate gold nanoparticles; the second group mice received an injection of PC-coated
silica-gold nanoshells, and the third group was the negative control (no particle injection).
Mouse Euthanasia, Organ Resection, and Histological Processing
Nanoparticles were allowed to circulate for 48 hours before mice were euthanized using CO2. The
pancreatic tumor, liver, and spleen were removed from each mouse for histological processing. Histology
was performed by the University of Louisville Pathology Laboratory (Louisville, KY, USA). Tissues were
cut into 4 µm sections and placed onto slides before undergoing a series of ethanol and xylene washes.
Cover slips were applied before experimental analysis.
Nanoparticle Detection using Hyperspectral Imaging
Hyperspectral imaging in combination with dark field microscopy was used to assess nanoparticle
uptake and distribution within histology tissue sections. The CytoViva® Hyperspectral Imaging System
(CytoViva Inc., Auburn, AL, USA) was used for this purpose. This system uses a Dage camera with a
microscope with dark field capability. Hyperspectral profiles are acquired using a Pixelfly camera and
visualized using ENVI 4.8 software (Exelis Visual Information Solutions, Boulder, CO, USA). To confirm
the identity of nanoparticles, spectral libraries were created using z-spectral profiles and compared to the
tissue samples. We found that spectral mapping was able to detect and confirm the nanoparticles within
tissue samples by using multiple tissue images (> 10) containing either nanoparticles or no nanoparticles.
Data analysis was performed with ImageJ. Regions of interest were randomly determined and particles
within these regions were counted to determine the concentrations in liver, spleen, and pancreatic tumor
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tissues. A sufficient number of regions were evaluated to ensure at least 90% accuracy based on
stereological analysis.
Statistical Analysis
Analyses used the two-tailed Student’s t-test with significant values being less than 0.05.
Statistically significant differences are illustrated with an asterisk (*) in the results.
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Results
Nanoparticle Synthesis and Characterization
The addition of a PC layer to citrate gold nanoparticles and silica-gold nanoshells was
accomplished using a layering process in which the charged head group of hexadecanethiol binds to the
nanoparticle (Figure 13), resulting in hydrophobic nanoparticles with hydrocarbon chains pointed outward
towards the surrounding environment. The addition of PC to the hexadecanethiol-coated nanoparticles
binds tail-to-tail creating water-soluble nanoparticles containing an inner layer suitable for hydrophobic
drug loading.

Figure 13. Synthesis of Two and Three Layer Nanoparticles. Briefly, citrate gold nanoparticles were
synthesized by the reduction of chloroauric acid by sodium citrate. The citrate is removed from the surface
by the addition of hexadecanethiol, which is used for the conjugation of PC. Silica-gold nanoparticles were
synthesized by first creating silica cores before adding ultra-small colloidal gold nanoparticles onto the
surface of the cores to create a thin layer of gold through a reduction process. The same modifications of
hexadecanethiol and PC were applied to the silica-gold nanoshells. TEOS: tetraethyl-orthosilicate.

Optical measurements of functionalized citrate gold nanoparticles and silica-gold nanoshells
confirmed nanoparticle identity and functionalization (Figure 14). Colloidal gold nanoparticles exhibit UV-
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Vis maximum absorbance values ranging between 510-550 nm, in agreement with the PC-coated
nanoparticles experiencing an optimal peak at 540 nm (Figure 14A). In comparison, previously synthesized
PEGylated citrate gold nanoparticles displayed a maximum wavelength of 533 nm [225]. Maximum
absorbance of silica-gold nanoparticles is based upon the radius of the silica core and size of the gold shell
surrounding the core, with smaller shells producing larger wavelengths. Silica-gold nanoshells synthesized
in this study displayed a maximum absorbance of 835 nm that is similar to silica gold nanoparticles with
~110nm diameter silica cores and ~10-15 nm gold coating (Figure 14B). In comparison, previously
synthesized PEGylated silica-gold nanoshells displayed a maximum absorbance of 820 nm. We have
previously shown that silica-gold nanoparticles commonly possess wavelengths ranging from 820-860 nm
based upon sizing and surface modifications [225].

Figure 14. UV-Visible Spectroscopy Spectra of Nanoparticles. (A) Citrate gold nanoparticles displayed a
maximum absorption at 540 nm. (B) Silica-gold nanoshells displayed a maximum absorption at 830 nm.

Further characterization elucidated information regarding hydrodynamic radii and surface charge
(Figure 15). The hydrodynamic radius has a crucial impact on deposition patterns in vivo as a thin electric
dipole layer of the solvent adheres to the surface of the nanoparticles as they move through a liquid
medium. The size determined through DLS was greater than the sizing information obtained visually by
SEM, which is a common occurrence. The PC-coated citrate gold nanoparticles had an average DLS size of
82.3 ± 9.4 nm (Figure 15A), while PC-coated silica-gold nanoparticles had an average size of 144.13 ± 11.7
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nm (Figure 15B). These DLS sizes can be contrasted with previously synthesized PEGylated citrate gold
nanoparticles and silica-gold nanoshells exhibiting sizes of 82.81±13.4 nm and 161.82±12.2 nm,
respectively. The size difference between citrate gold and gold nanoshells is expected to have an impact on
diffusivity within in vivo tumor tissue, in accordance with previous observations using 3D cell culture
[225]. The surface charge showed similar zeta potentials between the citrate gold nanoparticles and silicagold nanoshells of -23 mV (Figure 16A) and -31 mV (Figure 16B), respectively.

Figure 15. Hydrodynamic Radius of Nanoparticles Measured using DLS. (A) The radius of PC-coated
citrate gold nanoparticles was 82.3 ± 9.4 nm. The hydrodynamic radius of PC-coated silica gold
nanoparticles was 144.13 ± 11.7 nm.

Figure 16. Surface Charge of Nanoparticles Measured using the Zetasizer. The surface charge, or zeta
potential, of these nanoparticles displayed similar cationic surfaces with (A) the PC-coated citrate gold
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nanoparticles possessing a zeta potential of -23 mV. The PC-coated silica-gold nanoshells were slightly
more cationic at -31 mV.

Creation of Nanoparticle Spectral Libraries
Before nanoparticles were detected in tissue samples from mice, spectral libraries were created of
the PC-coated citrate gold nanoparticles and silica-gold nanoshells that could be later matched to the
images for detection (Figure 17). The spectral libraries were synthesized from samples of both types of
nanoparticles in solution. Visible color changes from green to yellow to red illustrated the shift of the
maximum absorbance wavelength of the nanoparticles. For PC-coated citrate gold nanoparticles, the
majority of nanoparticles in solution exhibited green color indicating the particles processed maximum
absorbance values within the lower range (500-600 nm) (Figure 17A). This was confirmed through the zprofile spectra mapping showing a maximum band ~550-570 nm. The solution of PC-coated silica-gold
nanoshells contained a significant concentration of red nanoparticles, indicative of absorbance at higher
wavelengths (>700 nm) (Figure 17B). As nanoshells exhibit wavelengths higher than colloidal gold
nanoshells, this also helped to confirm the identity of the nanoparticles.
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Figure 17. Hyperspectral Imaging of PC-coated Gold Nanoparticles. (A) Citrate gold nanoparticles were
primarily green, with a spectral profile indicating a maximum wavelength of 570 nm. (B) Silica-gold
nanoshells displayed an abundance of red and yellow nanoparticles, with a spectral profile maximum of
700 nm. While the actual maximum wavelength of silica-gold nanoshells in solution is between 820-860
nm, hyperspectral imaging is known to underestimate entities containing higher wavelength maxima. Size
bar corresponds to 20 µm.

Evaluation of Nanoparticle Uptake and Distribution
The creation of spectral libraries of PC-coated nanoparticles enables nanoparticle detection in
tissue samples. After nanoparticles extravasate from vasculature, they diffuse through the tissue composed
of cells and ECM. In some tissues, extravasation sources residing relatively close to each other can provide
a more homogenous layout of source points. Nanoparticle counts were obtained in the vicinity of source
points in histology sections to determine the uptake and distribution in sections of liver, spleen, and
orthotopic pancreatic tumor (Figure 18).
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Figure 18. Nanoparticle Penetration in Liver, Spleen, and Pancreatic Tumor. Citrate gold nanoparticle and
silica-gold nanoshell penetration measured in liver, spleen, and pancreatic tumor tissue samples. Distances
from the nearest source were measured using hyperspectral imaging. In the liver and pancreatic tumor,
citrate gold nanoparticles had a linear diffusion pattern, while the spleen had an exponential decline. Silica
gold nanoshells had an exponential decline, suggesting limited diffusivity in all three tissue types. Citrate
gold nanoparticles had highest extravasation close to their sources in the spleen while for silica gold
nanoshells extravasation was highest in the liver. All error bars denote standard deviation (n=3).

For citrate gold nanoparticles, the liver and pancreatic tumor on average exhibited a linear decline
in nanoparticle concentration from the nearest source, with 26.5 ± 8.2 and 23.3 ± 4.1 particles/100μm 2,
respectively, within 10 μm of the source and few nanoparticles penetrating beyond 50 μm (Figure 18). The
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spleen displayed on average a higher uptake of 35.5 ± 9.3 particles/100μm2 within 10 μm followed by an
exponentially decaying penetration pattern, also limited to ~50 μm (Figure 18).
Silica-gold nanoshell were uptaken the most within the liver showing on average 31.1 ± 4.1
particles/100μm2 within 10 μm of the nearest source, with penetration hindered beyond 30 μm (Figure 18).
The spleen and pancreatic tumor also exhibited limited penetration beyond 30 μm (Figure 18), with uptake
of 22.1 ± 6.2 and 15.8 ± 6.1 particles/100μm2, respectively, within 10 μm. While the penetration of citrate
gold nanoparticles suggests linear diffusion, the nanoshells displayed more of a decaying exponential
pattern further implying limited diffusivity. We hypothesize that the limited diffusivity of nanoshells in the
liver, spleen, and pancreatic tumor is size-dependent, thus larger particles (>150 nm) would experience
even greater diffusion limitations.
Nanoparticle Accumulation in Liver, Spleen, and Pancreatic Tumor
The average concentration of citrate gold nanoparticles was highest in the liver (1.09 ± 0.14
nanoparticles per µm2), as compared to the spleen (0.74 ± 0.12 nanoparticles per µm2) and pancreatic tumor
(0.43 ± 0.07 nanoparticles per µm2) (Figure 19A). In contrast, the average concentration of silica gold
nanoshells was 0.43 ± 0.07 nanoparticles per µm2 in the liver, 0.30 ± 0.06 nanoparticles per µm2 in the
spleen, and 0.20 ± 0.04 nanoparticles per µm2 in the pancreatic tumor (Figure 19A). Using the two-tailed
student t-test, statistically significant differences between the accumulation of nanoparticles in each tissue
are shown (all p-values < 0.05).
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Figure 19. Citrate gold nanoparticle (black bars) and silica gold nanoshell (grey bars) concentrations within
liver, spleen, and pancreatic tumor show differential uptake. (A) The liver exhibited highest concentration
of either citrate gold nanoparticles or silica gold nanoshells, followed by the spleen and the pancreatic
tumor. Statistically significant differences are signified by (*) with a p-value < 0.05, with statistical
differences between each tissue type for both citrate gold nanoparticles and silica gold nanoshells. Error
bars denote standard deviation. Hyperspectral imaging of nanoparticles in combination with dark field
microscopy highlights the density of extravasation sites that may affect the uptake of nanoparticles within
tissue. (B) The liver provides numerous extravasation sites. (C) The spleen also has numerous extravasation
sites, albeit to a lesser extent compared to the liver. (D) The pancreatic solid tumor has fewer sites, leading
to diminished nanoparticle uptake. Bars, 100 μm

Uptake of nanoparticles is a function of vasculature of an organ or tissue. The liver and spleen
with similar patterns of highly vascularized tissue are expected to present a higher number of nanoparticle
source points, while the pancreatic tumor with a more heterogeneous vascular pattern would have less.
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Dark-field tissue sections were compared to evaluate extravasation sites within the tissue (Figure 19B-D).
Some regions of pancreatic tumor may contain large quantities of sprouting vessels due to sporadic
angiogenesis, while other regions experience diminished vascular density with possibly few vessels
supporting large volumes of tissue. This heterogeneity may result in tumor tissue becoming hypoxic and
necrotic, with correspondingly restrained nanoparticle accumulation in these regions.
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Discussion
We synthesized PC-coated citrate gold nanoparticles and silica-gold nanoshells to study their
uptake and diffusivity within tissue in vivo. PC is the most abundant phospholipid found in cellular
membranes and thought to decrease possible immunogenicity [356]. The addition of PC was previously
shown to significantly reduce associated cytotoxicity and particle aggregation, while enhancing passive
targeting capabilities [357]. In previous work, we observed enhanced diffusivity of PC-coated nanoparticles
in 3D cell cultures, with superior uptake and penetration in comparison to PEGylated nanoparticles [225].
PEG is currently the most widely employed FDA-approved polymeric platform used in the synthesis of
medicinal nanoparticles for treating various cancers and related diseases, including Genexol-RM for
metastatic breast cancer, Oncaspar for acute lymphoblastic leukemia, and Neulasta for chemotherapyassociated neutropenia [358]. While PEGylation is effective in enhancing drug delivery, multiple adverse
effects have been associated with the use of PEG including possible immunogenicity, which is still debated
[359]. The evaluation of PC-coated nanoparticles may longer term enable an alternative therapeutic option.
We note that the only FDA-approved nanotherapeutic currently available for pancreatic cancer is
Abraxane, an albumin-bound form of paclitaxel [360].
In this study, the formation of a bilayer membrane around nanoparticles was achieved by first
adding hexadecanethiol, which displaced the outer coating of citrate and formed a hydrophobic
nanoparticle (Figure 13). Through the addition of PC, the hydrophobic tails of the hexadecanethiol interact
with the hydrocarbon chains of PC to form the membrane layer. The hydrophobic region between
hexadecanethiol and PC can potentially be utilized for entrapping hydrophobic drugs, resulting in enhanced
bioavailability. In addition, PC-coated silica-gold nanoshells exhibit wavelengths within the near infrared
(nIR) region, making them potential candidates for photothermal ablation therapy as well as diagnostic
imaging through multispectral optoacoustic tomography (MSOT) [18, 361-363]. Recently, specific uptake
of hybrid iron-oxide core gold-shell nanoparticles by pancreatic cells in photothermal therapy has been
demonstrated. Cells exposed to nanoparticles and laser irradiation produced dose-dependent temperature
increases and a reduction in cell proliferation, suggesting that photothermal ablation may be of use in the
treatment of pancreatic cancer [364].
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Detection of nanoparticles in tissue samples has been extensively accomplished using electron
microscopy techniques (TEM, SEM, STEM) [365], yet newer methodologies present opportunities.
Additional studies have utilized confocal microscopy to examine the translocation of nanoparticles in coculture cancer models [366]. While these models can detect nanoparticles, they lack the ability to confirm
the presence of nanoparticles in tissue based upon spectral mapping. Hyperspectral imaging of
nanoparticles in solution demonstrates the feasibility of determining the spatial location, agglomeration
status, wavelength differentiation, and partial size determination [367]. Using hyperspectral imaging,
nanoparticles can be further analyzed and characterized to determine properties such as surface
modifications.
In this study, we used hyperspectral imaging to analyze the uptake and distribution of gold
nanoparticles within tissue samples. We note that nanoparticle agglomeration can distort the results when
attempting to assess nanoparticle concentrations within regions of interest. Consequently, numerical data
gained from this method should be considered approximate and not absolute. Also, nanoparticle spectral
profiles can be altered by factors including agglomeration status, backscatter from other sources, and other
mechanisms. While the citrate gold nanoparticles exhibited similar spectra to those adapted from UV-Vis
spectroscopy, the silica-gold nanoshells displayed a lower maxima (Figure 14). Such small changes are
considered normal. Another common occurrence in detecting nanoparticles stems from the use of dense
tissue samples, in which light scattering from different tissue components may hinder proper view. For this
reason, spectral matching should be mapped for each image to computationally extract the nanoparticles,
providing a clear depiction of which positive pixels are nanoparticles as compared to other tissue elements.
The spatial distribution of vessels within organs can cause some data distortion as vascular source
points in mice reside within close proximity of each other [368]; nanoparticles extravasated from a
particular source point may thus overlap with those extravasated from a nearby source. This was considered
when counting the nanoparticles and was a reason to limit the distance of evaluation to 50 μm, which is the
typical inter-vessel distance in the murine liver [369].
Recently, we have evaluated uptake and penetration of functionalized nanoparticles in avascular
3D cell cultures. Diffusion is both size and surface modification dependent, shown by analyzing the
penetration of citrate gold nanoparticles and silica gold nanoshells (size difference ~80 nm) based on
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functionalization with hexadecanethiol (TL) and PC, or TL, PC, and HDL, and finding that coating with PC
or HDL increased uptake and penetration [225]. The results herein show that PC-coated citrate gold
nanoparticles exhibit a quasi-linear diffusion pattern in vivo similar to the 3D cell cultures (Figure 19A). In
contrast, PC-coated silica gold nanoshells experienced a steeper decline in concentration from the nearest
source point (Figure 19) compared that observed in 3D cell culture [225]. Further, the particle uptake
observed within 10 μm of the nearest source in the pancreatic tumor was on average 67% lower than
observed with these same cells in vitro.
While 3D cell cultures mimic the morphological structure of tissue in vivo, tissue found within
live subjects is more complex. This tissue is composed of a fully developed ECM and multiple cell types
(including cells of the immune system) that are in contact with the blood supply and the lymphatic system,
which may affect the deposition patterns and uptake of nanoparticles beyond the effects from 3D space.
The extravasation in vivo is also expected to be hindered by interstitial fluid pressure within tumor tissue as
has been shown in experimental as well as modeling studies [342, 345, 370]. The elevated concentration of
nanoparticles in the liver and spleen highlights the sequestering by the RES (Figure 19A). Overall, the
smaller citrate gold nanoparticles exhibited enhanced accumulation compared to the silica gold nanoshells.
This difference can be primarily attributed to their smaller size. Nevertheless, the hypo-vascularization in
the pancreatic tumor tissue can significantly hinder nanoparticle uptake regardless of size (Figure 19).
This study can be continued by examining the drug loading efficiency of the PC-coated
nanoparticles. Hydrophobic drugs could be loaded into the hydrophobic region between the
hexadecanethiol and PC, and thus facilitate their delivery through the hydrophilic tissue environment. To
enhance local release, one would require the use of gold particles which absorb light in a region transparent
to tissue, such as near infrared (nIR) absorbing gold nanoparticles (gold silica nanoshells, nanorods, or
gold-sulfide aggregate nanoparticles). Drug release would then be mediated by heating of the surface (using
the correct amount of energy via light dosing) to allow release of surface bound molecules. This method
would minimize damage to surrounding tissue. Further, the nIR wavelength associated with the gold silica
nanoshells in this study makes them potential candidates for photothermal ablation therapy. Citrate gold
colloid based particles should not be used for thermal ablation as the wavelength of light (~540 nm) used
for activation will cause harm due to absorption of energy by the tissue. Nevertheless, citrate gold NPs
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may be easier for designing a layered system for drug transport modeling studies [225]. Finally, by
analyzing diffusivity and distribution patterns of these nanoparticles in vitro and in vivo, mathematical
modeling could be applied to help design and predict treatment outcomes [295, 296, 336, 370, 371].
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CHAPTER IV
RELEASE KINETICS OF CISPLATIN AND PACLITAXEL FROM TWO AND THREE LAYER
NANOPARTICLES

Background
Gold Nanoparticles for Cancer Therapy
Tumor chemotherapeutic response can be significantly affected by drug physiochemical
properties, such as water solubility and bioavailability, as well as intrinsic and physiologic resistance by the
tumor tissue itself. In order to enhance tumor response while minimizing systemic toxicity, a variety of
drugs have been encapsulated in organic or inorganic nanoparticles, ranging in size from 1 to 1000 nm.
Gold nanoparticles, in particular, have been utilized as agents for drug delivery, thermal therapy, and in
vivo imaging, and as radio-sensitizers for both pre-clinical and clinical purposes [372]. An early-phase
clinical trial showed the effectiveness of 27-nm citrate gold nanoparticles functionalized with poly(ethylene)-glycol (PEG) while addition of tumor necrosis factor-α enhanced targeting of solid tumors and
increased tumor toxicity [283].
Cisplatin and Paclitaxel
Two commonly utilized chemotherapeutics in cancer treatment are cisplatin and paclitaxel [373].
Cisplatin inhibits cell proliferation through multiple mechanisms, including: binding with DNA to form
intra-stand adducts causing changes in DNA conformation, promoting mitochondrial damage leading to
diminished energy production, altering cellular transport mechanisms, and decreasing ATPase activity
within the cells [148, 374]. Paclitaxel enhances tubulin polymerization to stable microtubules and stabilizes
them against depolymerization, which results in mitotic arrest [375]. While both drugs are effective, they
are known to possess adverse reaction profiles. Cisplatin induces renal toxicity caused by its activation
within proximal and distal tubules, neurotoxicity by damaging Schwann cells of the myelin sheath, and
tumor lysis syndrome (TLS), which results in abnormal metabolic and electrolyte profiles [148]. Paclitaxel
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has shown dose-limiting hematological toxicity (e.g. neutropenia) and sensory neurotoxicity, along with
other adverse non-hematological toxicities including arthralgia, myalgia, and fluid retention [376]. In
addition to adverse profiles, the poor water solubility and low bioavailability of paclitaxel has hampered its
clinical use. The drug is administered in a solubilized form, Cremophor EL, to overcome minimal water
solubility; while the castor oil used to solubilize the drug enhances bioavailability, it is known to induce
histamine release resulting in hypersensitivity reactions in some patients [15, 377].
Drug Release from Nanoparticle Systems
The rate of drug release from nanoparticles is dependent upon the physiochemical properties of the
drug, attachment strength between drug molecules and the nanoparticle surface, and surface modifications
used in the synthesis process. Nanoparticles can be designed through alteration of these properties to
exhibit drug release profiles specific for a targeted cancer to help optimize treatment response. The addition
of surfactant PEG is known to escalate nanoparticle circulation time by one to two orders of magnitude
compared to freely circulating drugs, providing additional time for nanoparticles to localize in the solid
tumor tissue. Even without being actively targeted, studies have shown that PEG will increase nanoparticle
accumulation in solid tumors due to the enhanced permeation and retention (EPR) effect caused by the
irregular and leaky vasculature typically found in tumor tissue [378]. Through nanoparticle
functionalization, drug release may be modulated to ensure sufficient time for nanoparticles to localize in
the tumor (e.g., PEG-coated nanoparticles) or to release drug at specific locations (e.g., hypoxic regions)
within the tumor microenvironment [379]. While drug release profiles can significantly alter response in
situ, the surface modifications must also ensure that nanoparticles can successfully travel throughout
systemic circulation to the tumor, extravasate from the intratumoral capillaries, and diffuse throughout the
tissue to reach every malignant cell [380]. This can be a challenge as nanoparticles administered in vivo are
often sequestered and removed from systemic circulation by the reticuloendothelial system (RES) [381].
The heterogeneous cell cycling patterns typically found in tumors ideally require nanoparticle
accumulation with a sustained drug release. Paclitaxel-loaded gold nanoparticles have been extensively
utilized for decreasing toxicity and lowering chemoresistance in various cancers [89, 382]. Highly stable
PEG-coated gold nanoparticles loaded with paclitaxel have been synthesized, exhibiting a biphasic drug
release pattern with an initial burst followed by a slower release over the next 120 hours [383]. Studies
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have shown that cisplatin-loaded gold nanoparticles show similar release patterns [384-388]. “Smartsensing” pH-sensitive nanoparticles have been developed that release cisplatin in specific environments,
such as the acidic microenvironment of the tumor or within the cellular endosome once the nanoparticles
have entered the cell [25]. Recently, controlled release of cisplatin from magnetic nanoparticles has been
evaluated with the goal to minimize toxicity in non-cancerous tissues [389, 390].
Purpose of Study
In this study, we examine the release profiles of cisplatin and paclitaxel from novel two and three
layer gold nanoparticles for the purpose of aiding the development of gold-based nanotherapeutics. Two
layer gold nanoparticles were synthesized by adding hexadecanethiol and PC to the outside of gold cores.
The addition of PC to the outer layer of TL creates a hydrophobic region, similar to the lipid bilayer found
on liposomes, which can be utilized for loading hydrophobic drugs. For the three layer gold nanoparticles,
HDL was added to the two layer nanoparticles for the purpose of improving liver targeting [225]. For both
two and three layer gold nanoparticles, paclitaxel was loaded in the hydrophobic region between the TL
and PC. Cisplatin was loaded through non-covalent interactions onto the outside of two or three layer gold
nanoparticles. The release of drug was evaluated based upon particle surface modifications and drug
physiochemical properties to determine the rate of drug release from nanoparticles. Kinetic models were
evaluated to further assess the mechanisms of drug release, including: zero-order kinetic model, first-order
kinetic model, simplified Higuchi model, and Korsmeyer-Peppas mode [391].
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Methods
Materials
HAuCl4 (Alfa Aesar, Ward Hill, MA, USA), trisodium citrate (Fisher Scientific, Waltham, MA,
USA), 1-Hexadecanethiol (TL) (Sigma Aldrich), 100% Ethanol (Decon Labs, King of Prussia, PA, USA),
Chloroform (Sigma Aldrich), L-PC (Sigma Aldrich), HDL (Lee Biosolutions, St. Louis, MO, USA),
Phosphate-Buffered Saline (PBS) (Life Technologies, Grand Island, NY), Cisplatin (Sigma Aldrich),
Paclitaxel (Cayman Chemical, Ann Arbor, MI, USA), Acetonitrile (Sigma Aldrich), Trifluoroacetic acid
(TFA) (Sigma Aldrich)
Synthesis of Gold Nanoparticles
Particles were synthesized using a method in which gold chloroauric acid is reduced by trisodium
citrate as previously described [306]. In this process, 2.2–2.4 mL 1% weight/volume (wt/v) citrate is added
to 200 mL of boiling 0.01% wt/v HAuCl4, and the solution is allowed to continue boiling for 10 minutes to
promote the reaction of sodium citrate to citric acid. Once the reaction is completed, the solution cools at
room temperature before concentrated using a rotovapor (Buchi Rotovapor System, BÜCHI Labortechnik
AG, Flawil, Switzerland) to ∼20 mL. After the nanoparticles are concentrated, surface modifications were
added as described below.
Particle Functionalization
The first layer applied to the citrate gold nanoparticles was 1-hexadecanethiol dissolved in ethanol.
The thiol compound displaces the citrate bound to the core of the nanoparticles as thiol has a stronger
binding affinity for the surface of gold in comparison to citrate, creating a hydrophobic nanoparticle, as the
hydrocarbon chains of the thiol compound will point outward from the gold core. While stirring, 20 mL
pure ethanol was placed in a beaker with 60 μL 1-Hexadecanethiol being added secondly. The 1hexadecanethiol solution was added slowly to the nanoparticle solution over the next 10 minutes, while
also agitating the sample by sonication. After addition of 1-Hexadecanethiol, the sample was agitated for
two hours, and then placed for 12 hours on an orbital rocker (Boekel Scientific, Feasterville, PA, USA).
The sample was spun down, and the pellet was washed twice and resuspended in chloroform. The second
functionalization was the addition of the PC to the surface of nanoparticles. The stock solution was made
by diluting PC in chloroform, and 100 μL were added to the particles after the TL layer and allowed to set
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overnight on an orbital rocker. The solutions were transferred to glass tubes and the chloroform evaporated
at ambient temperature. This process completed the two layer citrate gold nanoparticles containing gold
core, TL, and PC. The three-layered nanoparticles were created by optimizing the ratio of HDL to particle
optical density (1 mg HDL per 20 OD nanoparticle), and allowed to react overnight after two hours of
agitation.
Loading Nanoparticles with Drug
Paclitaxel and cisplatin were loaded onto the nanoparticles in distinct regions to ensure optimal
loading efficiency. Paclitaxel was loaded after the addition of 1-hexadecathiol and before the addition of
PC. Briefly, after nanoparticles were placed on an orbital shaker for 12 hours, the solution was removed.
After nanoparticles were resuspended in 9 mL chloroform, an addition 1 mL of chloroform containing 5 mg
paclitaxel was added to the solution. Nanoparticles were agitated for two hours using sonication before the
solution was placed on an orbital rocker for six hours. The solution was further modified to add the second
layer of PC to the surface of the nanoparticles. While paclitaxel was loaded into the hydrophobic region
created between the TL and PC layer, cisplatin was loaded at two different areas dependent upon the
layering. For the two layer citrate gold nanoparticles, cisplatin was added after the addition of PC. This was
done by transferring the solutions to glass tubes and the chloroform evaporated at ambient temperature.
Next, the nanoparticles were resuspended in 10 mL ultrapure H 2O (Purelab Ultra, Elga Labwater, UK)
containing 7.5 mg cisplatin. For the three layer citrate gold nanoparticles, cisplatin was added after the
addition of HDL by synthesizing the particles as described above, yet after HDL was added to the particles
and allowed to react for two hours, the solution was removed, and 7.5 mg cisplatin was added. Excess
chemotherapeutic was removed from the solution by centrifuging the particles at 7000 rpm for 25 minutes,
removing the supernatant, and re-suspending the particles in the corresponding solvent. Washing was
performed twice.
Nanoparticle Characterization
Nanoparticle identity was verified as follows: (1) Maximum absorption wavelengths were
obtained using the Varian Cary 50 Bio Ultraviolet-Visible (UV-Vis) Spectrometer (McKinley Scientific);
(2) size and zeta potential measurements were obtained using the ZetaSizer Nanoseries ZS90 (Malvern
Instruments, Worcestshire, UK); (3) DLS (dynamic light scattering, also known as Photon Correlation
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Spectroscopy) to determine hydrodynamic size in solution based upon Brownian motion; (4) shape and size
were determined using a Zeiss Supra 35VP (Carl Zeiss, Oberkochen, Germany) SEM; (5) presence of lipids
on the particle cores was confirmed using a FTIR instrument (Perkin Elmer Spectrum BX; Perkin Elmer,
Waltham, MA, USA) and through visual analysis using the SEM.
In Vitro Drug Release Studies
In vitro drug release studies were carried out using dialysis tubing cellulose membrane with an
average flat width of 25 mm and 12,000 MW cutoff (Fisher Scientific, Waltham, MA, USA). The prepared
drug-loaded nanoparticles were added to dialysis tubes and subject to dialysis by submerging the tubing
into a beaker containing 500 mL 1X PBS at pH 7.4. The solution was agitated continuously throughout the
release study using a magnetic stirrer at room temperature covered with Parafilm to ensure no evaporation
would take place during the study. At established time intervals, 3 mL samples of PBS containing drug
were removed and replaced with fresh buffer to ensure a constant volume. The amount of drug in each
sample was determined using HPLC. Cumulative drug release versus time was expressed by the following
equation (Eq. 1):
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝐷𝑟𝑢𝑔 𝑅𝑒𝑙𝑒𝑎𝑠𝑒 (%) =

[𝐷𝑟𝑢𝑔]𝑡
[𝐷𝑟𝑢𝑔]𝑡𝑜𝑡𝑎𝑙

× 100

Eq. (1)

where [Drug]t refers to the concentration of drug release at time t and [Drug] total is the total amount
of drug loaded onto the nanoparticles.
Drug Detection using HPLC
Samples of paclitaxel and cisplatin were analyzed using a Waters Alliance e2695 HPLC equipped
with a Waters 2998 photodiode array UV/Vis detector and a µRPC C2/C18 ST 4.6/100 column (GE
Healthcare, catalog number 17-5057-01). Initial injection conditions were 100% water/0.1% TFA
immediately followed upon injection by 5 minutes with 100% water/0.1% TFA, 35 minutes of linear
gradient to 100% acetonitrile/0.1% TFA, 5 minutes at 100% acetonitrile, followed by a return to 100%
water/0.1% TFA to prepare the column for the next run. Total run time was 55 minutes. The flow rate was
0.5 ml/min. Spectrophotometric data were collected from 200 to 800 nm. The baseline for each run was
monitored at 260 nm and 280 nm. A standard calibration curve was created for paclitaxel (0.01 µM to 10
µM plus a blank sample) and cisplatin (2.5 µM to µ500 M plus a blank sample) by injection of pure
compounds dissolved in water or buffer.
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The peak corresponding to paclitaxel was integrated at 230 nm to minimize overlap of peaks
belonging to interfering compounds and to maximize peak area. Cisplatin was integrated at 380 nm for the
same reasons. After elution, peaks were integrated using Waters Empower software. A calibration curve
was generated by plotting peak area vs. concentration using Microsoft Excel. Analytical samples of each
compound were then compared to the standard curve to determine their approximate concentration.
Determination of Drug Encapsulation Efficiency and Drug Loading Efficiency
Drug incorporation efficiency (I.E.) (%) was expressed as the percentage of drug in the produced
nanoparticles with respect to the initial amount of drug that was used for synthesizing the nanoparticles
[392]. This calculation was determined using HPLC as described above in conjunction with the following
equation (Eq. 2):
𝐼. 𝐸. (%) =

𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑟𝑢𝑔 𝑖𝑛 𝑁𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 (𝑚𝑔)
𝐼𝑛𝑡𝑖𝑎𝑙 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑟𝑢𝑔 (𝑚𝑔)

× 100

Eq. (2)

Mechanism of Drug Release
To assess the mechanism of drug release, in vitro release patterns were analyzed using four kinetic
models: zero-order kinetic model, first-order kinetic model, simplified Higuchi model, and KorsmeyerPeppas model. The zero order model is associated with drug dissolution that is independent of drug
concentration (Eq. 3) [393]:
𝑄𝑡 = 𝑄0 + 𝑘0 𝑡

Eq. (3)

where Qt is the amount of drug dissolved in time t, Q0 is the initial amount of drug in solution, and
k0 describes the zero-order rate constant. The first order model describes drug release that is concentrationdependent (Eq. 4) [393]:
𝑑𝐶
𝑑𝑡

= −𝑘𝐶

Eq. (4)

where C refers to drug concentration and k is the first order rate constant. This equation can also
be expressed as (Eq. 5):
log 𝐶 = log 𝐶0 −

𝑘𝑡

Eq. (5)

2.303

where C0 corresponds to the initial concentration of drug. The simplified Higuchi model utilizes
the following equation to describe drug release from matrix and polymeric systems (Eq. 6) [394]:
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𝑀𝑡
𝑀∞

= 𝑘√𝑡

Eq. (6)

where (Mt/M∞) is the cumulative amount of drug released at time t, and k is the Higuchi constant
based upon the formulation of the system. The Korsmeyer-Peppas model describes drug release from
matrix and polymeric systems through the following equation (Eq. 7) [395]:
𝑀𝑡
𝑀∞

= 𝑘′𝑡 𝑛

Eq. (7)

where (Mt/M∞) is the cumulative amount of drug released at time t, k’ is the kinetic constant, and n
is the exponent that describes a particular diffusion mechanism.
The first 60% of drug release is typically sufficient for determining the best fit model of drug
release [396]. For each model, a graph was constructed using Microsoft Excel from which the rate constant
and correlation values were obtained by applying a linear regression fit. The zero-order kinetic model was
obtained by plotting cumulative % drug release vs. time. The first-order kinetic model was analyzed by
plotting log cumulative % of drug remaining vs. time. The Higuchi model was evaluated by plotting
cumulative % drug release vs. square root of time, while the Korsmeyer-Peppas model was analyzed by
plotting log cumulative % drug release vs. log time.
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Results
Nanoparticle Synthesis and Characterization
We have previously characterized the diffusivity and transport of two and three layer gold
nanoparticles in 3D cell cultures and in vivo tissue in Chapter 2, finding that they performed better than
PEG-coated versions. Here, we examine the in vitro release profiles of cisplatin and paclitaxel from such
nanoparticle formulations. We evaluate nanoparticles functionalized with TL and PC for the development
of an inner hydrophobic region with a surrounding hydrophilic exterior, or TL, PC and HDL as three
layered gold nanoparticles (Figure 20). To ensure proper synthesis and surface functionalization,
nanoparticles were characterized through UV-Vis (ultraviolet-visible) spectroscopy to determine maxima
absorbance, SEM for morphological and size analysis, DLS (dynamic light scattering) to determine
hydrodynamic size in solution based upon Brownian motion, zeta potential to determine surface charge,
and FTIR analysis to ensure the presence of surface modifications.

Figure 20. Nanoparticle Illustration of Synthesis and Functionalization. Nanoparticles were synthesized
with either two or three layers, in which a lipid containing a hexadecanethiol (TL) head group was applied
to the gold surface. This displaced the citrate stabilizer, forming a hydrophobic nanoparticle. The addition
of PC to the solution promoted water solubility as the hydrophobic tails of PC bound the tails of TL. The
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two layer gold nanoparticles (A) were compared to three layer nanoparticles (B), in which HDL was further
added to alter the in vivo reactivity, drug release profile, and enhancement of tumor targeting.

Optical measurements were performed through UV-Vis spectroscopy and offer information
regarding nanoparticle size, shape, and agglomeration status. The spectra of two layer gold nanoparticles
exhibited a maximum absorbance peak at 540 nm, while three layer gold nanoparticles displayed a similar
spectrum with a maximum absorbance of 541 nm (Figure 21A). This particular wavelength near 534-545
nm is characteristic for nanoparticles with a diameter 50-70 nm, as nanoparticle size is proportional to
maximum absorbance with larger nanoparticles shifting maximum absorbance values to higher spectral
wavelengths [313]. Visual determination of nanoparticle size was accomplished using SEM, showing that
two layer gold nanoparticles had an average size of 47.1 ± 12.6 nm, while three layer gold nanoparticles
were 33% larger with an average size of 62.8± 14.9 (Figure 21B). The size difference can be attributed to
the addition of HDL to the surface of PC.
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Figure 21. UV-Spectroscopy and Zeta Potential Analysis of Gold Nanoparticles. Gold nanoparticles were
characterized using UV-Vis spectroscopy to determine the maximum absorbance wavelength and with
scanning electron microscopy (SEM) for size analysis. (A) The maximum absorbance of two and three
layer gold nanoparticles was 542 nm and 537 nm, respectively. Nanoparticles optical density does not
correspond to actual O.D. as both spectra were modified to fit graph. (B) SEM showed the size of two layer
gold nanoparticles at 47.1 ± 12.6 nm and three layer gold nanoparticles at 62.8 ± 14.9 nm.

DLS establishes the hydrodynamic size of nanoparticles in solution by considering Brownian
motion. As nanoparticles travel throughout solution, a thin electric dipole layer of solvent adheres to their
surface, which in turn can hinder or assist nanoparticles in reaching their target destination. Figure 22
reveals the hydrodynamic size for two and three layer gold nanoparticles at 74.91 ± 13.3 nm and 85.26 ±
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18.7 nm, respectively (Table 2). The surface charge of two and three layer gold nanoparticles, determined
through zeta potential analysis as illustrated in Figure 20, shows that HDL-coated nanoparticles (-2 mV)
were more neutrally charged in comparison to anionic PC-coated gold nanoparticles at -20 mV (Table 2).
For comparison, un-coated gold nanoparticles possessed a zeta potential near -40 mV, while thiol coated
nanoparticles were approximately -30 mV.

Figure 22. Hydrodynamic Size of Gold Nanoparticles in Solution. Gold nanoparticles were characterized
using dynamic light scattering (DLS) to determine hydrodynamic size in solution and with zeta potential to
determine surface charge. (A) The hydrodynamic size of two and three layer gold nanoparticles was
determined to be 74.91 ± 13.3 nm and 85.26 ± 18.7 nm, respectively. (B) Two layer gold nanoparticles
exhibited an anionic charge of -20 mV, while three layer gold nanoparticles were more neutrally charged at
-2 mV.

Table 2
Characterization Results of Two and Three Layer Gold Nanoparticles
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FTIR was employed to confirm the presence of surface modifications (Figure 23). Spectra
obtained from two and three layer gold nanoparticles were compared with spectra of pure PC [397] and
HDL [333]. Two layer gold nanoparticles functionalized with TL and PC exhibited several signature peaks
that confirmed the presence of TL and PC onto the gold core. Signature peaks included PO 43− group
vibrations between ∼850–1000 cm−1, a C−O−C stretch ∼1100 cm−1, a [(-CH2)n] rocking vibration ~720 cm1

, both asymmetric and symmetric −CH2 (2880 cm−1) and −CH3 (2950 cm−1) stretch and vibration, and a -

CH2 stretching and scissoring at 1375 and 1470 cm-1, respectively. Slight differences in the spectra can be
attributed to other chemicals used in the synthesis of the layered nanoparticles, including TL and colloidal
gold. For HDL-coated nanoparticles, the asymmetric and symmetric −CH2 (2880 cm−1) and −CH3 (2950
cm−1) stretch and vibration occur along with C=O from the lipid ester ∼1700-1800 cm−1, along with amide
bond stretches between 1500–1700 cm−1, and a phospholipid P=O2 stretch ∼1250 cm−1. As these
nanoparticles were also coated with TL and PC, distinct bands from both TL and PC were expected to be
present in the spectra of the three layer formulation.
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Figure 23. Surface Modification Analysis using FTIR. Gold nanoparticle surface modifications were
confirmed using Fourier Transform Infrared Spectroscopy (FTIR). The peaks were matched with those of
pure PC and HDL. The PC-coated two layer gold nanoparticles exhibited multiple peaks that were used for
conformation, including a [(-CH2)n] rocking vibration ~720 cm-1, a PO43- group vibration between 8201000 cm-1, C-O-C stretch ~1100 cm-1, - CH2 stretching and scissoring (1375 and 1470 cm-1). The HDLcoated three layer gold nanoparticles exhibited several peaks including: asymmetric and symmetric −CH2
(2880 cm−1), −CH3 (2950 cm−1) stretch and vibration, C=O from the lipid ester between 1700-1800 cm−1,
amide bond stretches between 1500–1700 cm−1 and a phospholipid P=O2 stretch ∼1250 cm−1.

Drug Release from Two and Three Layered Gold Nanoparticles
Both two and three layer gold nanoparticles were loaded with either cisplatin or paclitaxel to
evaluate the effect that the surface modifications may have on hydrophilic and hydrophobic drug release
kinetics. The cumulative percent of drug release was plotted against time to analyze the drug release
kinetics for each case (Figure 24). For cisplatin-loaded two layer gold nanoparticles, an initial burst of 35.7
± 2.3% was observed during the first 5 hours, followed by a steady release for the next 14 days (336 hours),
with 64.0 ± 2.4% of loaded cisplatin released (Figure 24A). Three layer gold nanoparticles loaded with
cisplatin also showed an initial burst of 68.4 ± 1.0%, followed by a steady profile with 98.3 ± 2.6% of
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loaded drug released at the end of 14 days (Figure 24B). Drug release within the first 24 hours was plotted
separately to highlight the initial burst followed by the switch to a more linear profile (Figure 25).
Paclitaxel release from two layer gold nanoparticles showed a linear profile with only 22.3 ± 1.5% of
loaded drug being released at the end of 14 days, indicating that nearly 78% of entrapped drug was still
attached to the nanoparticles (Figure 24C). In contrast, the three layer formulation effectively released 97.8
± 2.3% of encapsulated drug by day 14 (Figure 24D). The first 24 hours were also plotted separately to
highlight the initial release (Figure 25).

Figure 24. Drug Release from Functionalized Two and Three Layer Gold Nanoparticles. Hydrophilic and
hydrophobic drug release profiles from gold nanoparticles coated with PC and TL (two layer), or PC, TL,
and HDL (three layer). (A) Cisplatin-loaded two layer gold nanoparticles exhibited a burst during the first 5
hours, with ~35% of drug being released. A steady release followed over the next 14 days. (B) Cisplatinloaded three layer gold nanoparticles also experienced an initial burst with ~70% of encapsulated drug
being released within the first 5 hours. Drug release then became steady for the next 14 days. (C) Paclitaxel
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release from two layer gold nanoparticles was steady with only ~20% of encapsulated paclitaxel released
during the 14 days. (D) Almost 100% of paclitaxel encapsulated within three layer gold nanoparticles was
released by 14. Error bars represent standard deviation (n=3).

Figure 25. First 24 Hours of Drug Release from Gold Nanoparticles. Graphs highlighting drug release from
two- and three-layer gold nanoparticles during the first 24 hours are included. Additional graphs illustrating
model fitting to release curves are also shown.

The amount of drug loaded onto the nanoparticles was determined indirectly by measuring the
amount of drug that did not load (Table 3). For two layer gold nanoparticles, 68.4 ± 7.1% of cisplatin and
78.9 ± 4.9% of paclitaxel were effectively loaded. For the three layer formulation, higher drug
incorporation efficiencies were obtained with 99.1 ± 0.7% of cisplatin and 99.4 ± 0.4% of paclitaxel
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loaded. Nearly 100% of paclitaxel became encapsulated, suggesting that even higher drug concentrations
may be possible.

Table 3
Drug Incorporation Efficiency of Two and Three Layer Gold Nanoparticles

Kinetic Models for Drug Release
Mathematical models may be useful to evaluate the kinetics and mechanism of drug release from
nanoparticles. The release curves from Figure 24 were fitted to four distinct models to determine which one
exhibited the highest correlation with experimental results (Table 4). Hydrophobic drug (paclitaxel) release
from three layer gold nanoparticles exhibited high correlation with the zero-order kinetic model and the
Korsmeyer-Peppas models, both with R2>0.98 (Figure 26). Release of paclitaxel from the two layer gold
nanoparticles also showed high correlation with the simplified Higuchi model (R 2=0.9862), possibly due to
the profile curve denoting an early stage of release since only 22.3 ± 1.5% of paclitaxel was unloaded by
day 14. Both two and three layer gold nanoparticles loaded with hydrophilic drug (cisplatin) correlated best
with the Korsmeyer-Peppas model with R2>0.98. Both the Higuchi and Korsmeyer-Peppas models are
typically used to describe drug release from degrading matrix and polymeric systems [398]. Although in
this study the particles were metallic, the results suggest that aggregate release of drug from multiple
particles confined within a dialysis bag may be modeled similar to a polymeric system which undergoes
degradation.

Table 4
Rate Constants and Correlation Coefficients Obtained from Modeling Drug Release from Two and Three
Layer Gold Nanoparticles through the following: zero-order kinetic model, first-order kinetic model,
simplified Higuchi model, and Korsmeyer-Peppas model.
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Figure 26. Paclitaxel release from three layer gold nanoparticles (points, representing average values) fitted
to kinetic models (lines). The first 60% of cumulative release was fitted to each kinetic model: zero-order
kinetic model by plotting cumulative % drug release vs. time, first-order kinetic model by plotting log of %
drug remaining vs. time, simplified Higuchi model by plotting cumulative % drug release vs. square root of
time, and Korsmeyer-Peppas model by plotting log cumulative % drug release vs. log time. Both the zeroorder kinetic and the Korsmeyer-Peppas models showed high correlation with R2>0.98.
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Discussion
We synthesized two and three layer gold nanoparticles to analyze the effect of surface
modifications on the loading and release kinetics of two commonly utilized chemotherapeutics, cisplatin
and paclitaxel, representing hydrophilic and hydrophobic drugs, respectively. Two layer gold nanoparticles
were synthesized through the addition of a TL layer and PC coating [225], thus creating a hydrophobic
region accessible to water insoluble drugs such as paclitaxel (Figure 20). Besides aiding in drug
entrapment, a PC coating around gold nanoparticles was previously shown to significantly reduce
nanoparticle cytotoxicity [357]. PC-coated gold nanoparticles were synthesized by first displacing the
citrate stabilizer with TL. The strong binding affinity felt by the head group of TL for the gold core creates
water insoluble nanoparticles, as the hydrophobic tails of TL point outward from the gold cores (Figure
20). Addition of PC to the outer layer of TL re-establishes water solubility of the nanoparticles, as the tail
of the PC molecule binds tail-to-tail with TL. This process is expected to effectively create a hydrophobic
region between the TL and PC layers that can be utilized for loading hydrophobic drugs. The two layer
nanoparticles may be considered analogous to liposomes, yet containing an inner gold core. Addition of the
bilayer to the outside of gold nanoparticles is expected to increase the bioavailability and decrease
immunogenicity, as PC is a primary component of all cellular membranes.
Three layer gold nanoparticles were synthesized through the addition of HDL to the surface of PCcoated two layer gold nanoparticles. This modification is expected to enhance tumor-targeting capabilities,
especially for hepatocellular carcinoma as HDL receptors are unregulated in liver cancer [329]. Cisplatin
was loaded after the addition of PC for the two layer gold nanoparticles or after the addition of HDL for the
three layer gold nanoparticles, and expected to exhibit faster release kinetics in comparison to paclitaxel
due to the weakness of the non-covalent linkages (Figure 20).
Nanoparticles were characterized to confirm proper synthesis and modifications. Currently, a set
of characterization standards for characterizing nanoparticles does not exist [399], thus this study utilized
common instrumentation to ensure size, surface charge, and surface functionalization. While SEM (Figure
21) and DLS (Figure 22) are two common techniques for determining nanoparticle size [400], measurement
variances are often seen between samples using both instruments [401]. Hydrodynamic sizes of
nanoparticles obtained via DLS are often larger than sizes determined through SEM analysis, yet this is

97

common as DLS considers the effects of Brownian motion in solution [401]. Nanoparticle surface charge
can affect the transport of nanoparticles in vivo. As the head groups of PC are negatively charged, it was
expected that two layer nanoparticles would be moderately anionic. A previous study showed that the zeta
potential of PC-coated nanoparticles varies based upon pH, from 14 mV at pH=5 to -40 at pH=7 [402]. Due
to the orientation of the PC onto the nanoparticles on top of the thiol compound, a slightly negative zeta
potential was obtained. The zeta potential of HDL coated nanoparticles was expected to be more neutrally
charged as HDL is a neutrally charged molecule [403]. These expectations were confirmed, as shown in
Table 1.
Previous studies have shown that highly cationic or anionic nanoparticles experience increased
uptake in the liver, thus inactivating the nanoparticles before they have time to reach the target destination
and resulting in possible liver toxicity [404-406]. It has been shown that nanoparticles with a slightly
negative charge may have low liver uptake and enhanced accumulation in solid tumors [404], thus
suggesting that nanoparticles with slightly negative surface charges will display improved biocompatibility,
reduced RES sequestering, and enhanced drug delivery to solid tumors.
FTIR confirmed the presence of surface modifications by comparing the peaks of two and three
layer gold nanoparticles to pure PC and HDL (Figure 23). Two layer gold nanoparticles coated with TL and
PC were expected to have a large peak associated with –CH2 and –CH3 groups (~3000 cm–1) along with
phosphate group vibrations ~900 cm–1 [334, 407]. While these bands were present in the nanoparticle
spectra, the intensity of the peaks were diminished from the spectra of pure PC. This can be attributed to
the layering process, as the PC is loaded on top of TL, and both are attached to gold cores. For HDL-coated
nanoparticles, bands were expected to show with lipid esters between 1700–1800 cm–1 and two amide
stretches between 1500–1700 cm–1 [333]. As the HDL is loaded on top of the PC-coated nanoparticles, PC
representative peaks were expected to be visible in the spectra of the three layer gold nanoparticles.
Cisplatin release from two and three layer gold nanoparticles showed an initial burst during the
first five hours followed by a steady release for the following 14 days (Figure 24 A-B). An initial burst is
common for nanoparticles, yet is highly dependent upon surface polymers and strength of drug attachment
[408]. As cisplatin was bound to the nanoparticles non-covalently, the initial burst was expected. In
comparison, paclitaxel showed a steady drug release profile (Figure 24 C-D). Minimal paclitaxel was

98

released within 14 days from the two-layer formulation, which can be attributed to its tight encapsulation
within the hydrophobic layer created by the TL and PC. While PC may be degraded inside the body, it will
stay relatively intact in PBS, thus not allowing most of the drug to escape.
However, the addition of HDL to the surface of PC disrupts the layer allowing for paclitaxel to
slowly release from the hydrophobic region. This hypothesis is supported by the work of Scherphof et al.
who determined that HDL could disrupt the structural integrity of liposomes synthesized with PC [409].
This previous work demonstrated that albumin encapsulated in liposomes could be effectively released by
adding HDL to the solution [409]. This effect could explain the difference between the two and three layer
gold nanoparticles loaded with paclitaxel, showing a 5-fold increase in release from the three layer
formulation coated with HDL in comparison to the two layer (Figure 24 C-D). This also suggests that the
addition of HDL may not be creating an actual layer on the outside of the nanoparticles, yet only inserting
itself into the PC layer.
Paclitaxel release was best fitted by the simplified Higuchi model for the two layer nanoparticles
and the Korsmeyer-Peppas model and zero-order kinetic model for the three layer nanoparticles, both with
correlation values >0.98. For these nanoparticles, the long term sustained release could make them suitable
candidates for therapeutic applications. Cisplatin release from two and three layer gold nanoparticles was
best modeled by the Korsmeyer-Peppas equation. Both the simplified Higuchi model and KorsmeyerPeppas models describe drug release from degrading matrix and polymeric systems, thus suggesting that
the aggregate drug released from multiple gold particles confined within a dialysis bag may be modeled
similar to a system which undergoes degradation. The Higuchi model is based upon the following
assumptions: (1) diffusion of drug only occurs in a single dimension, (2) negligible matrix swelling and
dissolution, (3) much smaller drug molecules than system thickness, (4) constant drug diffusivity, (5)
release environment acts as a perfect sink, and (6) much higher drug solubility than matrix initial drug
concentration [32]. The Korsmeyer-Peppas model is a semi-empirical relation also known as the power
law, in which the fraction of drug release is exponentially related to the time for release. Two main
assumptions include: (1) the equation is only applicable for the first 60% of drug release and (2) the release
must occur in a single dimension [410, 411]. The single dimension is constructed by the release of drug
radially outward from the source, thus making it possible to model a 1-D problem.
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For comparison, we also evaluated the Weibull model as a possible candidate for describing the
drug release. While this model is a general empirical equation that is widely applied to drug release from
pharmaceutical dosage forms, the model is limited by the inability to establish in vivo and in vitro
correlation and the lack of parameters that can be related to the drug dissolution rate [410]. The Weibull
model exhibited low correlation for cisplatin-loaded two and three layer gold nanoparticles, with R2 values
of 0.7617 and 0.8792, respectively. The model was a better fit for the paclitaxel-loaded nanoparticles, with
the two layer gold nanoparticles having R2=0.9313 and the three layer formulation with R2=0.9743.
In contrast to polymeric or matrix nano-materials in which drugs are loaded within the nanocarrier
structure, gold surfaces allow for drug molecule attachment via charge interactions and thiol-gold bonds
that approach covalent bonds in strength. Based on desired release profiles and sequestration of molecules
due to particular physical properties (such as charge and hydrophobicity), there may be applications for
which a layered system is easier to design using gold instead of polymeric nano-materials. Thus, citrate
gold particles represent an initial step to build a multilayer system on a gold surface, which can be used to
elucidate interactions with cells. The next step would be to transition to a gold coated particle capable of
absorbing light at a specified wavelength to create heat and to use this energy to release drugs from the
nanoparticle, thus leading to enhanced localized delivery. However, to enhance release requires particles
which absorb light in a region transparent to tissue, such as near-infrared absorbing gold nanoparticles
(nanorods, gold silica nanoshells or gold-sulfide aggregate nanoparticles). Citrate gold colloid based
particles are unsuitable for thermal absorption as the wavelength of light used to activate these particles
(~540 nm) will harm living tissues due to absorption of energy at this wavelength [412].
Enhanced understanding of hydrophilic and hydrophobic drug release kinetics from multi-layered
gold nanoparticles can result in the development of combinatorial treatment strategies targeting tumor cells.
This study analyzes the release kinetics of cisplatin and paclitaxel from TL, PC, and HDL coated versions
of citrate gold nanoparticles as a first step in this evaluation. The results may further help to calibrate
computational simulations that can provide insight into the complex dynamics of nanoparticle transport and
drug release within solid tumors [336, 371, 413].
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CHAPTER V
CYTOTOXICITY OF 2- AND 3- LAYER GOLD NANOPARTICLES IN 3D MODELS OF LUNG
CANCER

Background
Chemotherapeutic Delivery to Solid Tumors
Formation of hypoxic and necrotic portions of solid tumors arise from inefficient vascularization
and irregular angiogenesis, as the lack of blood vessel organization results in hypo-vascularization and
nutrient deprivation [414]. Similarly, chemotherapeutic delivery in vivo is hindered by diffusion limitations
and the increased interstitial fluid pressure (IFP) of solid tumors [415]. While circulating drug can exit the
highly fenestrated capillaries of the tumor [416], various biological barriers hinder the drug particle from
diffusing beyond 3-5 cell diameters from the extravasation site [417, 418]. Treatment failure results if a
therapeutic concentration of chemotherapeutic fails to effectively reach all cancer cells, including those in
hypo-vascularized portions of tumor [415]. As tumors elicit a 3-dimsensional (3D) morphology in the
body, it is important to understand the spatial geometry of drug diffusion within 3D cell cultures to develop
novel treatment modalities [419]. Several groups have incorporated the use of 3D cell cultures in
computational models to better understand the mechanisms of nutrient diffusion and drug transport in
cancerous spheroids [413, 420].
Cell Cultures: Monolayer versus Spheroid
While 2-dimensional (2D) monolayer cell cultures are commonly utilized for cytotoxicity testing,
they lack the physiological features of the in vivo condition and the spatial response of drug activity [421].
3D cell cultures are a closer representation of the morphological environment of solid tumors found within
the body, as they mimic the effects of the ECM components, nutrient diffusion gradients, and IFP
alterations [422, 423]. Thus, 3D cell cultures can provide additional details concerning the effectiveness
and toxicity of drugs not attainable through monolayer cell cultures. For example, Godugu et al. showed
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that the IC50 value of chemotherapeutics would increase between monolayer and 3D cell cultures, which
was linked to higher drug resistance in the 3D model [424]. While 3D cell cultures require more care and
planning then 2D cell cultures with a higher cost, newer methodologies such as hanging drop arrays
described by Tung et al. make it possible to perform high-throughput screening of compounds in 3D cell
cultures [425].
In 2014, lung cancer remains the leading cause of cancer-related death in the United States with an
overall 5-year survival rate of 17% [56]. While treatment options exist, the late onset of symptoms results
in 85% of cases being diagnosed at advanced disease when the 5-year survival rate is only 4% [56]. Current
treatment options for patients with inoperable tumors include chemotherapeutics and radiation therapy, yet
these options only provide an average extension of life between 2-12 months [426, 427]. Oftentimes,
chemotherapeutic treatment results in severe off-target toxicity as the compounds distributes to all tissues
in the body [428, 429], treatment failure as the drug molecules cannot reach all the cells residing within the
tumor due to inefficient vascularization [430], or the development of resistance mechanisms by the
cancerous cells such as P-glycoprotein by cancer cells can render the drug compound ineffective [431].
Research studies are underway to determine optimal methods for overcoming each of the issues in order to
more effectively treatment solid tumors. Previous studies utilizing nanoparticles for lung cancer treatment
have shown great potential for the treatment of lung cancer (please refer to the following review papers:
[432, 433]).
Purpose of Study
The last decade has shown that nanoparticles can be effective in the treatment of solid tumors for
several reasons, including their passive targeting capabilities resulting from the EPR effect [433], improved
ability to avoid systemic distribution by active targeting [434], and their avoidance of resistance
mechanisms by undergoing distinct mechanisms of endocytosis [435]. Additionally, the large surface area
to volume ratio of nanoparticles can be functionalization with polymers, drugs, or other compounds to
enhance targeting capabilities and bioavailability [436]. Cisplatin and paclitaxel are two commonly utilized
chemotherapeutics for the treatment of NSCLC [437], with cisplatin functioning in the nucleus by
disturbing DNA replication and paclitaxel functioning by stabilizing microtubules in the cytoplasm [438,
439].
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In this study, gold nanoparticles were modified with thiol and PC in the formation of a two-layer
system or thiol, PC, and HDL for a three-layer system. We have previously shown that both two- and threelayer gold nanoparticles showed superior diffusivity in comparison to PEGylated nanoparticles in 3D cell
cultures [225]. It was also shown that both two- and three layer gold nanoparticles could be loaded with
cisplatin and or paclitaxel and showed unique drug unloading profiles [440]. This study examines the use of
cisplatin or paclitaxel loaded nanoparticles in 2D and 3D cell cultures to determine their cytotoxicity in
three NSCLC cell lines.
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Methods
Synthesis of Citrate Gold Nanoparticles
Citrate gold nanoparticles were synthesized using a method in which gold chloroauric acid is
reduced by trisodium citrate described by G. Frens in 1973 [306]. In this process, 2.2–2.4 mL 1%
weight/volume (wt/v) trisodium citrate (Fisher Scientific, Watham, MA, USA) is added to 200 mL of
boiling 0.01% wt/v HAuCl4 (Alfa Aesar, Ward Hill, MA, USA), and the solution is allowed to continue
boiling for 10 minutes to promote the reaction of sodium citrate to citric acid. Once the reaction is
completed, the solution cools at room temperature before concentrated using a rotovapor (Buchi Rotovapor
System, BÜCHI Labortechnik AG, Flawil, Switzerland) to 20 mL. The addition of surface modifications
followed the protocol outlined below.
Nanoparticle Functionalization
1-Hexadecanethiol (Sigma Aldrich) was the first layer applied to the gold nanoparticles. The TL
compound has a stronger binding affinity for the surface of the gold nanoparticles, thus displacing the
citrate molecules. While stirring, 20 mL pure ethanol was placed in a beaker with 60 μL 1-Hexadecanethiol
dissolved in ethanol added secondly. The 1-Hexadecanethiol solution was added slowly to the nanoparticle
solution over the next 10 minutes, while also agitating the sample by sonication. After addition of 1Hexadecanethiol, the sample was agitated for two hours, and then placed for 12 hours on an orbital rocker
(Boekel Scientific, Feasterville, PA, USA). The sample was spun down, and the pellet was washed twice
and resuspended in chloroform. PC (Sigma Aldrich) was the second functionalization added to the
nanoparticles. PC was solubilized in chloroform (Sigma Aldrich) and 100 μL were added to the particles
after the TL layer and allowed to set overnight on an orbital rocker. The solutions were transferred to glass
tubes and the chloroform evaporated at ambient temperature. This process completed the two layer citrate
gold nanoparticles containing gold core, TL, and PC. The three-layered nanoparticles were created by
optimizing the ratio of HDL (Lee Biosolutions, St. Louis MO, USA) to particle optical density (1 mg HDL
per 20 OD nanoparticle), and allowed to react overnight after two hours of agitation.
Loading of Chemotherapeutic onto Nanoparticles
Paclitaxel (Cayman Chemicals, Ann Arbor, MI, USA) and cisplatin (Sigma Aldrich) were loaded
onto the nanoparticles in distinct regions to ensure optimal loading efficiency. Paclitaxel was loaded after
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the addition of 1-Hexadecathiol and before the addition of PC. Briefly, after nanoparticles were placed on
an orbital shaker for 12 hours, the solution was removed. After nanoparticles were resuspended in 9 mL
chloroform, an addition 1 mL of chloroform containing 5 mg paclitaxel was added to the solution.
Nanoparticles were agitated for two hours using sonication before the solution was placed on an orbital
rocker for six hours. The solution was further modified to add the second layer of PC to the surface of the
nanoparticles. While paclitaxel was loaded into the hydrophobic region created between the TL and PC
layer, cisplatin was loaded at two different areas dependent upon the layering.
For the two layer citrate gold nanoparticles, cisplatin was added after the addition of PC. This was
done by transferring the solutions to glass tubes and the chloroform evaporated at ambient temperature.
Next, the nanoparticles were resuspended in 10 mL ultrapure H2O (Purelab Ultra, Elga Labwater, UK)
containing 7.5 mg cisplatin. For the three layer citrate gold nanoparticles, cisplatin was added after the
addition of HDL by synthesizing the particles as described above, yet after HDL was added to the particles
and allowed to react for two hours, the solution was removed, and 7.5 mg cisplatin was added. Excess
chemotherapeutic was removed from the solution by centrifuging the particles at 7000 rpm for 25 minutes,
removing the supernatant, and re-suspending the particles in the corresponding solvent. Washing was
performed twice.
Nanoparticle Characterization
Nanoparticle identity was verified as follows: (1) Maximum absorption wavelengths were
obtained using the Varian Cary 50 Bio Ultraviolet-Visible (UV-Vis) Spectrometer (McKinley Scientific);
(2) size and zeta potential measurements were obtained using the ZetaSizer Nanoseries ZS90 (Malvern
Instruments, Worcestshire, UK); (3) DLS (dynamic light scattering, also known as Photon Correlation
Spectroscopy) to determine hydrodynamic size in solution based upon Brownian motion; (4) shape and size
were determined using a Zeiss Supra 35VP (Carl Zeiss, Oberkochen, Germany) SEM; (5) presence of lipids
on the particle cores was confirmed using a FTIR (Perkin Elmer Spectrum BX; Perkin Elmer, Waltham,
MA, USA) and through visual analysis using the SEM.
Evaluation of In Vitro Drug Release
The drug-loaded nanoparticles were placed into dialysis tubes and submerged into beakers
containing 500 mL 1X PBS at pH 7.4. The dialysis tubing cellulose membrane had an average flat width of
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25 mm and 12,000 MW cutoff (Fischer Scientific, Waltham, MA, USA) and was clipped at both ends to
ensure no particles could exit. The beaker was continually agitated using a magnetic stirrer and covered
with Parafilm to ensure no evaporation of PBS would take place as experiments were performed at 37 ̊C. At
various time intervals, 3 mL samples of the PBS solution with drug were removed and replaced with fresh
PBS to ensure a constant volume. Drug concentration of each sample was analyzed using HPLC.
Cumulative drug release was found using the following equation (Eq. 8):
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝐷𝑟𝑢𝑔 𝑅𝑒𝑙𝑒𝑎𝑠𝑒 (%) =

[𝐷𝑟𝑢𝑔]𝑡
[𝐷𝑟𝑢𝑔]𝑡𝑜𝑡𝑎𝑙

× 100

(Eq. 9)

where [Drug]t is the concentration of drug in the sample at time t and [Drug] total is the total amount
of drug loaded onto the nanoparticles.
Cell Culture
Three human NSCLC cell lines were used in this study: A-549, PC-9, NCI-H358. Cell lines were
maintained in RPMI 1640 medium (Cellgro, Corning Inc.) supplemented with 10% fetal bovine serum
(Cellgro, Corning Inc.) and 1% penicillin-streptomycin-glutamine solution (Cellgro, Corning Inc.) in a
humidified atmosphere of 5% CO2 at 37 ̊C. All cells were grown to 80% confluence before use in 2D or 3D
cell cultures.
Evaluation of Free Drug Cytotoxicity in 2D Cell Cultures
A-549, PC-9, and NCI-H358 cells were seeded into 24-well plates at a density of 2×104 cells per
well, and incubated at 37 ̊C for 24 hours. Media was removed from wells and replaced with 1mL fresh
RPMI-1640 media containing varying concentrations of drug for 48 hours. For cisplatin experiments, cells
were exposed to the following concentrations for 48 hours: 1024, 256, 64, 16, 4, 1, 0.25, 0.0625 µM. For
paclitaxel experiments, cells were exposed to the following concentrations for 48 hours: 1024, 256, 64, 16,
4, 1, 0.25, 0.0625 nM. After incubation, media was removed and cells were washed with 1X PBS. Cells
were detached using 250 µL 0.05% trypsin per well and an additional 250 µL of fresh RPMI-1640 media
was added to each well. Cells were counted visually using trypan blue (Cellgro, Corning Inc.) exclusion.
For determining statistically significant differences, each case was done in quadruplicate (n=4).
Evaluation of Free Drug Cytotoxicity in 3D Cell Culture
A-549, PC-9, and NCI-H358 cells were seeded into 24-well ultra-low cluster plates (Costar,
Corning Inc.) at a density of 1×105 cells per well, and shaken for ~10 minutes to promote aggregation of
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cells. Cells were then placed in an incubator 37 ̊C for 5 days for spheroid acclimation. After spheroid
formation, the media was removed while carefully avoiding the spheroid. 1mL of media containing either
cisplatin or paclitaxel at varying concentrations was added to the corresponding wells. For cisplatin
experiments, cells were exposed to the following concentrations: 1024, 256, 64, 16, 4, 1, 0.25, 0.0625 µM.
For paclitaxel experiments, cells were exposed to the following concentrations: 1024, 256, 64, 16, 4, 1,
0.25, 0.0625 nM. Spheroids were treated with drugs were incubated at 37 ̊C for 48 hours. After 48 hours,
drug-containing media was removed. 500 µL 0.05% trypsin was added to detach the individual cells of the
spheroid from each other and 500 µL fresh RPMI-1640 media was added to deactivate the trypsin. Cells
were counted visually using trypan blue exclusion. For statistically significant differences, each case was
done in quadruplicate (n=4).
Evaluation of Drug Loaded Nanoparticles in 3D Cell Culture
A-549, PC-9, and NCI-H358 cells were seeded into 24-well ultra-low cluster plates at a density of
1×105 cells per well, and shaken for ~10 minutes to promote aggregation of cells. Cells were then placed in
an incubator 37 ̊C for 5 days. Spheroids were exposed to the same concentration of nanoparticle-loaded
drug as free drug (see above). The dose of drug-loaded nanoparticle was calculated by considering two
parameters: (1) the loading efficiency from HPLC data showed the exact concentration of drug on
nanoparticles and (2) the percent of drug released at 48 hours. By considering both of these factors, the
amount of drug needed to reach each concentration was calculated.
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Results
Characterization of Nanoparticles
Diffusivity of two and three layer gold nanoparticles was previously shown to be superior in
comparison to PEGylated nanoparticles when tested in 3D cell cultures [225]. When these nanoparticles
were loaded with cisplatin or paclitaxel, they displayed unique release curves with cisplatin having an
initial burst of drug release followed by a steady release and paclitaxel displaying a sustained release curve
over a period of 14 days [440]. Here, we examine the cytotoxicity of two and three layer drug-loaded
nanoparticles in 2D and 3D cell cultures (Figure 27). Two layer nanoparticles were synthesized by first
adding TL and secondly PC, which created a hydrophobic region capable for loading water-insoluble
compounds. The three-layer nanoparticle contained an additional modification of the outer PC layer of
HDL.

Figure 27. Synthesis of two- and three layered gold nanoparticles. Nanoparticles were functionalized by a
layering process as depicted in this figure. (A) Before functionalization, gold nanoparticles were
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synthesized using a sodium citrate method resulting in a citrate-covered nanoparticle. (B) Hexadecanethiol
was added to the nanoparticle solution that displaced the citrate molecules, forming water-insoluble
nanoparticles. (C) To create a region suitable for loading of hydrophobic drugs, PC was added to the
nanoparticle solution, binding tail-to-tail with the thiol layer. (D) To further functionalize the nanoparticles,
a three-layer system was created by adding HDL to the surface of the PC-coated system.

Confirmation of the particle identity was gained through characterized using several techniques,
including: ultraviolet-visible (UV-Vis) spectroscopy to determine the maximum absorbance values,
dynamic light scattering (DLS) to determine hydrodynamic size in solution based upon Brownian motion,
SEM for analyzing the shape and size of particles, zeta potential for studying surface charge alterations,
and FTIR spectroscopy to determine surface modifications.
UV-Vis spectroscopy was performed to ensure nanoparticles were not agglomerating in solution
(add citation). Two and three layer nanoparticles displayed similar spectra with a shift of ~4 nm, with the
two layer nanoparticles having a maximum absorbance peak of 539 nm and the three layer nanoparticles
displaying a peak at 535 nm (Figure 28). Using SEM, sizing of two and three layer gold nanoparticles was
shown to be 54.7 ± 7.9 nm and 62.1± 8.8 nm, respectively (Figure 29). DLS provided further details
regarding the sizing of nanoparticles when in solution based upon the effects of Brownian motion. Sizing
from DLS is based upon the thin electric dipole layer of solvent that adheres to the surface of nanoparticles
[441]. The hydrodynamic size for two and three layer gold nanoparticles was 71.5 ± 9.7nm and 80.2± 12.4
nm, respectively (Table 5). Further characterization utilizing zeta potential analysis showed that three layer
nanoparticles displayed a relatively neutral surface charge of -6 mV, while two layer nanoparticles were
more anionic at -21 mV (Table 5).
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Figure 28. Gold nanoparticles were characterized using UV-Vis spectroscopy to determine the maximum
absorbance wavelength. The maximum wavelength for the two layer gold nanoparticles was 539 nm, while
the three layer gold nanoparticles produced a maximum absorbance of 535 nm.

Figure 29. Scanning electron microscopy was utilized to determine the size and shape of two and three
layer nanoparticles. Gold nanoparticles were mostly spherical in shape, yet contained a heterogeneous
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assortment of nanoparticle sizes. On average, the two and three layer nanoparticles were determined to be
54.7 ± 7.9 nm and 62.1± 8.8 nm, respectively.

Table 5
Characterization of 2- and 3-Layer Nanoparticles using UV-Visible Spectroscopy, Dynamic Light
Scattering, and Zeta Potential Analysis.

2-Layer Nanoparticles (TL/PC)
3-Layer Nanoparticles (TL/PC/HDL)

Max Wavelength
(wavenumber-1)
539
535

DLS (nm)
71.5 (9.7)
80.2 (12.4)

Zeta Potential
(mV)
-21 mV
-6 mV

FTIR was utilized to confirm the presence of PC and HDL onto the surface of nanoparticles
(Figure 30). The spectra of pure PC and HDL were used for comparison [333, 397]. There were several
peaks used to confirm the presence of TL and PC on the gold nanoparticles. Some of the key peaks
included a [(-CH2)n] rocking vibration at 720 cm-1, PO43− group vibrations at 900 cm-1, a C−O−C stretch at
1100 cm−1, and an asymmetric and symmetric −CH2 at 2880 cm−1 and −CH3 at 2950 cm−1 stretch and
vibration. Additional peaks were associated with the other chemicals used to synthesize the particles. HDLcoated nanoparticles exhibited several similar peaks to PC-coated nanoparticles, which were expected due
to the layering process. The asymmetric and symmetric −CH2 (2880 cm−1) and −CH3 (2950 cm−1) stretch
and vibration were still present from the PC-coating, yet several signature peaks of HDL also became
visible. These peaks included a C=O from the lipid ester between 1700-1800 cm−1, an amide bond stretches
between 1500–1700 cm−1, and a phospholipid P=O2 stretch at 1250 cm−1.
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Figure 30. FTIR spectroscopy of Nanoparticles. Spectra of pure PC and HDL were used for comparison.
Peaks used to confirm the presence of PC included a [(-CH2)n] rocking vibration at 720 cm-1, PO43− group
vibrations at 900 cm-1, a C−O−C stretch at 1100 cm−1, and an asymmetric and symmetric −CH2 at 2880
cm−1 and −CH3 at 2950 cm−1 stretch and vibration. HDL-nanoparticles exhibited additional peaks,
including a C=O from the lipid ester between 1700-1800 cm−1, an amide bond stretches between 1500–
1700 cm−1, and a phospholipid P=O2 stretch at 1250 cm−1.

Drug Release Kinetics
Release of paclitaxel and cisplatin from both two- and three layer nanoparticles was dependent
upon the type of drug loaded and the number of layers on the nanoparticle core. Paclitaxel was shown to
release drug much slower than cisplatin, which experienced an initial burst of drug release (Table 6). The
cumulative percent of paclitaxel released from the nanoparticles during the first 3 hours was 1.42 ± 0.12%
and 2.39 ± 0.27% for the two- and three layer nanoparticles, respectively. For the cisplatin-loaded system,
the two layer nanoparticles released 33.8 ± 2.6% of drug within the first 3 hours, while the three layer
system released ~2X this amount (59.1 ± 2.0%). At the end of 96 hours, none of the nanoparticle systems
had released the total amount of drug loaded. Results from a longer release experiment of 14 days have
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been published [440]. Three layer nanoparticles loaded with cisplatin released the most amount of drug
(78.9 ± 2.1%) at the end of 96 hours as compared to the two-layer system (49.7 ± 0.70%). For the
paclitaxel-loaded nanoparticles, the three layer system released 5X more drug as compared to the two layer
system.

Table 6
Cumulative Release of Drug at Various Time Intervals with Associated Loading Efficiency [440]

2-Layer
Nanoparticles
w/Cisplatin
2-Layer
Nanoparticles
w/Paclitaxel
3-Layer
Nanoparticles
w/Cisplatin
3-Layer
Nanoparticles
w/Paclitaxel

3
Hours
33.8
(2.6)

12
Hours
37.6
(2.7)

24
Hours
43.0
(1.1)

48
Hours
46.9
(1.5)

72
Hours
48.9
(0.51)

96
Hours
49.7
(0.70)

Loading
Efficiency
68.4 (7.1)

1.42
(0.12)

3.38
(0.13)

3.80
(0.11)

8.20
(0.09)

10.8
(0.11)

11.9
(0.90)

99.1 (0.7)

59.1
(2.0)

70.2
(0.94)

72.8
(0.87)

76.7
(1.84)

77.7
(1.1)

78.9
(2.1)

78.9 (0.7)

2.39
(0.27)

3.88
(0.10)

7.50
(0.9)

23. 1
(4.2)

36.5
(4.3)

55.7
(4.7)

99.4 (0.4)

Since cytotoxicity measurements were performed at 48 hours for cell culture experiments, the
amount of drug release at 48 hours from each of the nanoparticle systems was noted (Table 6). The two
layer nanoparticles released 46.9 ± 1.5% of cisplatin and 8.20 ± 0.09% of paclitaxel at 48 hours in PBS.
The three layer nanoparticles released 76.7 ± 1.84% of cisplatin and 36.5 ± 4.3% of paclitaxel at 48 hours.
The loading efficiency was determined by subtracting the amount of unbound drug from the amount of
drug utilized to synthesize the nanoparticles. The loading efficiency of two layer nanoparticles was 68.4 ±
7.1% of cisplatin and 99.1 ± 0.7% of paclitaxel. For the three layer nanoparticles, the loading efficiency of
cisplatin was 78.9 ± 4.9% and paclitaxel was 99.4 ± 0.4%.
Cytotoxicity of Free Drug in 2D and 3D Cell Cultures
The cytotoxicity of both free cisplatin and paclitaxel were measured in 2D and 3D cell cultures at
48 hours, as depicted in Figure 31. It was expected that 2D cell cultures would experience higher levels of
cytotoxicity as lower concentrations of drug in comparison to 3D cell cultures, as monolayer cell cultures
lack 3D morphology. In each cell line, 3D cell cultures showed more cell viability at higher concentrations
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of drug (Figure 31 A, C, E). Similar results were obtained for paclitaxel cytotoxicity experiments in A549,
H358, and PC9 cell lines (Figure 31 B, D, F). While lower concentrations did not correlate with significant
cytotoxicity differences, higher concentrations of paclitaxel produced a significant difference between the
cytotoxic effects in 2D versus 3D cell cultures. In each case, cells residing within 3D cell culture provided
to be more difficult to induce cytotoxicity in comparison to cells of monolayer cultures.

Figure 31. Cytotoxicity of free cisplatin and paclitaxel in three NSCLC (A549, H358, and PC9) cancer cell
lines. For reference, black bars represent free drug in 3D cell cultures, while grey bars are indicative of free
drug in 2D (i.e. monolayer) cell cultures. In all cases, the concentration of drug required to cause
cytotoxicity in 3D cells was higher than concentrations needed in 2D cell cultures. At concentrations of 1
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µM or higher for cisplatin (A,C,E), the difference in cell viability between 3D and 2D cell cultures was
significant. Concentrations of paclitaxel above 4 nM showed similar results (B,D,F).

Cytotoxicity of Drug-Loaded Nanoparticles in 3D Cell Cultures
Cytotoxicity of drug-loaded nanoparticles was tested in 3D cell cultures to determine their
effectiveness as potential therapies. For this reason, drug-loaded nanoparticles were compared to free drug.
Cisplatin-loaded two and three layer nanoparticles were tested in 3D cell cultures of A549, H358, and PC9
NSCLC cell lines. Similarly, paclitaxel-loaded nanoparticles were tested in the same cell lines with results
shown in Figure 32. The cisplatin-loaded nanoparticles showed similar performance to free drug in 3D cell
cultures at all concentrations. In A549 cell line, the two-layer platform outperformed the free drug at higher
concentrations (65 and 256 µM) (Figure 32A). Both two- and three layer nanoparticles showed superior
efficacy in comparison to free drug at higher concentrations (16, 64, and 256 µM) in H358 3D cell cultures
(Figure 32B). The PC9 cell line showed so statistically significant differences between the cytotoxicity of
free drug versus nanoparticle-loaded drug, yet the nanoparticle systems performed equally as well as free
drug (Figure 32C), which would still have benefits for possible therapeutic uses.
Two and three layer nanoparticles loaded with paclitaxel were also tested in 3D cell cultures to
determine their cytotoxicity in comparison to free paclitaxel (Figure 32). For the A549 (Figure 32B) and
PC9 (Figure 32F) cell lines, no statistical differences were seen between the cytotoxicity caused by free
paclitaxel versus the drug-loading nanoparticles. The cytotoxicity graphs do suggest that the nanoparticle
platforms performed similarly to free paclitaxel in each case. For the H358 cell line, the two-layer
nanoparticle outperformed free drug at higher concentrations of 65 and 256 nM (Figure 32D). Similarly,
the three-layer nanoparticle displayed similar cytotoxicity as the two layer nanoparticles at 256 nM.
Overall, paclitaxel-loaded nanoparticles performed similarly to free paclitaxel in each case.
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Figure 32. Cytotoxicity of drug-loaded nanoparticles in comparison to free drug in 3D cell cultures. For
reference, orange bars represent free drug in 3D cell cultures, green bars represent the two-layer
nanoparticle system, and dark blue represents the three layer nanoparticle system with cisplatin toxicity
being shown on the left column and paclitaxel toxicity on the right column in 3 NSCLC cell lines (A549,
H358, and PC9). In each case, the drug loaded nanoparticles showed similar efficacy to free drug.
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Discussion
This study examined the possible use of two and three layer nanoparticles for the delivery of both
hydrophobic and hydrophilic chemotherapeutics to lung cancer. More specifically, cisplatin and paclitaxel
were chosen due to their current effectiveness in treating NSCLC. To determine the effectiveness of two
and three layer nanoparticles at destroying cancerous lesions, these layered nanoparticles systems were
studied in both 2D (i.e. monolayer) and 3D cell cultures. Previous studies have determined that 3D cell
provide a more realistic morphology of cancerous tumors that are found within the body as they possess
similar characteristics [442].
The layering system was applied to the surface of gold nanoparticles to enhance their tumor
targeting capabilities, while decreasing possibly immunogenicity and possibly avoid the reticuloendothelial
system (RES) [443]. The RES includes macrophages of the liver and other areas noted for removing a large
portion of systemically injected nanoparticles in vivo [444]. Two layer nanoparticles were synthesized with
a TL layer followed by a PC layer, which was critical for the formation of a hydrophobic region capable of
loading water-insoluble drugs. This was accomplished as the tail groups of TL and PC bind tail-to-tail
creating a water-soluble nanoparticle with similar characteristics to liposomal delivery systems (Figure 27).
With this nanoparticle system, the region between the TL and PC acts as a hydrophobic bilayer allowing
for the loading of water-insoluble compounds. As liposomes cause less toxicity in vivo in comparison to
other nanoparticle platforms, the PC layer also acted as a camouflage to decrease possible immunogenicity
and increase bioavailability [445]. The three layer nanoparticles were constructed by adding an additional
layer of HDL to the surface of two layer nanoparticles, as shown in Figure 27.
While both cisplatin and paclitaxel are commonly used in combination therapy for lung cancer,
both compounds work quite differently in causing cell death and possess distinct adverse effects. While
cisplatin is a water-soluble drug capable systemic delivery in saline with 5% dextrose, paclitaxel is a
hydrophobic compound that requires castor oil [446]. Castor oil has been linked to severe toxicity in
patients receiving this drug [446]. For this reason, nanoparticles capable of delivering paclitaxel are of
particular interest. In this study, paclitaxel is loaded into the hydrophobic region of nanoparticles formed by
the TL and PC layers. With paclitaxel being loaded in this region, it was expected that paclitaxel would
exhibit a slower release from the polymeric systems. This was confirmed through drug release experiments.
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Cisplatin was expected to experience a faster drug release profile due to its location of binding, onto the
outer layer of PC for two layer nanoparticles or HDL for three layer nanoparticles. This faster release was
attributed to the weak non-covalent interactions made between the cisplatin compound and its binding
location.
After synthesis of two and three layer nanoparticles systems, characterization protocols were
utilized to ensure correct modifications were present. While there is no standard set of characterization
procedures at this time, we chose to use the common characterization tools followed by other groups. By
characterizing the size, surface charge, and surface modifications, the identity of the nanoparticle systems
could be confirmed. The wavelength of both two and three layer nanoparticles was within the common
range for citrate gold nanoparticles between 50-80 nm (Figure 27) [313]. Nanoparticle size was measured
using two different methods, both SEM and DLS (Figure 27 and Table 5). While sizing of nanoparticles
with SEM occurs optically, measurements of size with DLS take into account the effects of Brownian
motion that the particles may experience while traveling in solution. Sizing measurements by SEM and
DLS can vary with nanoparticles experiencing a larger hydrodynamic radius through DLS in comparison to
SEM measurements [447].
Zeta potential is another useful tool for characterizing nanoparticles as it provides information
regarding the surface charge of nanoparticles (Table 5). The surface charge can have significant effects on
nanoparticle travel inside the body, as proteins and other components of the body have zeta potentials that
may attract or repel the nanoparticle. For example, it is documented that nanoparticles possessing a neutral
charge are less likely to be removed by the liver and spleen in comparison to highly cationic or anionic
nanoparticles [448, 449]. The two layer nanoparticles with an outer layer of PC were expected to produce a
slight negative surface charge. Previously, it was shown that zeta potential measurements vary with the pH
of the solution that nanoparticle, with more acidic environments (pH ~5) producing a more positively
charged surface area, while neutral pH (~7) produced nanoparticles with negative surface charges [450]. In
comparison, HDL nanoparticles were expected to possess a neutral surface charge, as the HDL molecule is
relatively neutral as well [332].
Furthermore, it was critical to ensure that nanoparticles were functionalized correctly by analyzing
the chemical moieties on the surface. FTIR was utilized to ensure the presence of PC and HDL on the
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surface of the gold nanoparticles (Figure 30). This was accomplished by comparing the representative
peaks of PC and HDL with spectra of gold nanoparticles and pure PC and HDL. Since nanoparticles were
constructed using a layering process, it was expected that some bands would be seen in both the two and
three layer nanoparticle systems. The amide bond stretches between 1500-1700 cm-1 and lipid ester linkage
near 1700-1800 cm-1 were the primary two bands that confirmed the presence of HDL [333].
Release of cisplatin and paclitaxel from nanoparticles was measured for 96 hours to determine the
necessary doses for cytotoxicity experiments (Table 6). Cisplatin-loaded nanoparticles displayed an initial
burst of drug release, a common occurrence for compounds possessing weak interactions with the
nanoparticle surface. Paclitaxel-loaded nanoparticles provided a steady release of drug during the 96 hours
of release, which was attributed to the efficiency of loading within the hydrophobic layer. In both cases,
addition of HDL augmented the total amount of drug released during the experiment. We hypothesized that
this was due to a disturbance in the PC-coating caused by the HDL components. A previous study by
Scherphof et al. showed that albumin-loaded liposomes exposed to HDL would effectively release most of
their payload as the HDL components disrupted the membrane integrity of the liposome [409]. This also
provides evidence that the HDL components may be integrating itself into the PC layer and not creating an
actual “three layer” particle.
Previous studies have shown that 3D nanoparticles are superior to 2D cell cultures for cytotoxicity
experiments [421, 451]. Several companies have developed newer and easier methodologies for creating
and utilizing 3D cell cultures in the laboratory [424, 451]. The 3-dimensional morphology of 3D cell
cultures promotes a spherical shape, in which only the cells residing on the periphery of the spheroid are
exposed to the environment. When both 2D and 3D cell cultures are treated with drugs, differences in
cytotoxicity become visible. In monolayer cell cultures, the cells produce a single layer allowing ensuring
that the majority of will be exposed to drug. This does not hold true for 3D cell cultures as only cells of the
outer periphery are exposed to drug, with inner regions of the spheroid experiencing lower levels of
chemotherapeutic and possible necrosis [452]. For this reason, higher concentrations of chemotherapeutics
are required to actively kill the cells residing within the center regions of the spheroid (Figure 31).
Cytotoxicity experiments showed that two and three layer gold nanoparticles showed similar efficacy to
free drug in all cases (Figure 32). In some instances, drug-loaded nanoparticles outperformed the free drug.
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We hypothesize the effectiveness of the nanoparticle systems can be attributed to their ability
diffuse throughout the tissue gaining access to cells residing within inner regions of the spheroid. While
drug molecules can diffuse from the surface of spheroid inward, diffusion limitations only permit short
distances of travel for free drug, as most drug will be uptaken by the cells on the periphery of the spheroid.
Previously, two- and three layer nanoparticles were shown to diffuse from the periphery of 3D cell cultures
inward more effectively than previously designed PEGylated particles [225]. As the nanoparticles are
constantly releasing drug as they diffuse from the periphery of the spheroid inward, the cells being exposed
are receiving adequate concentrations of drug effective for cellular apoptosis.
This study analyzed the cytotoxicity of two and three layer gold nanoparticles in 3D cell cultures
to determine the possible applications for in vivo work in the future. As the particles showed similar
efficacy to the freely drug, we would expect that the nanoparticles would function well in vivo as the
nanoparticles are more likely to accumulate in the tumor as compared to freely circulating drug. Results
from this study also support the possibility of attaching both paclitaxel and cisplatin a single nanoparticle,
allowing for a combination treatment in the future.
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CHAPTER VI
SUMMARY AND CONCLUSIONS
The purpose of this project was to examine the use of drug loaded gold nanoparticles as potential
drug delivery agents for the treatment of solid tumors. This was accomplished by analyzing the diffusivity
of gold nanoparticles in 3D cell cultures, measuring the uptake of gold nanoparticles in vivo when injected
systemically, interpreting the drug-loading capabilities of functionalized gold nanoparticles, and to
determine the efficacy of these drug-loaded gold nanoparticles in 2D and 3D cell cultures.
The ability to modify the surface of nanoparticles makes them well adaptable for several
applications including the delivery of chemotherapeutics to solid tumors. This project specifically utilized
nanoparticles modified using a layering process, in which surface functionalization of thiol and PC created
two layer nanoparticles, and an additional layer of HDL onto the PC layer formed the three layer
nanoparticles. It was hypothesized that the addition of PC would decrease possible immunogenicity and
immune cell uptake in various filtering organs in the body. As HDL is up-regulated in some forms of
cancer, it was predicted that three layer nanoparticles might have additional benefits from the PC-coated
nanoparticles.
Two and three layer citrate gold nanoparticles and silica gold nanoshells were synthesized. While
both citrate gold nanoparticles and silica gold nanoshells are both metallic nanostructures, they differ in
size and applications. Synthesis of nanoparticles and accurate modifications were confirmed using several
characterization techniques described in the methods section. It was also predicted that PC- coated
nanoparticles would be able to diffuse greater distances from vasculature due to its similar structural
composition in comparison to cellular membranes. For comparison, previously developed PEGylated
nanoparticles were utilized. Our hypotheses were confirmed in this study as the two and three layer
nanoparticles diffused further from vasculature in comparison to PEGylated nanoparticles, suggesting that
PC- and HDL- coated nanoparticles may potentially be able to delivery drug deeper into tumors. In
addition, this study showed that smaller citrate gold nanoparticles accumulated in 3D cell cultures at higher
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concentrations in comparison to silica gold nanoshells. In the pancreatic cancer cell line, S2VP10, the two
layer nanoparticles showed superior diffusivity in comparison to PEGylated and HDL-coated nanoparticles.
For this reason, two layer citrate gold nanoparticles and silica gold nanoshells were used for in vivo
experimentation.
After analyzing the diffusivity of gold nanoparticles in 3D cell cultures, the two layer
nanoparticles were examined in vivo. Mice with orthotopic pancreatic adenocarcinomas were injected with
two layer gold nanoparticles to determine the accumulation efficiency in the tumor vs. filtering organs (i.e.
liver and spleen). The diffusivities of the nanoparticles from vasculature were also measured to determine
which particle could more effectively exit the fenestrations of the solid tumor. This was accomplished
using dark field microscopy in combination with hyperspectral imaging, using the CytoViva Hyperspectral
Imaging system. Results from this study showed a size-dependent hindrance of nanoparticle diffusion, as
the PC-coated silica gold nanoshells diffused shorter distances from vasculature in comparison to smaller
citrate gold nanoparticles. As the size difference is 3:1, this was expected. An overall accumulation of
colloidal gold nanoparticles was higher in the tumor, liver, and spleen in comparison to silica gold
nanoshells. Since citrate gold nanoparticles showed superior efficacy compared to silica gold nanoshells,
the smaller nanoparticles were chosen for the remainder of this project for drug loading and in vitro
experimentation.
Since the colloidal gold nanoparticles displayed higher accumulation in vivo, they were utilized to
determine drug loading capabilities and release kinetics. Drug release from nanoparticles is a complex
process dependent upon the physiochemical properties of the nanoparticle and drug molecule. Since the
nanoparticles were layered, the TL and PC surface modifications created a region of hydrophobicity around
the nanoparticle optimal for loading the water-insoluble compound paclitaxel. On the outside of the
nanoparticles, cisplatin was loaded and interacted through non-covalent interactions. Results from this
study showed that paclitaxel released slower than cisplatin, which was attributed to method of drug loading.
The addition of the third layer (HDL) was shown to puncture the PC layer of the nanoparticles, promoting
the release of more paclitaxel from the hydrophobic layer. By understanding the amount of drug released at
various time intervals, we were able to design cytotoxicity experiments to test the efficacy of these novel
nanotherapeutic systems.
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The efficacy of cisplatin and paclitaxel-loaded colloidal gold nanoparticles were evaluated in 3D
cell cultures. Results from this study showed that drug-loaded nanoparticles performed similarly to free
drug in each case. As the nanoparticles are targeted to tumors, unlike freely circulating drug, we would
expect the nanoparticles to perform well in an animal model. Also, nanoparticles could result in less liver
and kidney toxicity as drug release is delayed from nanoparticle systems, unlike free drug, which
accumulates in the liver faster.
In conclusion, the two and three layer nanoparticles system is a potential candidate for cancer
therapy. Additional studies are needed to determine the effectiveness of the nanoparticle compounds in
animal models. Future prospects for this project include the co-delivery of two drugs simultaneously.
Additionally, more studies are needed to examine potential toxicities associated with both two and three
layer nanoparticles.
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Teaching Experience
2014

Dental Hygiene’s Pharmacology Course- Instructor, University of Louisville


2013-2014

Developed course materials and lectures covering topics such as drugs affecting the
central nervous system (CNS), peripheral nervous system (PNS), and immune
system.
 Facilitated lecture-based and discussion-driven teaching plans to promote active
learning
 Developed critical thinking questions for discussion and exam purposes
Undergraduate Basic Pharmacology Course-Instructor, University of Louisville


2013

Developed teaching plans and lectures on subjects including drug metabolism, drug
elimination, antibiotics, and cardiovascular and renal pharmacology
 Provided additional learning opportunities outside of class time to ensure students
were comfortable with material
Graduate Teaching Academy, University of Louisville


2012

This 12-month program covered topics such as: collaborative student work,
classroom management, assessment techniques, active learning, productive
discussions, teaching statements, learning-centered syllabi, micro-teaching, peer
feedback, and synthesizing rubrics.
 Constructed personal philosophy of teaching statement along with professionally
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2012-2014
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